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Reactive oxygen species (ROS) are well documented regulators of various cell fate 
processes. The tight balance between the levels of intracellular superoxide (O2
-
) and 
hydrogen peroxide (H2O2) is particularly critical in governing death signaling 
pathways. While an increase in H2O2 has been shown to promote the execution of cell 
death machineries, a tilt in O2
-
:H2O2 ratio in favor of O2
-
, conversely, creates a 
cellular milieu that favors cell survival. Here, we seek to elucidate the mechanism(s) 
underlying the pro-survival properties of O2
- 
anion both in vivo and in vitro. Using 
Jurkat, Hela and MDA231 cells as models, we demonstrate that an elevated O2
-
:H2O2 
ratio induced by either diethyldithiocarbamate (DDC) inhibition or SiRNA-mediated 
knockdown of SOD1 resulted in the increased phosphorylation of Bcl-2 specifically 
at Ser70 (S70), a phenomenon which was further shown to enhance the antiapoptotic 
activity of Bcl-2 and thus rendering the cells resistant to chemotherapeutics such as 
etoposide and doxorubicin. O2
- 
induced Bcl-2 phosphorylation at S70 was further 
shown, via co-immunoprecipitation and confocal microscopy techniques, to be due to 
a disruption in the interaction between Bcl-2 and the catalytic core of protein 
phosphatase 2A (PP2A), though the B56δ regulatory subunit which targets the PP2A 
core enzyme to its substrates still remained attached to Bcl-2 at the mitochondria. 
Further, we provide evidence that the detachment of the B56δ-Bcl-2 complex from 
PP2A catalytic core is due to the selective tyrosine nitration of B56δ by peroxynitrite 
that originated from O2
- 
induced by SOD1 silencing or DDC treatment. Indeed, 
bioinformatics analysis identified Tyr289 as a nitration-prone tyrosine residue on 
B56δ which, upon site-directed substitution to a non-nitratable phenylalanine residue, 
prevented the disruption of B56δ from the catalytic core, and more importantly, 
abrogated the accumulation of S70 phosphorylated Bcl-2 (S70 pBcl-2) and the pro-
x 
 
survival effects of O2
-
 upon SOD1 silencing and DDC treatment. Importantly, 
analysis of clinical lymphoma biopsies revealed a strong inverse relationship between 
SOD1 expression and S70 pBcl-2 while immunoprecipitation assay further 
demonstrated that B56δ is highly tyrosine nitrated in primary lymphoma tumours 
with low SOD1 expression. Taken together, our data demonstrate a novel mechanism 
in which an increased O2
-
:H2O2 ratio could augment the chemoresistance of cancer 
cell, via tyrosine nitration-mediated inhibition of B56δ-containing PP2A and the 
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1 Reactive Oxygen Species – An overview  
Reactive oxygen species (ROS) is a collective term for reactive molecules that are 
derived from molecular oxygen (O2). It encompasses not only the oxygen radicals 
such as superoxide (O2
-
) and hydroxyl radical (OH·), but also the non-radical 
derivative of O2 such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO
-
). ROS 
greatly differs in their respective chemistry and reactivity, with certain species being 
highly selective in their reactions against biological molecules, while others reacting 
with everything in proximity [1]. Due to their fairly reactive nature, ROS has been 
conventionally treated as agents of detriment, though research over the years has 
proven otherwise. It is now recognized that the biological activity of ROS goes 
beyond the spontaneous oxidative damage of biological molecules as most reactive 
species are now acknowledged for their roles in various important physiological 
processes. 
Here, we provide a brief overview of the biochemistry and intracellular source(s) of 
various important ROS before we attempt to address the huge arsenal of intracellular 
antioxidant machinery that is available to counter the reactive nature of ROS. The 
physiological role of various reactive species would also be discussed in subsequent 




1.1 Superoxide anion (O2
-
) 





 anions, in essence, is an immediate derivative of O2 with an additional unpaired 
electron at the outermost orbital of the molecule, thus making it an anionic radical. 
Despite the prefix “super”, O2
- 
does not readily react with biological molecules in 
aqueous solution [1] and it is not known to oxidize amino acids as well [2]. There are, 
however, evidence suggesting that iron-sulphur cluster-containing proteins such as 
aconitase and fumarase are readily attacked and inactivated by O2
-
, and this, in part, is 
due to the heightened tendency of O2
- 
to be electrostatically attracted to the positively 
charged iron-containing active site [3, 4]. Despite its poor reactivity with biological 
proteins, O2
- 
could still react rapidly with other ROS members such as H2O2 and NO 
to form more noxious reactive species. These reactions (addressed in chapter 1.2.1 
and chapter 1.3.1) are part of the reason why O2
- 
is toxic to the cell when present in 
excess.  
 
1.1.2 Sources of intracellular O2
-  
1.1.2.1    Mitochondria electron transport chain 
In eukaryotes, the mitochondria electron transport chain (ETC) is one of the major 
contributors of intracellular O2
-
. As a result of inefficient electron transport activity, it 
is estimated that approximately 0.1-0.2% of electrons are leaked out from the ETC for 
the partial reduction of O2 into O2
- 
[5-7] amidst electron transfer processes. With 
respect to this, the mitochondrial complex I [8-10] and complex III [10-12] are the 
two main culprits implicated for the by-production of O2
- 
anions from the 
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mitochondria respiratory machinery, although under certain circumstances, complex 
II can partake in the production of  O2
- 
as well [13]. Besides the ETC, other 
mitochondrial enzymes have also been implicated as O2
- 
producers [14-16], with the 
Krebs cycle enzyme complexes, α-ketoglutarate dehydrogenase and pyruvate 
dehydrogenase, being the two most notable sources of O2
- 
formation [17, 18]. 
Although the exact mechanism(s) involved in the production of O2
- 
by these enzyme 
complexes is not yet fully understood, the flavin prosthetic group in these enzymes 
was suggested to be the main catalyst for the transfer of electron from NADH to O2 
[17].  
 
1.1.2.2    NADPH Oxidase Complex 
Other than the mitochondria, the NADPH oxidase (NOX) complexes are also among 
the major producers of intracellular O2
-
. The NOX complex comprises the NOX 
catalytic subunit as well as a series of regulatory proteins that aids in the catalytic 
activity of NOX in catalysing the single electron transfer from NADPH to O2 for the 
formation of O2
-
. A total of seven NOX homologues have been identified to date. 
They are namely, NOX1-5, DUOX1 and DUOX2 [19-24]. NOX2, together with its 
regulatory members (p22phox, p47phox, p40phox, p67phox and the small GTPase 
RAC1) [25-27], was the first NOX complex to be identified, where it was discovered 
as a membranous protein that catalyses the “oxidative burst” in phagocytes as a 
defence mechanism against evading pathogens [28]. NOX1, NOX3, and NOX4 were 
subsequently identified as prototypes of NOX2, whereas NOX5, DUOX1 and 
DUOX2 were found to possess an additional calmodulin domain which allows for 
their respective regulation by intracellular Ca
2+ 
fluxes [19-24]. These NOX enzymes 
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are expressed in a variety of tissues where they serve as a constitutive source of 
O2
- 
for various signalling purposes [19-24]. 
Although all NOX isoforms are transmembrane proteins, their subcellular spatial 
distribution nonetheless vary substantially, as they have been described in a variety of 
membranous structures such as the plasma membrane, endosomes, endoplasmic 
reticulum (ER) and the nuclear envelope  [29-32]. In fact, evidence suggests that 
certain NOX isoforms could even be targeted to subcellular microdomains such as 
lipid rafts and focal adhesions, thus allowing for the localized production of O2
- 
for 
regulatory purposes [29-32]. Of note, O2
- 
produced by the NOX complexes are 
channelled out to extracellular lumens instead of directly into the cytosol [33]. 
However, reports have shown these anionic radicals are capable of
 
diffusing back via 





1.1.2.3    Xanthine oxidase and other potential sources of intracellular O2
-
 
Xanthine oxidase is an enzyme involved in the catabolism of purine where it 
catalyses the oxidation of hypoxanthine to xanthine, and subsequently to uric acid 
[35]. During this process, O2 is being reduced into both O2
-
 and H2O2 [1, 35]. 
However, studies have shown that the majority of hypoxanthine/xanthine oxidation 
process is catalysed by a separate enzyme, xanthine dehydrogenase, which does not 
produce O2
- 
as by-products [1, 35]. Thus, xanthine oxidase may not be a significant 
contributor to the production of intracellular O2
- 
under physiological conditions.  
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Apart from xanthine oxidase, there are also some other minor sources of intracellular 
O2
- 
such as cytochrome P450, indolemamine 2,3-dioxygenase, aldehyde oxidase as 
well as the haem containing myoglobins and haemoglobins [1, 36, 37]. Some of these 
enzymes are exclusive to the intestinal cells and liver (cytochrome P450, 
indolemamine 2,3-dioxygenase, aldehyde oxidase) while the haemoglobins and 
myoglobins are found in erythrocytes and muscle tissues respectively. These sources, 
however, are generally not known to be major contributor to the changes in 
intracellular redox milieu.  
 
1.2 Hydrogen Peroxide (H2O2) 
1.2.2 Biochemistry of H2O2  
H2O2 is not a radical, as it does not possess an unpaired electron in its outermost 
orbital. It is soluble in aqueous solution, and due to its uncharged nature, H2O2 could 
easily diffuse through lipid membranes. Like O2
-
, H2O2 is very selective in its 
biological reactivity. The molecule, when present on its own, does not react with 
DNA, lipids as well as most amino acids [1]. However, H2O2 is known to directly 
oxidize the thiol groups (-SH) of cysteine residues in a reversible manner [1, 38]. 
This, in fact, may be one of the most important properties of H2O2 which enables it to 
serve as an intracellular signalling molecule, especially when thiol groups are often 
an integral part of various enzymatic active sites.  
While H2O2 on its own may not be as reactive as other ROS, it could, however, be 
reduced into potentially more damaging molecules in the presence of transition 





) and hydroxyl radical (OH·) in the presence of ferrous metal [39, 
40].   
  
 
Another reaction involving the formation of OH· from H2O2 is the Haber-Weiss 
reaction. This reaction requires a transition metal catalyst (iron or copper) and 
requires O2
- 
as an electron donor as well [41]. The net reaction is as follow: 
  
 
In principle, these reactions form the basis of the damaging effects of H2O2 in vivo, 
for the hydroxyl radical, an end product of these reactions, is an extremely reactive 
ROS. When formed, hydroxyl radical often results in extensive oxidative damage as it 
could rapidly oxidize DNA, lipids, proteins and almost all biological molecules 
adjacent to it [1].  
 
1.2.2 Sources of intracellular H2O2  
Unlike the production of O2
- 
by the NOX complexes, no enzyme is known to 
intentionally produce H2O2 in the cell. In vivo, H2O2 are typically produced as by-
products of the various biological processes catalysed by the oxidase enzymes. For 
instance, the mitochondrial monoamine oxidases are amongst the major contributors 
of mitochondrial H2O2. The monoamine oxidases catalyse the oxidative deamination 
of monoamines, leading to the formation of aldehydes and ammonium ions, as well as 
H2O2 as a by-product [42]. Other than the monoamine oxidases, the xanthine oxidase 
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is another example of enzyme that could produce H2O2 whilst performing its function 
[35]. However, as aforementioned (chapter 1.1.1.3), xanthine oxidase is not the main 
enzyme involved in the oxidation of xanthine and it is unlikely to be a major source 
of cellular H2O2.   
In fact, a major portion of cellular H2O2 is contributed by the dismutation of O2
-
 into 
H2O2 by the superoxide dismutase (SOD) enzymes. A total of three isoforms have 
been identified in eukaryotic cells to date, all of which are extremely efficient in their 
catalytic conversion of O2
-
 into H2O2. Thus, with the constant production of O2
- 
from 
the mitochondria as well as other enzymatic sources, it is of no surprise that the 
majority of cellular H2O2 stems from the dismutation of these O2
- 
by the SODs. Due 
to their role in the removal of O2
-
, SODs are considered as part of the cellular 
antioxidant machinery, and for this reason, a more detailed discussion of the enzyme 
in the following chapter on cellular antioxidant systems is warranted. 
 
1.3 Nitric Oxide (NO) 
1.3.1 Biochemistry of NO  
Strictly speaking, NO belongs to the family of reactive nitrogen species (RNS). Due 
to the presence of an oxygen moiety, however, NO is sometimes loosely termed as 
ROS as well. Despite being a radical species with an unpaired outer-orbital electron, 
NO is a relatively poor oxidant as compared to other reactive species. If a “biological 
reactivity scale” does indeed exist, NO would have ranked amongst the lowest of all 
ROS/RNS, for the radical itself reacts very slowly, if at all, with most biological 
molecules [1]. Because of this, NO is postulated to have a half-life of up to hours in 
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vivo, and it could diffuse for a fairly long distance within the cell, or even traversing 
the plasma membranes to adjacent cells in certain instances [43]. While NO does not 
react readily with biological molecules, it nonetheless possesses great affinity to the 
haem-prosthetic group of various biological proteins. Allosteric binding of haem by 
NO often alters the activity of target proteins, and it is this attribute that bestows NO 
with the ability to act as secondary messengers in the cell. Indeed, a classical example 
of NO as a physiological signalling agent is none other than its role as an 
endothelium-derived relaxation factor [44, 45], whereby the  binding of NO to the 
haem-prosthetic group of guanylate cyclase (GC) is known to activate the synthesis of 
cyclic guanosine monophosphate (cGMP) by GC, which in turn triggers a sequential 
series of signalling events that eventually culminate into the relaxation of smooth 
muscle cells [44, 45].  
While most of the signalling activity of NO has been conventionally attributed to 
allosteric haem-binding or increase in cGMP, it is now suggested that the signalling 
role of NO could also involve the direct modification of protein by the radical as well 
[46-48]. Specifically, it was proposed that NO could directly impact protein activity 
by S-nitrosylation – the coupling process of an NO moiety to the thiol group of 
cysteine residues to form S-nitrosothiols [46-48]. However, the significance of this 
reaction in a complex biological milieu remains debatable, for the exact chemical 
reaction involved in the direct attack of NO to cysteinyl thiol group is still poorly 
understood, and some recent evidence has suggested that the rate of this reaction is 
negligible [49].  
Notwithstanding the poor biological reactivity of NO, the nitrosative oxidation of 
various biological molecules could still be frequently observed upon an increased in 
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intracellular NO level, thus raising the question of how exactly does NO exert its 
damaging effects in biological systems. While NO may not directly attack biological 
molecules, the radical itself could still react with other radical species to form more 
reactive, and hence potentially more damaging, molecules. Amongst the most 
commonly described reaction is the formation of ONOO
- 
that stems from the radical 
fusion of NO and O2
-
. Formation of ONOO
-
, in fact, was once believed to account for 
majority of the nitrosative modifications processes in an NO dominated intracellular 
environment [1], only to be recently challenged by evidence suggesting that NO may 
directly react with cysteinyl thiol groups as well [46-48]. 
 
1.3.2 Sources of intracellular NO 
The biosynthesis of NO is performed by a family of enzymes known as the nitric 
oxide synthases (NOS) [50]. The catalytic mechanism of NOS involves an initial 
single electron reduction of O2, and its subsequent incorporation into the guanidine 
nitrogen of L-arginine for the formation of NO and L-citrulline. The electron required 
for this process is supplied by NADPH and the transfer of electron to the haem-
catalytic center of NOS is mediated by a flavin mononucleotide (FMN)-prosthetic 
group located at the c-terminal tail of the enzyme [51]. 
 A total of three NOS isoforms has been identified to date – neuronal NOS (nNOS or 
NOS1), endothelial NOS (eNOS or NOS2) and inducible NOS (iNOS or NOS3). 
nNOS and eNOS are found pre-dominantly expressed in the neuronal and endothelial 
cells, respectively, in a constitutive manner [52]. iNOS, on the other hand, is 
inducible in a variety of tissues by stress signalling cues such as inflammatory 
cytokines endotoxins and oxidative stress [52]. However, expression of iNOS is not 
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always inducible, as it is constitutively present in the respiratory epithelial cells [53] 












When formed in biological fluids, about 20% of ONOO
- 
is protonated to 
peroxynitrous acid (ONOOH), a neutral molecule that could permeate lipid 
membranes. Both ONOO
- 
and ONOOH are extremely strong oxidants and nitrating 
agents. ONOO
-
, when formed in amounts that could overwhelm cellular antioxidant 
defences, is often associated with oxidative damage of various biological molecules 
[58]. Oxidative DNA strand breaks, deamination of DNA bases, lipid peroxidation 
and nitrative/oxidative protein damage are amongst the most common injuries 
inflicted by an overwhelming production of intracellular ONOO
- 
 [59-64]. 
While dogmatic view places ONOO
-
 as a major agent of detriment during period of 
oxidative distress, it is now beginning to be recognized that ONOO
- 
is not always 
damaging in nature. Mounting evidence suggests that ONOO
-
 could serve as 
important signalling molecules in various physiological pathways by means of post-
translational modification of biological proteins [58, 65-70]. One of the best 
described ONOO
-
-mediated protein modification is the S-nitrosylation of cysteine 
residues. Unlike NO, ONOO
-
-mediated S-nitrosylation of cysteinyl thiol group is well 
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characterized, involving a direct nucleophilic nitrosation of thiol group by ONOO
-
, 




-mediated S-nitrosylation of proteins is reversible, and often leads to the 
inactivation of target proteins [67, 70], though there are instances whereby S-
nitrosylation could stimulate the activation of enzymes as well [72].  
In addition to S-nitrosylation, ONOO
- 
could alter protein activity via the nitration of 
tyrosine residues as well. ONOO
-
-mediated tyrosine nitration is not a straight forward 
process, as it involves an initial transition metal-catalysed decomposition of 
ONOO
- 
to nitronium cation (NO2
+
) before an electrophilic attack of the electron-rich 
tyrosine aromatic ring could occur [73, 74]. The net reaction is the formation of 3-




 3-NT has been widely used as a biomarker of oxidative damage, the detection of 
which has often been perceived as a pathological indicator in various diseases [75]. It 
is not until recent decades that the role of tyrosine nitration in physiological signalling 
processes is being realized. The addition of an –NO2 group changes the chemistry as 
well as the steric profile of a tyrosine residue [74]. If relevant tyrosine residue(s) is 
nitrated, this could alter protein function and conformation, impose steric restrictions, 
and even inhibit tyrosine phosphorylation of the nitrated residue [66, 68, 74, 76-78]. 
12 
 
Therefore, it does not come as a surprise that ONOO
-
, when present at a moderate and 
non-damaging level, could act as a mediator of various biological processes. 
 
2 Cellular Antioxidant Defences  
2.1 Superoxide Dismutases 
The SODs are a family of enzymes responsible for the catalytic conversion of O2
-
 into 
H2O2. The catalytic activity of SODs involves a metal-containing catalytic center that 
serves to accelerate the disproportionation of two O2
-
 molecules into H2O2 and 
molecular oxygen [1, 79]. 
 
A total of three isozymes has been identified to date – SOD1 (CuZnSOD), SOD2 
(MnSOD), and SOD3 (ECSOD). SOD isozymes differ in their structure, subcellular 
distribution, as well as their metal-containing catalytic center. SOD1 is predominantly 
localized in the cytosol [80, 81], though there are some evidence demonstrating its 
presence in the mitochondrial intermembrane space as well [82, 83]. The enzyme 
utilizes a copper (II) ion (Cu
2+
)  for its catalytic dismutation of O2
- 





is required to stabilize the enzyme [1]. SOD2, on the other hand, is 
primarily localized to the mitochondrial matrix [81, 84] and its catalytic activity is 
driven by a manganese (III) ion (Mn
3+
). SOD3 or extracellular SOD (ECSOD) is 
essentially an SOD1 enzyme with a secretory leader sequence which allows it to be 
secreted out of the cell for the elimination of extracellular O2
- 
[85, 86].  
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While SODs are considered as part of the cellular antioxidant defences on account of 
their role in the eradication of O2
-
 from cellular systems, their catalytic activity could, 
ironically, lead to the potential formation of more noxious oxidants as well. H2O2, if 
left unattended, could be converted into extremely injurious molecules such as OH· 
(via Fenton chemistry; chapter 1.2.2). Therefore, a complete protection against O2
- 
could only be achieved if the rate of H2O2 removal matches, if not supersede, the 
activity of SODs. Fortunately, mammalian antioxidant defences is pillared by a large 
arsenal of antioxidant machineries capable of eradicating H2O2. 
 
2.2 Catalase 
Catalase is a haem-protein responsible for the neutralization of intracellular H2O2 [87, 
88]. It is widely expressed in most tissues, particularly in the liver. Like SOD, 
catalase catalyses a dismutation reaction, whereby one H2O2 molecule is reduced to 
H2O while another H2O2 molecule is simultaneously oxidized to form O2 in a single 
catalytic cycle [1].  
 
Notably, catalases are mostly confined in peroxisomes, with only some traces of the 
enzyme in the mitochondria and ER [5, 89]. Thus, the need for an additional defence 
mechanism against cytosolic and mitochondrial H2O2 is obvious; a task well managed 
by the gluthathione peroxidases (Gpx), the peroxiredoxins (Prx), as well as the 




2.3 Gluthathione Peroxidases 
Gpx are a family of selenium-containing enzymes that is widely expressed across 
various tissues. They catalyse the neutralization of H2O2 into innocuous H2O 
molecules by coupling the reduction of H2O2 to the oxidation of reduced gluthathione 
(GSH) [1, 90, 91].  
 
 
GSH, a thiol-containing tripeptide (Glu-Cys-Gly), is therefore a critical hydrogen 
donator in this reaction.  
Subsequent regeneration of GSH is achieved by the enzyme gluthathione reductase, 
which catalyses the reduction of oxidized gluthathione (GSSG) back into its reduced 
form by employing NADPH as the proton donor [1, 90, 91].  
 
 
Of note, GSH by itself, serves also as an important antioxidant. The thiol-containing 
tripeptide could rapidly react with a wide variety of reactive species, including 
ONOO
-
 and OH·, scavenging these deleterious molecules even in the absence of any 
enzymatic influences [90, 91]. Thus, the role of gluthatione reductase in maintaining 




2.4 Peroxiredoxins and Thioredoxins  
Prx belongs to a family of peroxidase enzymes involved in the enzymatic degradation 
of H2O2, organic hydroperoxides, and ONOO
-
 [93, 94]. They are ubiquitously 
expressed in the cytosol of most tissues, while some isoforms are also found in the 
mitochondria as well [95, 96]. Members from the Prx family contains cysteinyl-thiol 
groups (cys-SH) in their respective active site for the catalytic reduction of various 
peroxides whilst being oxidized to either cysteine sulphonic acid (cys-SOH) or 
disulphide groups (cys-S-S-cys) [95, 96]. The regeneration of catalytically active Prx 
from oxidized Prx is accomplished by the thioredoxins (Trx) oxido-reductase system, 
another family of redox proteins that is equally dependent on cys-SH groups for their 
catalytic activity [97]. Thus, Prxs are also known as thioredoxin-dependent 
peroxidase enzymes.  
The Trxs contains two cys-SH groups that would be equally oxidized to disulphide 
group upon its catalytic activation of Prx [98, 99]. Regeneration of reduced Trx is 
subsequently achieved by the thioredoxin reductase (TR) which contains an flavin 
adenine dinucleotide (FAD) prosthetic group to draw its hydrogen atom from 
NADPH [98, 99]. Together, the Prxs and Trxs form a redox cycle that serve to 
neutralize various peroxides and oxidants by utilizing NADPH as the ultimate proton 




Figure A: Peroxides reduction by the peroxiredoxin-thioredoxin redox-cycle.  
Prx: peroxiredoxin, Trx: thioredoxin, TR: thioredoxin reductase, FAD: flavin adenine dinucleotide, 
NADP
+
: Nicotinamide adenine dinucleotide phosphate. Figure adapted from Chae et. al. [99].  
16 
 
3 Apoptotic Cell Death 
Apoptotic cell death, or apoptosis, is a genetically pre-determined cellular suicidal 
program employed by multicellular organisms for the clearance of unwanted cells 
that may be damaged, redundant, ectopic, or even those that are potentially 
dangerous. The term apoptosis was first coined by Kerr et al. to describe a common 
cell death mechanism that appears to be pre-programmed, and shared by many tissues 
as well as cell types [100]. The morphological features described, which now serve as 
the hallmarks of apoptosis, are nuclear condensation and fragmentation, cellular 
shrinkage, and blebbing of cellular membranes [100, 101]. Eventually, these events 
are followed by the formation of apoptotic bodies (membrane bound cellular 
fragments) which will be removed by phagocytic cells [100, 101]. Via apoptosis, 
cellular contents from unwanted cells could thus be rapidly assimilated and recycled 
for other cellular processes.   
A delicate balance between cell proliferation and cell death is essential for the 
homeostatic regulation of cell numbers and tissue size, as well as the normal 
development of various organs; apoptosis is especially pivotal to these processes. 
During foetal development for instance, apoptosis is responsible for the shaping of 
inter-digit spaces for the proper formation of fingers [102]. Apoptosis is also required 
for the ablation of self-recognising immune cells in maturing lymphoid organs [103]. 
Importantly, the eradication of pathogen-infected cells or mutated rogue cells also 
necessitates the service of the apoptotic cell death machinery, deregulation of which 
would result in the development of various pathological conditions, including cancer. 
Evasion of apoptosis, as a matter of fact, is one of the most salient phenotype 
exhibited by malignant tumours [104, 105].  
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3.1 Caspases – the mastermind of apoptosis 
Apoptosis is a highly regulated process involving an intricate network of signalling 
events well-coordinated for the death execution of cells. The signalling pathways en 
route to the execution of apoptosis is highly dependent on the type of death trigger. 
However, irrespective of the death cues or pathways involved, apoptotic signalling 
would ultimately converge into the activation of a highly conserved family of 
proteases known as the caspases.  
The term “C-asp-ase” originates from the ability of these proteases to cleave peptide 
bonds after an aspartate residue as well as their common possession of a cysteine-
containing active site [106]. A total of 13 caspase isoforms have been identified in 
humans, seven of which (caspase-2, -3, -6, -7, -8, -9, and -10) are known to be 
involved in apoptosis [107]. The other caspases are either involved in the regulation 
of inflammatory responses (caspase-1, -4 and -5), or have yet been functionally 
characterized (caspase-11, -12, -13) [107]. The apoptotic caspases can be further 
categorized as the initiator caspases (caspase-2, -8, -9, and -10) or the effector 
caspases (caspase-3, -6, -7) based on their respective functional contribution to the 
apoptotic pathway [107]. 
Notwithstanding their role as proteases, activation of caspases does not lead to the 
indiscriminatory degradation of proteins. Rather, each caspase member cleaves only a 
specific set of target proteins based on the recognition of the sequence flanking the 
targeted Asp-X peptide bond [108]. The number of caspase substrates is advancing 
towards 1000 to date [109]. While a significant portion of these substrates may not be 
functionally relevant to the apoptotic pathway, the proteolytic activities of caspases 
are nonetheless the main drivers of apoptosis. For instance, caspase-mediated 
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cleavage of the nuclear lamin is responsible for nuclear shrinkage and budding [110, 
111], while the cleavage of ICAD, an inhibitor of caspase-activated DNAse (CAD), 
by the executioner caspase-3, activates the DNAse activity of CAD for the cleavage 
and fragmentation of DNA during apoptosis [112].  
All caspases are initially expressed as inactive zymogen (procaspase) which will only 
be proteolytically processed into their respective mature form during apoptosis [108]. 
Activation of procaspases could proceed via several mechanisms, depending on the 
type of apoptotic cues as well as the caspase isoform(s) involved. Two major 
signalling pathways have been identified for the activation of caspases (and hence 
apoptosis) to date. They are namely, the extrinsic or death receptor pathway, and the 
intrinsic or mitochondrial pathway (Figure B).  
 
3.2 Extrinsic pathway 
The extrinsic apoptotic pathway is responsible for the transmission of extracellular 
apoptotic cues into intracellular molecular circuitry for death execution. Also known 
as the death receptor pathway, the extrinsic pathway is initiated by ligand binding of 
death receptors at the cell surface. Cell surface death receptors are members from the 
tumour necrosis factor (TNF) receptor family. Examples of death receptors and its 
corresponding ligand include CD95/APO-1 (FasR/FasL), DR3/Apo3L, DR4/TRAIL-
R1, DR5/TRAIL-R2, and TNFR1/TNFα [113].  
Ligand binding results in the clustering of death receptors and the recruitment of 
adaptor proteins at the cytoplasmic end of the death receptor, and the type of adaptor 
protein(s) being recruited is determined by the cytoplasmic domain of the death 
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receptors [113-115]. For instance, Fas-associated death domain (FADD) is recruited 
to oligomerized FasR upon FasL ligation [114]. Binding of the adaptor proteins to the 
death receptors marks the formation of the death inducing signalling complex (DISC), 
a multiprotein complex required for the multiple recruitment of procaspase-8, which 
in turn allows for their mutual cleavage and self-activation [116]. Upon caspase-8 
activation, the signalling pathway(s) that ensues depends on whether the activation of 
caspase-8 is sufficiently robust for the direct cleavage and activation of executioner 
caspases (type I cells), or, if insufficiently strong, caspase-8 may engage the intrinsic 
apoptotic machinery for the complete execution of death signals (type II cells) [117]. 
The latter scenario involves the cleavage of Bid, a pro-apoptotic member of the B cell 
lymphoma-2 (Bcl-2) family proteins, by activated caspase-8. Truncated Bid (t-Bid) 
then translocate to the mitochondria for the initiation of the intrinsic apoptotic 
pathway [118].  
 
3.3 Intrinsic pathway 
The intrinsic apoptotic pathway is initiated in response to a vast array of non-
receptor-mediated stimuli such as DNA damage, cytotoxic agents, growth factor 
withdrawal, UV radiation and oxidative stress, among others. Irrespective of death 
trigger, however, the intrinsic pathway would ultimately involve the permeabilization 
of mitochondrial outer membrane (MOMP) as the decisive event for death execution 
[119].  
The mitochondria, apart from their role as cellular powerhouses, serve also as 
confinement spaces for a variety of death regulatory proteins. The electron shuttling 
protein, cytochrome c, is the most prominent amongst all. Upon activation of the 
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intrinsic pathway, MOMP results in the release of cytochrome c (and other death-
inducing factors as well) from the mitochondria intermembrane space (IMS) into the 
cytosol [120, 121]. Cytosolic cytochrome c would then bind and stimulate the 
oligomerization of apoptotic protease activating factor-1 (Apaf-1), forming a 
multiprotein platform which allows for the recruitment of procaspase-9 in an ATP-
dependent manner [121]. The assembly of cytochrome c, Apaf-1, ATP, and 
procaspase-9 constitute the core component of a crucial apoptotic complex termed the 
apoptosome [122]. Unlike the other caspases, proteolytic cleavage of procaspase-9 is 
not obligatory for its activation, for the sole recruitment of procaspase-9 into the 
apoptosome is reportedly sufficient for the allosteric activation of caspase-9 [123]. 
Once activated, capsase-9 could then kick start a caspase-mediated proteolytic 
cascade by cleaving the executioner caspases (caspase-3 in particular), eventually 
leading to the cleavage of substrates that elicit the apoptotic phenotype. In addition to 
cytochrome c, other pro-apoptotic proteins released from the IMS includes 
Smac/DIABLO and HtrA2/Omi, both of which are shown to antagonize a family of 
caspase inhibitory proteins known as the inhibitors of apoptosis proteins (IAP) [124, 
125].  
Whereas caspases are the main apoptotic drivers downstream of MOMP, the Bcl-2 
family proteins, in contrast, govern apoptotic signalling upstream of the 
mitochondria. Members from the Bcl-2 family can be functionally categorized as 
either pro-apoptotic or anti-apoptotic members [126-128]. How exactly Bcl-2 and its 
cousins regulate MOMP is not entirely clear, though it is generally thought that a 
constant state of mutual antagonism exists between the pro- and anti-apoptotic Bcl-2 
members, and the party that edged out from this biological tug of war would hold the 
last say on the integrity of the outer mitochondria membrane (OMM). Several 
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mechanisms have been proposed regarding the complex interplay amongst Bcl-2 
protein members which could perturb the integrity of OMM, though none of them has 
been proven definitively [126-128]. These hypotheses would be described in further 












Figure B: Extrinsic and intrinsic apoptotic pathways.  
The extrinsic pathway is exemplified here by the stimulation of CD95 death receptor by CD95L. This 
resulted in the formation of DISC and the autocatalytic activation of caspase-8. There are two ways 
caspase-8 could mediate apoptosis, either by direct proteolytic activation of caspase-3, or via the 
cleavage of Bid. Truncated Bid could then translocate to the mitochondria for the induction of MOMP. 
The intrinsic pathway on the other hand, is tightly regulated by the Bcl-2 family members. Upon the 
induction of MOMP, cytochrome C is released from the IMS where it forms the apoptosome together 
with Apaf-1 and procaspase-9. This brings about the activation of caspase-9 as well as the downstream 





3.4 The anti-apoptotic B Cell Lymphoma-2 protein 
Bcl-2, as its name implies, was first discovered in follicular B cell lymphomas as a 
translocated gene at the t(14,18) chromosomal breakpoint, fusing it with the 
immunoglobulin heavy-chain promoter and rendering the gene constitutively 
hyperexpressed in these tumours [129]. Bcl-2 is primarily found in the mitochondria 
where it functions to preserve the integrity of the OMM [130]. There are, however, 
some reports demonstrating its residence in the nuclear envelope and the ER as well 
[131].  
Structurally, Bcl-2 comprises two central hydrophobic α-helices, surrounded by six 
amphipatic α-helices of varying length [132, 133]. This tertiary structure could be 
further classified into four functional domains termed the Bcl-2 homology (BH) 
domains (Figure C). BH1, BH2 and BH3 domains form a hydrophobic groove which 
allows for the heterodimerization of Bcl-2 with other pro-apoptotic Bcl-2 members 
[133]. BH4 on the other hand, serves to stabilize the BH1-BH3 hydrophobic regions 
[133]. BH3 and BH4 domains are bridged by a long unstructured loop that is 
amenable to post-translational modifications (phosphorylation in particular), 
providing an additional avenue for more refined modulation of Bcl-2 anti-apoptotic 
activity [134-137].  
Despite its antagonizing role on the intrinsic apoptotic machinery, hyperexpression of 
Bcl-2 on its own is not tumorigenic, for retroviral transduction of the oncoprotein into 
murine bone marrow cells could only protect against apoptotic death triggers but does 
not promote malignant growth and proliferation [138]. Bcl-2, however, could 
synergize with other oncoproteins to promote carcinogenesis. For instance, Bcl-2, 
when co-expressed with c-myc in double transgenic mice models (Eμ-myc/Bcl-2), 
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greatly enhanced lymphomagenesis by promoting the survival of cells against 
apoptotic onslaught in response to dysregulated c-myc expression [139]. While Bcl-2 
is known to protect the integrity of OMM, how exactly Bcl-2 and its relatives 
modulates MOMP and the intrinsic apoptotic pathway is still uncertain. Several 













Figure C: Three-dimensional structure of Bcl-2. The anti-apoptotic Bcl-2 protein contains four BH 
domains: BH1 (red), BH2 (purple), BH3 (yellow) and BH4 (blue). BH3 and BH4 are adjoined by an 
unstructured loop, also known as the flexible loop domain (FLD), which is susceptible to 




3.4.1  Regulation of MOMP by the Bcl-2 family proteins 
Bcl-2 works hand in hand with its relatives in regulating MOMP and the intrinsic cell 
death machinery. Anti-apoptotic Bcl-2 members (Bcl-2, Bcl-Xl, Mcl-1, Bcl-A1 and 
Bcl-w) serve to preserve mitochondria integrity via the sequestration of pro-apoptotic 
Bcl-2 members. They contain all four BH domains (BH1-4) and are predominantly 
embedded in the OMM [141]. The pro-apoptotic Bcl-2 members, on the other hand, 
can be subdivided into the BH3-only members (Bid, Bim, Bad, Bik, BMF, HRK, 
Noxa and Puma) and the BH1-3-containing members (Bak and Bax) [141]. The latter, 
when activated, serve as effector molecules that could form homo-oligomeric pores at 
the OMM to elicit MOMP [142]. The BH3-only proteins promote MOMP by 
activating Bax/Bak, but how they exert their influence over the effector proteins is 
where the conundrum lies. 
Several distinct mechanisms have been proposed to explain how BH3-only proteins 
control the interplay between the Bax/Bak and the anti-apoptotic Bcl-2 members. It 
was first suggested that BH3-only members could directly bind to and promote the 
oligomerization of Bax/Bak, with evidence demonstrating that at least two BH3-only 
members, Bid and Bad, evoke MOMP via this pathway [143-145]. Subsequent 
studies, however, contrastingly showed that BH3-only proteins act as sensitizers, 
instead of direct activators, by binding anti-apoptotic Bcl-2 members and releasing 
Bax/Bak for MOMP execution [146]. While it was suggested the sensitizers could in 
fact be eliciting MOMP by displacing the direct activators from anti-apoptotic Bcl-2 
members [141], attempts into integrating these two hypotheses were rendered nought 
when successive studies demonstrated that the sensitizers and the direct activators 
could effectuate intrinsic apoptotic cell death in the absence of one another [145, 147, 
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148]. Although the mechanism(s) underlying Bax/Bak activation remains elusive, it is 
clear, at the very least, that Bax/Bak are indispensable in death execution involving 
the BH3-only proteins [149], while Bcl-2 and its anti-apoptotic relatives oppose this 
pathway. 
 
3.4.2  Phosphoregulation of anti-apoptotic Bcl-2 
Protein phosphorylation is a fundamental mechanism in the regulation of cellular 
signalling processes. Reversible phosphorylation at serine, tyrosine, and threonine 
residues in particular, provides an additional dimension to the control of protein-
protein interactions, protein conformations, and their functional activities. Likewise, 
the anti-apoptotic Bcl-2 protein is not exempted from the regulatory influence of 
various cellular kinases and phosphatases as well. 
There are four known phosphorylation sites on Bcl-2 – Thr56, Thr69, Ser70 and 
Ser87 [136, 137, 150-152], though most attention have been accorded to the three 
residues (T69, S70 and S87) located on the FLD domain owing to their direct 
influence on the anti-apoptotic function of Bcl-2 [136, 137, 150, 151]. A vast array of 
kinases have been implicated in the phosphorylation of Bcl-2, the most prominent 
being the three MAP kinases – JNK, ERK and p38 [151, 153-158], while several 
other kinases such as protein kinase C (PKC) [159], protein kinase B (PKB/Akt) 
[160], cyclin dependent kinase 1 (Cdk1) [161] and Src kinase [162] may 
phosphorylate Bcl-2 as well. Protein phosphatase 2A (PP2A) and protein phosphatase 
1 (PP1), on the other hand, are the main Bcl-2 phosphatases known to antagonize 
these kinases [163-165].  
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The functional consequence(s) of Bcl-2 phosphorylation is debatable. In support of a 
pro-apoptotic effect, hyperphosphorylation of Bcl-2 at the FLD residues (T69, S70 
and S87) by JNK1 is invariably reported to inactivate Bcl-2 in a taxol (a microtubule 
binding agent)-dependent manner [151, 166, 167]. However, contradicting these 
reports, PKC and ERK1/2-mediated multisite phosphorylation of Bcl-2 at exactly the 
same residues have also been shown to enhance the anti-apoptotic properties of Bcl-2 
[159], while the expression of multisite phosphomimetic Bcl-2 mutants (by mutating 
the phosphorylatable residues to glutamate residues; T69E, S70E, S87E) produced 
similar protective effect as well [136, 168]. The downstream mechanisms suggested 
by these studies were equally confusing. On one hand, JNK1-mediated Bcl-2 
phosphorylation was shown to trigger the dissociation of Bax from Bcl-2 upon taxol 
treatment [169], but on the other, ERK1/2-stimulated Bcl-2 phosphorylation stabilizes 
the heterodimerization of Bcl-2 with Bax [158].  
While it is difficult to pinpoint the role of hyperphosphorylated Bcl-2 in cell fate 
processes, there appears to be a better consensus regarding the effect of monosite 
(S70) phosphorylation of Bcl-2 on cellular regulation of apoptotic response. 
Irrespective of stimuli, S70 phosphorylation of Bcl-2 appears to endow tumour cells 
with greater resistance against cytotoxic agents. Growth factors such as IL-3 and 
erythropoietin, or the PKC-modulator, bryostatin, have all been demonstrated to 
protect against etoposide-induced cell death in IL-dependent myeloid cells by 
stimulating the phosphorylation of Bcl-2 at S70 [137]. Nicotine-dependent activation 
of ERK1/2 was also shown to promote chemoresistance by phosphorylating Bcl-2 
exclusively at S70 [170]. In addition, inhibition of PP2A either by okadaic acid or by 
polyamine depletion resulted in the specific accumulation of S70 phosphorylated Bcl-
2 (S70 pBcl-2) which in turn abrogated TNF-α-induced apoptosis in intestinal 
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epithelial cells [171]. Conversely, the potent PP2A activator, ceramide, induces cell 
death by stimulating the dephosphorylation of Bcl-2 at S70 [164]. It was based on 
these studies that S70 is proposed as the key functional activation site of Bcl-2, while 
the two adjacent phosphorylatable residues provides further avenue for more refined 
modulation of Bcl-2 in a context-dependent manner [172]. Congruent to this 
hypothesis, S70E phosphomimetic Bcl-2 mutant with adjacent residues mutated to 
non-phosphorylatable alanine residues (T69A, S70E, S87A) completely abrogated the 
death-inducing activity of taxol [136], a microtubule-damaging agent previously 
shown to elicit cell death via hyperphosphorylation of Bcl-2 [151, 173], implying that 
phosphorylation of T69 and S87 is key to taxol-induced cell death while 
phosphorylation of S70 alone counters it.  
 
 
4 ROS and the apoptotic cell death machinery 
While ROS are conventionally perceived as toxic agents, there is now growing 
appreciation on the role of ROS as important signalling molecules in various cellular 
processes. Contemporary research has implicated ROS in a plethora of physiological 
pathways including, but not limited to, the regulation of glucose metabolism, cellular 
motility and migration, cellular proliferation and differentiation, cellular immune 
response, and even vascular remodelling processes [32, 174-179]. In addition, ROS is 
also known to be the culprit of a variety of pathological conditions, with Alzheimer 
disease, diabetes mellitus, atherosclerosis and cancer among those diseases being 
associated with a dysregulated production of intracellular ROS [140, 179-184]. 
28 
 
In the context of carcinogenesis, numerous tumorigenic pathways are known to be 
under the governance of ROS as well. For instance, NOX-derived ROS has been 
implicated not only in vascular endothelial growth factor (VEGF)-driven angiogenic 
processes [185], but also in epithelial-mesenchymal transition and metastasis of 
tumour cells [186]. In addition, mitochondrial ROS has also been described as a 
modulator of various cellular demise pathways such as the autophagic cell death 
machinery [187]. Nevertheless, one of the best characterized roles of ROS in the 
process of carcinogenesis remains its regulatory influence on the apoptotic cell death 
machinery. 
 
4.1 ROS as biphasic regulators of apoptosis 
The modulatory role of ROS in cell fate decisions is highly dependent on the dose as 
well as species of ROS involved. Excessive, uncontrolled production of ROS leads to 
cellular necrosis as a result of indiscriminatory oxidative damage of essential 
biological molecules such as nucleic acids, lipids and proteins [188-190]. A 
moderately high amount of intracellular ROS, on the other hand, was shown to trigger 
apoptosis via selective oxidation (and activation) of death-regulatory molecules [188-
190].  
Such differential effects of ROS are best exemplified by experiments demonstrating 
that H2O2, when directly added into cells at low μM range (10-100 μM), induced 
apoptosis, whereas doses of H2O2 beyond 500 μM resulted pre-dominantly in necrotic 
cell death [188-190]. Several molecular players have been implicated in H2O2-
induced apoptosis, amongst which is the pro-apoptotic Bcl-2 family member, Bax. 
Mitochondrial translocation of Bax and cytochrome c release was clearly detected 
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upon an elevation of intracellular H2O2, indicating that H2O2 could evoke death 
response by engaging the intrinsic apoptotic machinery [191]. Alternatively, H2O2 
could also promote the activation of JNK, which in turn triggers MOMP and the 
egress of cytochrome c via the inactivation of anti-apoptotic Bcl-2 members such as 
Bcl-2, Bcl-Xl and Mcl-1 [192, 193].  
ROS, however, is not solely pro-death. Contrary to the dogmatic view of ROS as 
damaging agents, emerging studies suggests that a mild pro-oxidant state (low level 
of ROS) is conducive for survival and proliferative signalling [194-198]. In this 
regards, non-toxic level of NOX-derived ROS has been shown to promote tumour 
survival and proliferation by positively regulating the PI3-kinase/Akt pathway and its 
downstream effectors such as the oncogenic transcription factor β-catenin as well as 
the anti-apoptotic Mcl-1 protein [194]. Also, oxidative inactivation of the tumour 
suppressor PTEN (a negative regulator of the PI3-K/Akt pathway) has also been 
implicated in survival signalling by ROS [195]. Notably, low level of ROS could also 
elicit proliferative response by activating growth-related genes such as c-fos and c-
myc [196]. Thus, cell fate signalling is extremely sensitive to intracellular level of 
ROS, with lower concentrations clearly serving as growth/survival signals.  
Research over recent years has progressed further into delineating the precise reactive 
species involved in these death regulatory pathways. To that end, studies have shown 
that redox-regulation of cell fate signalling is highly dependent on the critical balance 
between the two major oxygen species, O2
- 
and H2O2 [191, 198-202]. A tilt in redox 
equilibrium towards the accumulation of intracellular H2O2 sensitizes tumour cells 
towards apoptotic stimuli [191, 203, 204], whereas an intracellular redox milieu 
dominated by O2
- 
promotes survival signalling (Figure D) [179, 198-200]. 
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Corroborating this is the observation that an enhanced conversion of O2
- 
to H2O2 via 
SOD1 overexpression suppresses tumour growth and sensitizes tumour cells towards 
drug-induced apoptosis [198, 205, 206], while conversely, pharmacological inhibition 
or genetic knockdown of SOD1 abetted tumour chemoresistance, irrespective of 
death triggers [198, 199]. In another model of viral-induced apoptosis, elevated levels 
of intracellular O2
- 
was found to serve as survival signals while strategies to reduce 
O2
- 
assisted death execution [207]. From these evidence, O2
- 
is clearly oncogenic 
whereas the converse is true with high levels of H2O2. 
Figure D: The role of ROS in oncogenesis. Under normal homeostatic conditions, a healthy balance 
between the two major ROS, O2
- 
and H2O2 exists. Such balance is controlled by an array of antioxidant 
enzymes, deregulation of which could potentially affect cell fate decisions. In cancer cells with 
defective SOD enzymes, redox equilibrium is tilted in favour of O2
-
, thus endorsing a more recalcitrant 
phenotype. On the contrary, a tilt in favour of H2O2 generates a milieu that favours apoptotic signalling. 
For these reasons, O2
- 
was proposed as an onco-ROS while H2O2 as an onco-suppressor-ROS. Figure 





4.2 Oncogene-mediated pro-oxidant state – Bcl-2 as a prime example 
Thus far, most evidence implicating O2
-
 as a survival factor were either garnered via 
genetic manipulation of antioxidant enzymes or via the introduction of 
pharmacological compounds. However, recent evidence suggests that certain 
oncogenes could also exert their tumorigenic authority by promoting the 
accumulation of intracellular O2
-
. For instance, the secretory protein angiopoietin-like 
4 (ANGPTL4) was shown to promote a high intracellular O2
-
:H2O2 ratio by activating 
NOX in an autocrine manner [202]. This in turn triggered the PI3K/Akt and ERK1/2 
survival pathways and rendered tumours refractory to anchorage-dependent cell death 
[202].  
Similarly, the anti-apopototic Bcl-2 protein was also demonstrated to confer tumour 
chemoresistance by augmenting the level of intracellular O2
-
 [200].  In addition to its 
canonical role in preserving OMM integrity, Bcl-2 was found to be reliant on a O2
-
-
dominated pro-oxidant state for its anti-apoptotic phenotype. Scavenging of O2
- 
abrogated the pro-survival function of Bcl-2 and sensitizes tumours towards drug-
induced apoptosis, indicating that O2
- 
is crucial for Bcl-2-induced chemoresistance 
[200]. Subsequent studies showed that the pro-oxidant milieu in Bcl-2 overexpressing 
tumour cells stems from the ability of Bcl-2 to promote mitochondria O2
- 
production 
by engaging the mitochondrial electron transport machineries [208].  
Interestingly, a protein-protein interaction was detected between Bcl-2 and the Vα 
subunit of mitochondria complex IV, and this was reportedly the central mechanism 
in which Bcl-2 drives respiration-dependent O2
- 
production [209]. Intriguingly, Bcl-2 
itself appears to be redox sensitive, for the oncoprotein was also shown to be capable 
of adjusting mitochondrial O2
- 
production in response to fluctuations in intracellular 
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redox status, ensuring that intracellular O2
- 
is confined within a range conducive for 
survival [208, 209]. However, little has been reported regarding the cellular target(s) 
of O2
- 
which mediates its pro-survival properties.  
Indeed, despite its current well-recognized role as a death-inhibitory signal, how O2
- 
exercises its anti-apoptotic authority remains an unanswered question, not only in the 
context of Bcl-2-induced chemoresistance but also in other survival pathways 
mediated by O2
-
. The search of a direct cellular target of O2
- 
has proven to be 
daunting, particularly when O2
- 
anions rarely, if at all, reacts with biological 
molecules [1]. While it is plausible that O2
- 
signal for survival via an alternative 
reactive species such as ONOO
-
 (Chapter 1.1), this remains a conjecture and further 
investigation would be necessary to validate such postulations.  Considering the 
pivotal role of O2
-
 in mediating tumour survival, future elucidation of how O2
- 




5 Protein Phosphatase 2A 
PP2A is a ubiquitously expressed serine/threonine phosphatase that is integral to a 
plethora of cellular signalling pathways. The enzyme functions as a heterotrimeric 
complex comprising an enzymatic core, formed by the catalytic subunit (PP2A-C) 
and the scaffolding subunit (PP2A-A/PR65), which is recruited to its substrate by a 
diverse set of B regulatory subunits [210-212]. In contrast to its counterpart of 400 
over kinases, only two isoforms (α and β) with fairly broad range of substrate 
specificity have been reported for each member of the PP2A catalytic core (Figure E) 
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[213, 214]. Enzymatic specificity of PP2A holoenzyme is therefore endowed by the 
wide variety of PP2A-B regulatory subunits which serve to recruit and target the 
catalytic core to its specific substrate. Moreover, the B regulatory subunits also 
dictate the subcellular distribution of the heterotrimeric holoenzyme [210, 212, 215].  
The human genome encodes for at least 15 regulatory subunits of PP2A that could be 
further divided into four regulatory families – B/B55/PR55, B’/B56/PR61, B”/PR72, 
and B”’/PR93/PR110 (Figure E) [212, 216]. Numerous members of these B 
regulatory families could be further spliced into a variety of transcript variants, with a 
total of 26 isoforms being identified to date [212]. Thus, this provides the avenue for 
a huge diversity of heterotrimeric complexes that could be possibly assembled from 
the A, B and C PP2A subunits. In addition, there is a differential expression of PP2A 
regulatory subunits in different tissues at different developmental phases, thereby 
allowing for a dynamic combination of heterotrimeric PP2A complexes with distinct 
roles during the course of development [210, 215, 217, 218].  
PP2A is an essential phosphatase in numerous cellular processes and the deletion of 
PP2A-Cα gene is embryonic lethal in mice [219, 220]. Physiological processes 
involving PP2A include, but not limited to, the regulation of cell cycle progression, 
cytoskeleton dynamics and cellular motility, as well as the development of various 
tissues and organs [221-224]. Importantly, PP2A is also well recognized for its 










Figure E: Schematic overview of PP2A holoenzyme.  
The PP2A holoenzyme is a heterotrimer consisting of an A scaffolding subunit (PR65/PP2A-A), a 
catalytic subunit (PP2A-C) and a B regulatory subunit. PP2A-A and PP2A-C forms the catalytic core 
and each has two isoforms (α or β), with α isoform being the pre-dominant isoform for both subunits. 
The B regulatory subunits on the other hand, can be divided into four families - B/B55/PR55, 
B’/B56/PR61, B”/PR72, and B”’/PR93/PR110, with each family comprising of more than three 
regulatory members. B’/B56 family for instance, comprises at least eight members, with B56α, B56β, 
B56γ1, B56γ2, B56γ3, B56δ, and B56ε being the most notable members [215]. The B regulatory 
subunits serve to recruit the AC core to its substrate, while the A scaffolding subunit mediates the 
assembly of the B and C subunit. The catalytic subunit is responsible for the removal of phosphate 
group from its substrate as depicted in the figure. 
 
5.1 The tumour suppressive role of PP2A 
PP2A was first casted into the limelight as a potential tumor suppressor when okadaic 
acid, a selective inhibitor of PP2A, was found to abet carcinogen-induced 
tumorigenesis in mice models [225]. Subsequently, it was reported that polyoma 
middle T and Simian Virus 40 (SV40) small T antigen-induced carcinogenesis is 
contributed, at least in part, by their respective ability to displace certain B subunits 
from the AC catalytic core of PP2A [226, 227]. In further support of a tumour 
suppressive role, extensive sequencing of human tumor samples revealed a high 
incidence of mutations and loss of heterozygosity (LOH) in the PR65β (PP2A-A) 
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gene while inactivating mutations has also been reported, albeit at a lower frequency, 
in the PR65α scaffolding subunit as well [228-231]. 
PP2A has also been implicated in the suppression of numerous oncogenes as well as 
the potentiation of its fellow tumour suppressors. Amongst the most notable targets of 
PP2A is the proto-oncoprotein c-myc [232]. C-myc is a transcription factor for a large 
array of mitogenic factors and its deregulation is frequently associated with neoplastic 
transformation of cells [233, 234]. Phosphorylation of c-myc at Ser62 stabilizes the 
oncoprotein and this is opposed by B56α-containing PP2A enzyme (PP2AB56α). Thus, 
PP2AB56α is a potent suppressor of c-myc-mediated mitogenic events. 
Besides c-myc, another prominent target of PP2A is the tumour suppressor 
retinoblastoma protein (pRb) [235]. pRb is a principle checkpoint protein involved in 
the regulation of cell cycle progression [236, 237]. It binds and suppresses 
transcription factors (such as E2F) that modulates the expression of proteins involved 
in cell cycle progression and proliferation [236, 237]. Phosphorylation of pRb by 
cyclin-dependent kinases (CDKs) dislodge pRb from its mitogenic interacting 
partner, thereby promoting cell cycle progression and cellular proliferation  [236, 
237]. Thus, to prevent the uncontrolled proliferation of cells, pRb needs to be 
reactivated (via dephosphorylation at T826) and this task is assumed by PP2A 
complexes harbouring the PR70 (a member of B” family) regulatory subunit [235]. 




5.2 PP2A and the apoptotic cell death machinery 
Many of the oncoproteins/tumour suppressors under the governance of PP2A are 
pivotal components of the apoptotic cell death machinery, and the B56 family 
members are among the most frequently implicated in regulating these death 
regulatory proteins [212]. For example, PP2AB56γ1 plays an integral role in the 
regulation of p53-dependent apoptotic execution [238]. p53 is a potent tumour 
suppressor renowned for its regulatory role in the cell cycle and apoptosis.  
PP2AB56γ1-mediated dephosphorylation of p53 at thr55 was reported to enhance the 
stability of p53 in response to DNA damage by impeding ubiquitin-mediated 
proteasomal degradation of the tumour suppressor [238]. This in turn results in the 
accumulation of p53 and the expression of its downstream pro-apoptotic targets such 
as Puma, Noxa and Bax [238], thereby inducing apoptosis.  
The extracellular signal-regulated kinases (ERK) are known targets of PP2AB56γ1 as 
well [239]. Both isoforms, ERK1 and ERK2, are integral components of the MAP 
kinase cascade, a signalling pathway most notable for its positive regulatory role on 
cellular proliferation and survival [240]. Activation of ERK1/2 necessitates their 
respective phosphorylation at thr202/tyr204 [239], which is in turn antagonized by 
PP2AB56γ1, thereby suppressing the mitogenic and survival effect of ERK1/2 in 
response to external growth factors [239]. Interestingly, there are evidence 
demonstrating that ERK1/2 could also be activated by ROS through the oxidative 
inhibition of PP2A, indicating the potential involvement of ROS in PP2A-mediated 
signalling pathways [241, 242].  
Another prominent target of PP2A that is involved in apoptotic signalling is the anti-
apoptotic Bcl-2 protein [164, 171]. Bcl-2 was first identified as a potential target of 
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PP2A when ceramide, a potent activator of PP2A, was found to trigger apoptosis by 
inducing the dephosphorylation (and hence inactivation) of Bcl-2 specifically at S70 
[164]. This was also supported by work demonstrating that okadaic acid, a selective 
inhibitor of PP2A, inhibited TNF-α-induced apoptosis in intestinal cells by increasing 
the levels of activated S70 pBcl-2 [171]. Subsequent studies showed that ceramide 
treatment promoted mitochondrial translocation of B56α and importantly, co-
immunoprecipitation assay identified a direct association between Bcl-2 and B56α 
[243]. Together, these findings suggest a direct role of PP2AB56α in the regulation of 
the mitochondrial apoptotic pathway.  
In general, PP2A is a major driver of the apoptotic cell death machinery.  
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6 Aims and Objectives  
As outlined in the preceding chapters, O2
-
 has been widely reported to be a survival 
signal, particularly in a redox environment with an elevated O2
-
:H2O2 ratio [179, 198, 
199, 202]. However, the exact mechanism(s) in which O2
- 
mediates survival 
signalling is still enigmatic. In light of numerous reports describing that both Bcl-2 
and its kinases/phosphatases are potentially redox responsive (chapter 4.2) [241, 244-
249], and also the fact that Bcl-2 phosphorylation at its FLD could alter its anti-
apoptotic activity (chapter 3.4.2), we asked the question whether the pro-survival 
properties of O2
- 
could be mediated by a redox-based regulation of Bcl-2 
phosphorylation which enhances its anti-apoptotic function.  
To that end, we aimed to first:  
 determine if O2
- 
generated by either pharmacological inhibition or genetic 
knockdown of SOD1could promote chemoresistance by modulating the level 
of phosphorylated Bcl-2, and if so, 
 investigate the molecular mechanism(s) underlying this phenomenon. 
With respect to the latter objective, we have subsequently identified the enzyme 
PP2A as an integral part of O2
-
-mediated survival pathways and moving forward from 
these findings, we sought to further: 
 elucidate the exact PP2A B regulatory subunit(s) involved in O2
-
-dependent 
signalling processes, and lastly, 
 elucidate how this subunit(s), together with its catalytic core, can be 
regulated by O2
- 




MATERIALS AND METHODS 
 
1 Cell lines and cell culture 
MDA-MB-231 breast cancer cell lines and Jurkat T-lymphocytic leukemia cells were 
purchased from American Type Culture Collection (ATCC, Rockville, MD) and 
maintained in Roswell Park Memorial Institute 1640 medium (RPMI, Hyclone, 
Logan, Utah, USA) supplemented with 1% L-glutamine, 1% penicillin/streptomycin 
and 10% FBS. Hela cervical carcinoma cells were also purchased from ATCC but 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Hyclone, Logan, Utah, 
USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, Irvine, CA) and 
1% penicillin/streptomycin (Hyclone, ThermoScientific, Waltham, MA). HK-1 human 
nasopharyngeal carcinoma cell line were generous gift from Dr. Bert Vogelstein (The 
Johns Hopkins University School of Medicine, Baltimore, MD, and maintained in 
RPMI 1640 (Hyclone Logan, Utah, USA) supplemented with 1% L-glutamine, 1% 
streptomycin-penicillin and 10% FBS. All cell lines were maintained in a humidified 
incubator at 37
o
C with 5% CO2 and sub-cultured in 75cm
2
 flasks (Nunc, NY, USA) 
every three days with a subculture ratio of 1:8 or according to suppliers’ 
recommendations. Only cells from less than 25 passages were used for the 
experiments.  
 
2 Reagents and chemicals 
Diethyldithiocarbamate (DDC), Dimethyl-9,9′-biacridinium dinitrate (Lucigenin), 
4,5-Dihydroxy-1,3-benzenedisulfonic acid (Tiron), 5-fluorouracil (5-FU), cisplastin, 
etoposide, doxorubicin, PD98059, diphenlyiodonium (DPI), phenylmethylsulfonyl 
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fluoride (PMSF), aprotinin, pepstatin A, leupeptin, sodium fluoride (NaF), sodium 
orthovanadate (Na3VO4), sucrose, HEPES,  crystal violet, bromophenol blue, DMSO, 
TritonX-100, tween 20, EDTA, DTT, Tris and glycine were all purchased from 
Sigma Aldrich, St. Louis, MO, USA. 4-Amino-5-Methylamino-2',7'-
Difluorofluorescein Diacetate (DAF-FM diacetate) was procured from Molecular 
Probes, Invitrogen, Eugene, OR, USA. Proteinase K was from Invitrogen, Eugene, 
OR, USA. 5,10,15,20-Tetrakis(4-sulfonatophenyl)porphyrinato Iron (III), Chloride 
(FeTPPS) was purchased from Merck, Darmstadt, Germany while pure ONOO
-
 was 
from Cayman, USA. Coomassie Blue reagent was from Pierce Biotechnology 
(Rockford, IL, USA). 10x PBS, 10 x SDS, Tris HCl buffer (pH 7.4) were purchased 
from NUMI Media Preparation Facility (NUS, Singapore). 
 
3 Antibodies 
Primary antibodies for western blot analysis: 
Rabbit polyclonal primary antibodies for the specific detection of Thr69 phospho-
Bcl-2, Ser87 phospho-Bcl-2, GAPDH, Prohibitin, and VDAC1 were purchased from 
Santa Cruz, CA, USA, while mouse monoclonal primary antibodies for PP1-C, B56α, 
and β-actin were also from Santa Cruz, CA, USA as well. Rabbit polyclonal primary 
antibodies against S70 phospho-Bcl-2, Thr202/Tyr204 phospho-ERK1/2, 
Thr180/Tyr182 phospho-p38 and Ser259 phospho-Raf were attained from Cell 
Signalling Technology, Inc. Danvers, MA, whereas mouse monoclonal primary 
antibodies against total ERK1/2, total p38, PP2A-A and HA-tag were all from the 
same source as well. Mouse monoclonal antibodies specific for Bcl-2, Bak, p53, 
SOD1, and SOD2 were from BD Pharmingen, San Diego, CA, USA. Mouse 
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monoclonal antibodies against PP2A-C (clone 1D6) and 3-nitrotyrosine both from 
Upstate, Millipore Corporation, Billerica, MA, USA. Rabbit polyclonal 
Ser202/Thr205 anti-phospho-PHF-Tau antibody (clone AT8) was from Thermo 
Scientific, Waltham, MA, USA. COX Vα mouse monoclonal antibody was purchased 
from Mitosciences, Eugene, OR, USA. Rabbit polyclonal Thr183/Tyr185 anti-
phospho-JNK1/2 antibody was purchased from Calbiochem, San Diego, CA, USA 
while Thr826 phospho-pRb rabbit polyclonal antibody was from Abcam, Cambridge, 
UK. Goat anti-mouse and anti-rabbit IgG HRP conjugated secondary antibodies were 
both purchased from Pierce Chemical Co. Rockford, IL. Lastly, 3NO2-Y289 specific 
rabbit polyclonal antibody was custom made by GenicBio Limited, Shanghai, China.  
Primary antibodies for immunoprecipitation: 
Rabbit polyclonal anti-Bcl-2 and anti-HA antibodies were purchased from Santa 
Cruz, CA, USA. Rabbit polyclonal PP2A-C and B56δ antibodies (clone UT98) were 
generous gifts from Prof. David Marc Virshup from DUKE-NUS, Singapore.  
 
4 Plasmids and SiRNAs 
pCEP4 empty vector, pCEP4-HA-B56α, pCEP4-HA-B56β, pCEP4-HA-B56γ1, 
pCEP4-HA-B56δ and pCEP4-HA-B56ε plasmid constructs were generous gifts from 
Prof. David Marc Virshup from DUKE-NUS, Singapore.  
pcDNA-Bcl-2 plasmid was provided generously by assoc. Prof Marie-Veronique 
Clement, NUS, Singapore. The S70A and S70E Bcl-2 mutants were kindly generated 
from pcDNA-Bcl-2 plasmid by Mr. Stephen Chong for general lab usage.  
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pcDNA3.1 empty vector was purchased from Invitrogen, Eugene, OR, USA. 
The set of four ON-TARGETplus SOD1 specific SiRNAs were purchased from 
Dharmacon Technologies (Thermo Fisher Scientific), Lafayette, CO, USA and the 




SISOD1-D:  CAAUAAACAUUCCCUUGGA 
The SMARTpool SiRNAs specific for SOD1 is a mixture of these four SiRNA 
sequences and was purchased from the same company as well. 
 
5 Calcium phosphate-based transfection of adherent cells 
The Calcium Phosphate Mammalian Transfection Kit (Clonetech Laboratories Inc., 
Palo Alto, CA) was used for the transfection of siRNAs in all adherent cells 
(MDA231 and HK-1). Cells were first cultured to a confluency of about 40% in 6-
well plates prior to transfection. Irrespective of cell lines, the cell culture medium was 
changed to fresh DMEM supplemented with 10% FBS, 1% L-glutamine and 1% 
penicillin/streptomycin just before transfection. 50 nM of SiRNA was used for each 
transfection. To prepare the transfection mixture, siRNAs were first diluted in sterile 
dH2O, followed by addition of 12.4 μl of 2.5 mM CaCl2 in a total amount of 100 μl. 
The SiRNA-CaCl2 mixture was then mixed with an equal volume of the DNA 
precipitation buffer (2X HEPES-buffered saline) in a drop-wise manner while gently 
vortexing the tube. Following this, the resultant mixture was incubated for 20 minutes 
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at room temperature before being added into the cells. Cell culture medium was 
refreshed with normal cell culture medium 24 hours post-transfection. Cells were 
only harvested for experiments 48 hours after transfection reagents were added. 
 
6 Electroporation-based transfection of Jurkat cells 
The Neon
TM
 Electroporation transfection system (Invitrogen, Eugene, OR, USA) was 
employed for the transfection of plasmids or SiRNAs into Jurkat cells. Prior to 
transfection, appropriate number of 100 mm cell culture dishes were filled with 10ml 
of RPMI-1640 (supplemented with 2 mM L-glutamine and 10% FBS but without 
streptomycin-penicillin) and pre-warmed to 37
o
C. Desired amount of cells (up to 10 
million cells/dish) were harvested, pelleted at 800 rpm and washed with 1X 
Dubelco’s Phosphate-Buffered Saline (PBS containing NaCl, Na2PO4 and KCl but 
not Ca2+ and Mg2+) before being resuspended in the Resuspension Buffer R 
provided by the manufacturer. 6 μg of plasmids (or 200 μM of SiRNA) were then 
added into the cell suspension and the resultant SiRNA/DNA-cell mixture was then 
loaded into the 100 μl Neon tips using the specialized Neon pipette. After ensuring 
that no bubbles were introduced into the electroporation tips, the cells were then 
electroporated via the Neon electroporation system at 1150 V/30 ms for a total of 2 
pulses. Once electroporation is completed, cells were immediately transferred into the 
100 mm petri dishes containing the pre-warmed RPMI-1640 medium (antibiotics 
free). Cells were subsequently maintained at 37°C / 5% CO 2 / 95% humidity for 24 





7 Determination of protein concentration 
Quantitation of protein concentrations were performed using the Coomassie™ Plus 
Protein Assay Reagent in a 96-well format. Protein standards with concentration 
ranging from 0.25 – 2 mg/ml were first prepared from BSA. 1 μl of the sample of 
interest was mixed with 200 μl of the Coomassie dye and its absorbance was 
measured at 595 nm using the Spectrafluor Plus spectrophotometer (TECAN, GmbH, 
Grödig, Austria). Sample protein concentration was then calculated by comparing the 
absorbance value for each sample with that of the protein standards. 
 
8 Western blot analysis 
Normalized protein samples were mixed with appropriate volumes of Lammelli 
loading buffer (100 mM Tris-HCL pH 6.8, 10% SDS, 20% glycerol, 25% DTT, 0.1% 
bromophenol blue) and heated at 100°C for 5 minutes. The samples were loaded into 
the wells of a desired percentage acrylamide resolving gel and subjected to sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at 100 V and 30 
mA for about two hours using the Bio-Rad Mini-PROTEAN 3 Cell (CA, USA). 
Precision Plus Protein™ Dual Color Standards (Bio-Rad, CA, USA) was included in 
each gel as a protein molecular size marker. Resolved proteins were then transferred 
onto a polyvinyl difluoride (PVDF) membrane by the semi-dry transfer method at 30 
V and 270 mA for 45 minutes using the Hoefer™ TE 77 semi-dry transfer unit 
(Amersham Biosciences, NJ, USA). The membrane was then blocked with 5% (w/v) 
fat-free milk in Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBST) for an 
hour with continuous rocking at 80 rpm. Excess milk was then washed off with TBST 
(3 X 10 minutes). The membrane was subsequently probed for the protein of interest 
45 
 
with the relevant primary antibody at 1:1000 dilution in TBST overnight at 4
o
C 
together with gentle rocking. Unbound primary antibodies were washed off with 
TBST (3 X 10 minutes) and probed again with the appropriate horse radish 
peroxidase (HRP)-conjugated secondary antibody at 1:5000 dilution in TBST 
containing 1% (w/v) fat-free milk for one hour at room temperature. The membrane 
was again subjected to three washes to remove excess secondary antibody before the 
addition of HRP substrates (SuperSignal Chemiluminescent Substrate from PIERCE, 
IL, USA). The desired proteins were next detected with Kodak Biomax MR X-ray 
film and subsequently scanned for further analysis using the Fuji Xerox Workcentre 
3119 scanner.  
 
9 Co-immunoprecipitation (co-IP) assay 
For each sample, about 10 million cells were harvested and pelleted at 1200 rpm and 
subsequently resuspended in ice-chilled co-IP lysis buffer (0.5% Nonidet P40, 50 mM 
Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, and a cocktail of protease inhibitors, 1 
mM PMSF, 10 μg/ml aprotinin, 20 μg/ml pepstatin A, 10 μg/ml leupeptin, 1 mM 
NaF, 1 mM Na3VO4). Cell suspensions were then incubated on ice for 10 mins 
followed by a freeze-thaw cycle at -80
o
C to ensure complete lysis of cells. After 
thawing, cell lysates were centrifuged at 16,000g for 10 min for the removal of DNA. 
The resultant supernatant were then added with 15 μl protein A agarose beads (Santa 
Cruz, CA, USA) and subjected to constant mixing at 4
o
C for an hour on a rotator. 
After an hour, the agarose beads were removed by centrifugation at 16,000g for 3 
minutes to remove any proteins that are non-specifically bound to protein A. Upon 
the removal of agarose beads, protein concentration were determined for each sample 
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and normalized to 1000 μg protein lysate per sample. Each sample were then added 
with 3 μg of primary antibody and again subjected to constant mixing at 4oC 
overnight. Then, 30 μl of protein A agarose beads were added into the samples for an 
additional 3 hours at 4˚C to ensure that all antibody-protein complexes are thoroughly 
captured by the protein A agarose beads. After which, the beads were then washed 
three times with 500 μl of ice-chilled co-IP lysis buffer and resuspended in 30 μl of 
loading buffer (100 mM Tris-HCL pH 6.8, 10% SDS, 20% glycerol, 25% DTT, 0.1% 
bromophenol blue). All samples were then boiled for 15 min to release the 
immunocomplexes before being analyzed via western blot.  
 
10 Mitochondrial-cytoplasmic fractionation  
Approximately 5 million cells were harvested, washed once with ice-cold PBS and 
pelleted by centrifugation at 1200 rpm for 5 minutes at 4°C. The pellet was 
resuspended in 10 volumes of mitochondrial extraction buffer A (50 mM PIPES-
KOH pH 7.4, 220 mM mannitol, 68 mM sucrose, 50 mM KCl, 5 mM EGTA, 2 mM 
MgCl2, 1 mM DTT) containing a cocktail of protease inhibitors (1 mM PMSF, 10 
μg/ml aprotinin, 20 μg/ml pepstatin A, 10 μg/ml leupeptin, 1 mM NaF, 1 mM 
Na3VO4) and incubated on ice for 20 minutes. After incubation, cells were 
homogenized with a manual homogenizer for 25 strokes and then centrifuged at 300 
g, 4°C for 5 minutes. Received pellet consists of nuclei and broken mitochondria and 
will therefore be discarded while the resultant supernatant is subjected to an 
additional round of centrifugation at 1000g, 4
o
C, for 10 more minutes to ensure that 
all fragmented nuclei or cells are completed pelleted from the cell extract, leaving 
behind the cytosolic fraction as well as the heavy membrane fraction (mainly 
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mitochondria) in the supernatant. The supernatant obtained was then transferred into a 
new microcentrifuge tube and centrifuged at 13000 g for 15 minutes at 4°C. The 
received pellet would then consist of intact mitochondria fraction while the 
supernatant comprises mainly the cytosolic content. The mitochondrial pellet was 
subsequently resuspended with RIPA lysis buffer (50 mM Tris HCl pH 7.5, 150 mM 
NaCl, 1% v/v Nonidet P-40, 0.1% v/v SDS, 1 mM EDTA) containing a cocktail of 
protease inhibitors (1 mM PMSF, 10 μg/ml aprotinin, 20 μg/ml pepstatin A, 10 μg/ml 
leupeptin, 1 mM NaF, 1 mM Na3VO4) and used for further experimentation (western 
blot or PP2A activity assay).  
 
11 Immunofluorescence confocal microscopy 
For Jurkat T-leukemic cells: 
Approximately 5 X 10
5 
cells were harvested and centrifuged at 1200 rpm, 4°C for 5 
minutes. Received pellet was then washed once with 1ml of ice cold PBS and 
subsequently fixed with 1ml of 4% paraformaldehyde at room temperature for 20 
minutes with gentle shaking at every 5 minutes intervals. Following fixation, cells 
were centrifuged at 1200 rpm, 4°C for 10 minutes and washed twice with 1ml ice 
cold PBS before being subjected to further permeabilization using 200 μl of 0.05% 
TritonX-100 (room temperature  for 5 minutes). After permeabilization, cells were 
then pelleted at 16,000 g, 4°C for 10 minutes, then washed twice with 1 ml of ice cold 
PBS, and resuspended in 1ml of blocking buffer (2% BSA and 5% FBS dissolved in 
1X PBS). Blocking of potential non-specific binding sites was achieved via constant 
rotation of sample in blocking buffer at 4°C overnight.  
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Following blocking, 100 μl of the cell suspension was then pipetted onto a 
polylysine-coated microscope glass slide and subsequently air dried on the glass slide 
at room temperature. Thereafter, cells were incubated with the primary antibodies of 
interests at a concentration of 1:100 for two hours. Then, the slide was washed twice 
with ice cold 1X PBS, followed by an additional hour of incubation with 1:200 
dilution (in blocking buffer) of Alexafluor-488 anti-mouse secondary antibody 
(Invitrogen, Eugene, OR, USA) and Alexafluor-568 anti-rabbit secondary antibody 
(Invitrogen, Eugene, OR, USA). After secondary antibody incubation, cells were 
washed twice with ice cold PBS again before being sealed with a coverslip for 
subsequent analysis. All cells were imaged with Olympus Fluoview FV1000 confocal 
microscope and images were analysed using Olympus Fluoview 3.0 viewer. 
For MDA231 breast carcinoma cells: 
Approximately 2 x 10
5 
cells were directly plated on polylysine-coated glass coverslip 
and fixed directly on the coverslip with 2% paraformaldehyde (in 1X PBS) for 15 
minutes at room temperature. After which, cells were washed thrice with 1X PBS 
followed by permeabilization with 0.1% TritonX-100 (in 1X PBS) for 10 minutes at 
room temperature. Thereafter, cells were washed again with 1X PBS for three times 
before being blocked with 5% BSA (in 1X PBS) for one hour at room temperature. 
Subsequent procedures involved the incubation of cells with primary antibodies and 




12 MTT cell viability assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, from Sigma 
Aldrich, St. Louis, MO, USA) is a tetrazolium salt that is readily reduced to purple 
formazan crystals in mitochondria of living cells. Solubilized formazan crystals can 
easily be quantitated colorimetrically, thereby serving as a quick and simple tool for 
the semi-quantitation of viable cells. Briefly, about 50,000 cells were mixed with 50 
μl of 4 mg/ml MTT (dissolved in RPMI-1640) in a 96-well format and incubated for 
2 hours at 37
o
C. After incubation, cells were centrifuged at 3000 rpm for 10 minutes. 
The supernatant was then removed and the remaining formazan crystals were 
dissolved in a cocktail of 200 μl DMSO and 10 μl of Sorenson’s glycine buffer (0.1 
M glycine and 0.1 M NaCl, adjusted to pH 10.5). Cell viability was then quantitated 
spectrophotometrically at an absorbance wavelength of 570 nm using a Spectrafluor 
Plus spectrophotometer (TECAN, GmbH, Grödig, Austria). All samples were 
prepared in triplicates and the average value was calculated for further analysis. Data 
presented are representative of mean±SD of at least three independent experiments. 
 
13 Crystal violet cell viability assay 
Crystal violet assay was employed for the assessment of cell viability of adherent cells. 
After drug exposure, cells were washed once with 1X PBS and subsequently incubated 
with 0.2 ml of crystal violet solution (0.75% crystal violet, 50% ethanol, 1.75% 
formaldehyde and 0.25% NaCl) for 10 minutes at room temperature. Thereafter, non-
viable cells were washed off together with excess crystal violet using distilled water and 
then air dried at room temperature. Images of the crystals were then captured using a high 
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resolution scanner and viability of cells could be directly discerned from the amount of 
viable cells that have retained the dye. 
  
14 Caspase activity assay 
Caspases 8, 9 and 3 activities were assayed using 7-amino-4-trifluoromethyl 
coumarin (AFC)-conjugated substrates (BioMol, Plymouth Meeting, MA, USA). 
Approximately 5 x 10
5
 Jurkat cells were plated in 12-well plates and immediately 
subjected to the intended drug treatment regimen. Thereafter, cells were harvested 
and washed with 1X PBS, resuspended in ice-chilled lysis buffer (BD Pharmingen, 
San Diego, CA, USA), and incubated on ice for 10 minutes. Protein concentration 
was determined for each sample was determined using the Coomasie Plus protein 
assay reagent (Pierce Biotechnology, Rockford, IL, USA) and normalized to 50 μg 
protein per sample.  Following this, 50 μl of 2X reaction buffer (10 mM HEPES, 2 
mM EDTA, 10 mM KCl, 1.5 mM MgCl2, 10 mM DTT) and 1 μl of the fluorogenic 
caspase-specific substrates (DEVD-AFC for caspase-3, LETD-AFC for caspase-8, 
and LEHD-AFC for caspase-9) were added into each sample and incubated at 37
o
C 
for one hour. Caspase activity was then determined by measuring the relative 
fluorescence intensity at 505 nm with excitation at 400 nm using a Spectrafluor Plus 
spectrophotometer (TECAN, GmbH, Grödig, Austria). All data are mean±SD of three 
independent experiments are presented as fold changes in caspase activity in relative 




15 Measurement of cellular O2
- 
via Lucigenin chemiluminescence assay  
Lucigenin is a highly sensitive chemiluminescent probe that is readily reduced by O2
-
. 
The reduced form of lucigenin emits strong luminescent signals and could therefore 
be detected for the semi-quantitation of intracellular O2
-
. In this assay, approximately 
3 million cells is required per sample. Harvested cells were first pelleted, washed 
once with 1X PBS and lysed with 450 μl of ATP releasing buffer (Sigma Aldrich, St. 
Louis, MO, USA). Immediately upon lysis, chemiluminescence was monitored at 0.5 
second intervals for a total of 30 seconds using a Berthold Sirius Luminometer 
(Berthold detection systems GmbH, Bleichstrabe/Pforzheim/Germany). Lucigenin is 
auto-injected into the samples by the luminometer, and the luminescence emitted by 
reduced lucigenin would be reflected as relative light units (RLU). Protein 
concentration of the remaining lysate was determined using the Coomasie Plus 
protein assay reagent (Pierce Biotechnology, Rockford, IL, USA) and subsequently 
normalized against the luminescent signals detected for each sample. All data are 
mean±SD of three independent experiments and are presented as RLU/μg protein. 
 
16 Flow cytometry analysis of intracellular NO 
Intracellular NO was monitored by flow cytometry with the NO-sensitive fluorescent 
probe, DAF-FM diacetate (Molecular Probes, Invitrogen, Eugene, OR, USA). DAF-
FM diacetate is a cell permeable probe that readily reacts with NO to form a 
benzotriazole which emits detectable fluorescence that allows for the semi-
quantitation of intracellular NO. Approximately 1 x 10
6
 cells were pelleted and then 
resuspended with 100 μl of plain RPMI-1640 containing 5 μM DAF-FM reagent. 
Resuspended cells were then incubated for 15 minutes at 37
o
C, washed twice with 1X 
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PBS, and resuspended again in fresh medium. Stained cells were immediately 
analyzed by flow cytometry (Beckman-Coulter Epics ALTRA flow cytometer) with 
excitation set at 510 nm and cell counter at 10000 events. Subsequent data analysis 
was done using WinMDI software. 
 
17 Measurement of PP2A activity (serine/threonine phosphatase assay) 
PP2A activity was measured using the serine/threonine phosphatase assay system 
provided by Promega, Madison, WI, USA. The molybdate/malachite green employed 
in this assay reacts rapidly with inorganic orthophosphate to form a green complex 
which allows for the colorimetric determination of free phosphate groups released 
from synthetic phospho-peptides by the serine/threonine phosphatase(s) of interest. 
The synthetic phospho-peptide, RRA(pT)VA, provided in the assay system is specific 
to the protein phosphatase 2 (PP2A, PP2B and PP2C) family enzymes but not the PP1 
phosphatases. Furthermore, members of the PP2 family differs in their respective 
optimal buffer conditions. Therefore, by manipulating with the reaction buffer 
condition, the assay system could be tailored to the measurement of a specific PP2 










chelator) would therefore be specific for the enzymatic activity of PP2A 
(Table 1). 
For the measurement of PP2A activity in Jurkat cells, approximately 1 x 10
6 
cells 
were harvested and pelleted via centrifugation at 1200 rpm for 5 minutes at room 
temperature and subsequently lysed with RIPA lysis buffer (50 mM Tris HCl pH 7.5, 
150 mM NaCl, 1% v/v Nonidet P-40, 0.1% v/v SDS, 1 mM EDTA) supplemented 
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with a cocktail of protease inhibitors (1 mM PMSF, 10 μg/ml aprotinin, 20 μg/ml 
pepstatin A, 10 μg/ml leupeptin) but not phosphatase inhibitors such as NaF and 
Na3VO4. Lysates were subsequently channelled through the Sephadex columns 
provided by the manufacturer for the removal of free endogenous phosphates. Protein 
concentration of the flowthrough lysates were then determined and normalized to 5 
μg protein per reaction. The reactions were then initiated by adding the desired 
amount of lysates to a mixture of 10 μl 5X PP2A-specific reaction buffer (250 mM 
pH 7.2 imidazole, 1 mM EGTA, 0.1% 2-mercapthoethanol, 0.5 mg/ml BSA), 5 μl of 
1 mM phosphopeptide, and topped up to 50 μl in a 96-well plate using phosphate free 
dH2O. After 20 minutes of incubation, the reactions were stopped by adding 50 μl of 
the molybdate dye additive provided by the manufacturer. Samples were thereafter 
incubated for an additional 30 minutes to allow for complete colour development of 
the molybdate-malachite green dye. Thereafter, samples optical densities (OD) were 
measured at an absorbance of 600 nm using a Spectrafluor Plus spectrophotometer 
(TECAN, GmbH, Grödig, Austria).  The exact concentration of free phosphates 
released in each reaction can be determined by comparing the OD values of each 






Table 1: Enzymatic activity of various phosphatases in the presence of different inhibitors.  




18 Construction of Y289F-B56δ mutant via site-directed mutagenesis  
Site-directed mutagenesis of tyrosine-289 in B56δ to a phenylalanine residue was 
performed using the Quikchange II XL Site-directed Mutagenesis Kit provided by 
Stratagene, La Jolla, CA, USA. The primers designed (desired mutations are 
underlined) for mutagenesis are as follows: 
Forward primer:  
5’-CATCTTCTACAGGTTCATCTTCGAGACGGAGCATCACAACGG-3’ 
Reverse primer:  
5’CCGTTGTGATGCTCCGTCTCGAAGATGAACCTGTAGAAGATG-3’ 
Primers were PCR amplified (Mastercycler gradient, Eppendorf, USA) with pCEP4-
4HA-B56δ as template plasmid (Figure F) and the parameters used were as provided 
by the manufacturer. Briefly, each reaction contains 125 ng of each oligonucleotide 
primers, 10 ng of the plasmid template, 1 μl of the supplied dNTP mix, 1 μl of 
PfuUltra HF DNA polymerase (2.5U/μl), 5 μl reaction buffer, 3 μl Quikchange 
proprietary solution and topped up to a final volume of 50 μl. The primers were 
subjected to 18 cycles of amplification, with each cycle consisting of a 50 seconds 
denaturation step at 95
o
C, an annealing step of 60
o
C for 50 seconds and an elongation 
step of 20 minutes at 68
o
C. After PCR amplification, amplification products were 
treated with 1 μl Dpn I for one hour at 37 oC for the digestion of methylated parental 
(non-mutated) DNA templates. After which, Dpn I-treated amplification products 
were precipitated with 0.3 M sodium acetate and 70% ethanol at a volume of 2.5X of 
PCR amplification products. Precipitated DNA was subsequently redissolved in 5 μl 
of dH2O and the entire amount was used for the following transformation procedure.  
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Transformation of the PCR amplification product was performed using the XL10-
Gold ultracompetent cells provided by the manufacturer. For each transformation 
reaction, 5 μl of the precipitated PCR amplification product were added to 45 μl of 
ultracompetent cells together with 2 μl of β-mercaptoethanol. Thereafter, the 
transformation reaction was incubated ice for 30 minutes followed by a 30 seconds 
heat pulse at 42
o
C. After which, the transformation reaction was incubated in ice for 
an additional 2 minutes, then added with 0.5 ml of NZY
+ 
broth (pre-heated to 42
 o
C) 
and incubated with at 37
o
C for one hour with shaking at 225 rpm. After 
transformation, the competent were streaked on ampicillin-containing agar plates an 
incubated overnight for 18 hours. Colonies formed were subsequently picked and 
amplified with 5 ml of LB broth at 37
o
C for an additional 18 hours. Following this, 
plasmid clones were extracted from the bacteria cultures using Qiagen miniprep kit 
(Qiagen, Venlo, Netherlands), analysed via DNA gel electrophoresis, and 












Figure F: Vector backbone of pCEP4-4HA B56δ.  
4HA-tagged B56δ cDNA was cloned into a pCEP4 backbone via the NotI (5’) and BamHI (3’) cloning 
sites. Plasmid is a generous gift from Prof David Marc. Virshup (DUKE-NUS, Singapore) and the 
empty vector backbone pCEP4 was from Invitrogen, Eugene, OR, USA. Plasmid map was adapted 
from Addgene, plasmid #14536. 
 
19 Extraction and purification of primary lymphoma tumours  
The clinical lymphoma samples were surgically excised by surgeons from the 
National University Hospital (NUH) after receiving patients’ consent under a protocol 
approved by the National University of Singapore’s Institutional Review Board. After 
the clinical biopsies were received, single cell suspension were obtained from the 
lymphoma biopsies by grinding the tissues between two glass slides and strained 
through MACS separation filter. Cell suspensions were subsequently maintained in 
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RPMI supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin 
before being used for further experiments. For long term storage of lysates, 
lymphoma cells were harvested and lysed with either RIPA lysis buffer or co-IP lysis 
buffer (both supplemented with protease inhibitors) and stored in -80
o
C freezer.  
 
20 Statistical analysis 
All experiments were performed for at least 3 times, except for experiments involving 
clinical lymphoma biopsies. Numerical data were presented as mean±SD. The paired 
student’s t-test (two-tail, unequal variance) was used when comparisons were made 








 promotes tumour chemoresistance by inducing Serine70 Bcl-2 
phosphorylation  
1.1 Diethyldithiocarbamate (DDC) induced a parallel increase in both 
intracellular O2
- 
and S70 pBcl-2 
As aforementioned, the mechanism(s) underlying the pro-survival properties of O2
-
 
has yet been established and we seek to investigate if O2
- 
is relaying its oncogenic 
effect by affecting the phosphorylation status of Bcl-2 at the FLD.  
Given the frequent overexpression and the importance of Bcl-2 in various 
hematopoietic malignancies [138, 250-253], Jurkat T-lymphocytic leukemia cell was 
first chosen as the model to evaluate the effect of O2
- 
on the phosphorylation status of 
Bcl-2 at the FLD and the induction of intracellular O2
-
 was achieved by preventing 
the conversion of O2
- 
to H2O2 via a known inhibitor of SOD1, DDC [1]. Interestingly, 
treatment of Jurkat cells with two selected doses of DDC (100 μM and 200 μM) 
resulted in a parallel increase in the level of both intracellular O2
- 
(Figure 1B) and 
Serine70 phosphorylated Bcl-2 (S70 pBcl-2) in a time-dependent manner (Figure 
1A). This shed the first hint on a potential link between O2
- 
and the phosphorylation 
of Bcl-2. 
There are three phosphorylation sites on the FLD (T69, S70 and S87) known to 
influence the anti-apoptotic function of Bcl-2 [136, 151, 153, 166, 171, 254]. Thus, to 
assess if DDC-induced Bcl-2 phosphorylation is specific to the S70 residue, we 
subjected Jurkat cells to an increasing doses of DDC treatment and evaluated the 
phosphorylation status of both T69 and S87 upon 4 hours of treatment. Whereas DDC 
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treatment resulted in a dose-dependent increase in S70 pBcl-2, neither T69 nor S87 
exhibited any noticeable increase in phosphorylation levels (Figure 1C), indicating 
that DDC-induced Bcl-2 phosphorylation is specific only to S70. This observation is 
consistent with previous studies demonstrating that the phosphorylation of Bcl-2 
specifically at S70 positively regulates its anti-apoptotic activity [136, 137, 158, 164, 
170, 171, 243].  Of note, DDC-induced S70 pBcl-2 upregulation peaked at a 
concentration of 400 μM and would thus be used as the effective working 
concentration for subsequent experiments. 























Figure 1: DDC induced Bcl-2 phosphorylation specifically at S70.  
A. Treatment of Jurkat cells with the indicated doses of DDC over four treatment time points (30 mins, 
1, 2 and 4 hours) demonstrated a time-dependent increase in the level of Ser70 phosphorylated Bcl-2 
(S70 pBcl-2).  
B. Intracellular O2
- 
was measured via Lucigenin-based chemiluminescence assay in Jurkat cells upon 
DDC treatment. Intracellular O2
- 
level was clearly elevated in 200 μM DDC-treated cells across all 
treatment time points. * p < 0.01 as compared to control. 
C. Treatment of Jurkat cell with an incremental dose of DDC for 4 hours demonstrated a specific 
increase in the phosphorylation of Bcl-2 at S70 but not other (S87 and T69) phosphorylation sites on 
the FLD. 
D. Lucigenin chemiluminescence assay demonstrated a dose-dependent increased in intracellular O2
- 
level that correlated well with the increase in S70 pBcl-2 upon 4 hours of DDC treatment. All data are 






*p < 0.01 





1.2 Scavenging of O2
- 
abrogated DDC-induced S70 bcl-2 phosphorylation 
In attempt to verify that the observed increase in S70 pBcl-2 is indeed mediated by 
O2
- 
rather than an independent side effect of DDC, we pre-incubated Jurkat cells with 
a O2
- 
scavenger, tiron [255], and investigated whether this could abrogate the 
upregulation S70 pBcl-2 induced by DDC. Indeed, increased scavenging of DDC-
induced O2
- 
production by an incremental doses of tiron (Figure 2B) brought about a 
corresponding decline in DDC-induced S70 pBcl-2 level (Figure 2A), indicating that 
O2
- 
is truly the effector molecule in DDC-induced phosphorylation of Bcl-2 at S70.  
Not restricting ourselves with a single cancer model, we repeated the preceding 
experiments in a panel of three different adherent cells lines to provide further 
evidence that the effect of DDC-induced O2
- 
on the level of S70 pBcl-2 is not 
exclusive to only Jurkat cells. The cell lines selected are, namely, Hela Cervical 
carcinoma cells, MDA-231 breast carcinoma cells, and HK-1 Nasopharyngeal 
carcinoma cells, in which all were chosen based on the considerable amount of 
endogenous Bcl-2 expressed in these cells.  In good agreement with our findings in 
Jurkat T-lymphocytic leukemia cells, DDC treatment brought about a significant 
increase in S70 pBcl-2 level in all three selected cell lines (Figure 2C), while pre-
treatment with 5 mM of tiron reversed the effect of DDC on S70 Bcl-2 
phosphorylation. These data suggest that the regulation of S70 Bcl-2 phosphorylation 
by O2
- 
























Figure 2: Pre-treatment of tiron abrogated the effect of DDC on S70 Bcl-2 phosphorylation.  
A. Jurkat cells were pre-treated with different doses (1 mM, 3 mM or 5 mM) of O2
- 
scavenger, tiron, 
before treatment with 400 μM DDC for an additional 4 hours. Tiron pre-treatment clearly blocked the 
positive effect of DDC on S70 pBcl-2. 
B. Lucigenin-based measurement of intracellular O2
- 
showed successful scavenging of O2
- 
upon 
increasing doses of tiron pre-treatment in Jurkat cells. Note that S70 pBcl-2 levels correlated well with 
intracellular O2
- 
levels. Data are presented as mean±SD of at least three independent experiments. 
C. Hela cervical carcinoma, MDA231 breast carcinoma and HK-1 nasopharyngeal carcinoma cell lines 
were pre-treated with 5 mM tiron for an hour before treatment with either 200 μM (Hela) or 400 μM 
(MDA231 and HK-1) of DDC for 4 hours. The optimal dose of DDC for each cell lines was 













1.3 SiRNA-mediated downregulation of SOD1 mimicked the effect of DDC  
As with the use of most pharmacological inhibitors, the effects of DDC on S70 pBcl-
2 could potentially be due to an unintended pharmacological action that goes beyond 
the inhibition of SOD1. Therefore, to verify our findings with DDC, we employed 
SiRNA-mediated gene knockdown strategies to investigate the functional 
consequences of SOD1 downregulation on the level of S70 pBcl-2. Here, we 
demonstrated that silencing of SOD1 in MDA-231 cells with a mixed pool of four 
SiRNA sequence resulted in a significance increase in intracellular O2
- 
level (Figure 
3A and 3B), which in turn, corresponded well with a concurrent increase in the level 
of S70 pBcl-2 in the cells. Indeed, data here is in great congruence with observations 
attained from the pharmacological inhibition of SOD1 by DDC, thus ruling out the 
possibility of spurious observations due to the poor specificity of pharmacological 
inhibitors. 
 
In addition, the experiment was also repeated with the four different SOD1-targeted 
SiRNA sequences employed in isolation (Figure 3C). This serves to ensure that the 
findings from these studies would be specific to SOD1 silencing, instead of an off-
target silencing effect by the pool of mixed SiRNA sequences. In line with our 
observations attained with a mixed pool of SiRNAs, western blot analysis 
demonstrated that successful silencing of SOD1, with three (A-C) out of four 
independent SiRNA sequences, invariably augmented S70 pBcl-2 level in Jurkat T-
lymphocytic leukemia cells (Figure 3C), further reaffirming that the observed 



















Figure 3: SiRNA-mediated downregulation of SOD1 induced S70 phosphorylation of Bcl-2   
A. Western blot analysis of MDA231 cells 48 hours after transfection with a SMARTpool of four 
SiRNA sequence specific against SOD1. S70 pBcl-2 was clearly elevated upon successful silencing of 
SOD1. 
B. Lucigenin chemiluminescence assay demonstrated an elevated intracellular O2
- 
level upon silencing 
of SOD1 in MDA231 cells. S70 pBcl-2 level positively correlated with intracellular O2
- 
level. Data 
shown are mean±SD of at least three independent experiments. 
C. Western blot analysis of Jurkat cells 48 hours after transfection with four individual SiRNA 
sequence specific against SOD1 (arbitrarily denoted as SiSOD1-A, B, C and D). Similar to MDA231 













1.4 Treatment of bovine SOD1 led to a reduction in S70 pBcl-2 
A key feature in the regulation of cellular signalling processes is reversibility. Thus, if 
an augmented intracellular O2
- 
level induced by the silencing of SOD1 led to an 
increase in S70 pBcl-2, an enhanced conversion O2
- 
to H2O2 via the overexpression of 
SOD1 would be expected to yield an opposing effect. To that end, we capitalized on 
the commercial availability of a cell permeable bovine SOD1 enzyme (bSOD1), 
rather than employing conventional plasmid-based overexpression of SOD1, for the 
dismutation of O2
-
 and tested if bSOD1 treatment could lead to the dephosphorylation 
of Bcl-2.  
Jurkat cells were directly incubated with reconstituted bSOD1 enzyme (1,000 U/ml or 
3,000U/ml) over a series of four different time points (4, 8, 16 and 24h) and 
subsequently harvested for western blot analysis (Figure 4). A moderate decline in 
S70 pBcl-2 was detected after 8 hours of 3,000 U/ml bSOD1 treatment, while more 
obvious reduction of S70 pBcl-2 was only observed upon 16 or 24 hours of bSOD1 
treatment (Figure 4). This is intriguing, for the dephosphorylation of Bcl-2 at S70 
upon bSOD1 treatment appeared to be relatively delayed in comparison to the time 
taken for S70 pBcl-2 induction by DDC (started even before 4 hours of DDC 
treatment; Figure 1A). The possibility of such delayed response being due to an 
inferior bSOD1 enzymatic efficacy (in relative to human SOD1) is fairly remote, 
since bSOD1 is known for an enzymatic efficacy comparable to that of human SOD1 
in various cell culture experiments [256-258]. In fact, such kinetics incoherence 
provides indications that Bcl-2 dephosphorylation at S70 induced by bSOD1 
potentially involved intermediary mechanism(s) with greater latency in relative to the 
phosphorylation process induced by O2
-
. Although the underlying mechanism(s) is 
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still uncertain, these data nonetheless provide strong evidence that the level S70 pBcl-
2 is tightly coupled to intracellular O2
- 
level, which in turn, is inversely correlated 
with the expression status of SOD1 in the cell. More importantly, O2
-
-mediated S70 








Figure 4: bovine SOD1 treatment suppressed the phosphorylation of Bcl-2 at S70. 
Jurkat cells were treated with two doses of bSOD1 (1 kU and 3 kU) across four different time points. 
Phosphorylation level of Bcl-2 at S70 has clearly declined after 16 hours of bSOD1 treatment. bSOD1 
was reflected as a lower molecular weight band (2 kDa lighter) in relative to human SOD1. In this 
experiment, X-ray film was subjected to a longer exposure time (as compared to other western blot 
figures) during the detection of S70 pBcl-2 in order to achieve a greater contrast between untreated and 




1.5 Pre-treatment of DDC promoted chemoresistance in tumour cells 
Both O2
- 
and S70 pBcl-2 are well documented for their capability in abetting tumour 
survival [136, 137, 158, 164, 170, 171, 179, 198, 199, 243]. Therefore, this begs the 
question of whether pharmacological inhibition or genetic silencing of SOD1 could 
also induce tumour chemoresistance in a similar manner. 
To this end, we assessed the potential death-inhibitory effect of  SOD1 inhibition by 
pre-incubating Jurkat T-lymphocytic leukemia cells with an hour of 400 μM DDC 
before respectively treating the cells (for an additional 18 hours) with four different 
chemotherapeutic agents known to elicit the mitochondrial apoptotic pathway. Of the 
four anti-cancer compounds tested, it appears that both 5-fluorouracil (5-FU) and 
cisplastin are fairly ineffective in evoking a death response in Jurkat T-leukemic cells 
albeit relatively high doses of compound were already in used (Figure 5A). On the 
contrary, both doxorubicin (Doxo) and Etoposide (Eto) potently reduced the viability 
of Jurkat cells in a dose-dependent manner (Figure 5A). Importantly, while treatment 
of Jurkat cells with 400 μM of DDC alone did not significantly affect cell viability, 
pre-incubation of Jurkat cells with DDC consistently mitigated the death-inducing 
effect of both doxorubicin and etoposide across the range of chemotherapeutic doses 
tested (Figure 5A). Also, the same death-inhibitory effect of DDC was also observed 
in Hela cells when we engaged a similar experimental strategy using incremental 
doses of doxorubicin and evaluated cell viability via crystal violet assay (Figure 5B). 
Here, protection conferred by DDC pre-treatment was especially pronounced at 5 μM 
and 10 μM doxorubicin treatments, with the loss in cell viability induced by 

























Figure 5: DDC pre-treatment protected against drug-induced cell death. 
A. MTT cell viability assay of Jurkat cells. Cells were pre-treated with one hour 400 μM DDC before 
treatment with the indicated doses of chemotherapeutic agents – 5-fluorouracyl,  cisplastin, etoposide 
and doxorubicin. While Jurkat cells were resistant to both 5-fluorouracyl and cisplastin, DDC pre-
treatment clearly rescued Jurkat cells from the death-inducing effect of etoposide and doxorubicin. 
Data are mean±SD of three independent experiments. 
B. Crystal violet cell viability assay performed on Hela cells pre-treated with 200 μM DDC followed 
by treatment with an incremental doses of doxorubicin. DDC pre-treatment clearly protected against 






1.6 Pre-treatment of DDC abated etoposide- and doxorubicin-induced 
activation of caspase-9 and caspase-3 
Given that all apoptotic pathways converge to the activation of caspases, we next 
tested the protective effect of SOD1-inhibition using a fluorogenic-based caspase 
activity assay to provide additional support to the findings from cell viability assays. 
Jurkat cells were first pre-incubated with DDC for an hour, followed by an additional 
6 hours of either 2.5 μM etoposide or 1 μM of doxorubicin, before being assayed for 
the activity of the three major caspases – caspase-8, -9 and -3. Consistent with the 
phenotype of mitochondria-targeting drugs, both doxorubicin and etoposide clearly 
engaged the initiator caspase of the intrinsic apoptotic machinery, caspase-9, as well 
as the executioner caspase-3 for their respective death-inducing activity. Whereas the 
activity of both caspase-9 and -3 were dramatically increased in etoposide (up to 3 
fold) and doxorubicin (up to 4 fold) treated cells, caspase-8, as the initiator caspase of 
the extrinsic (receptor-based) apoptotic pathway, were barely activated in both 
instances of drug treatment (Figure 6A & 6B). More importantly, DDC pre-treatment 
greatly abated the activation of caspases induced by both doxorubicin and etoposide 
treatment (Figure 6A & 6B). Indeed, this observation is in good consensus with the 
notion of O2
- 
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Figure 6: Pre-treatment of DDC abrogated drug-induced caspase-9 and caspase-3 activation. 
A & B. The activity of caspase-8, -9, and -3 were determined in Jurkat cells via their respective 
fluorogenic substrates as detailed in materials and methods. Jurkat cells were first pre-treated with one 
hour of 400 μM DDC followed by an additional 6 hours of 2.5 μM etoposide (Figure 6A) or 1 μM 
doxorubicin (Figure 6B) treatment. Both caspase-9 and caspase-3 activity induced by etoposide or 
doxorubicin were clearly abolished by DDC pre-treatment. All data shown are mean±SD of at least 








1.7 Silencing of SOD1 protected against doxorubicin- and etoposide-induced 
cell death 
To further attest our findings with DDC, the cytoprotective effect of SOD1 inhibition 
against doxorubicin and etoposide induced cell death was also validated by SiRNA-
mediated gene knockdown techniques. In this assay, 2.5 μM and 1 μM were chosen 
as the optimal death-inducing dose of etoposide and doxorubicin respectively. SOD1-
targeted SiRNA was first introduced into Jurkat T-leukemic cells for 48 hours via 
electroporation techniques, before being subjected to an additional 18 hours of drug 
treatment. As would be expected, SiRNA-mediated silencing of SOD1 yielded similar 
observations to that attained from pharmacological inhibition of SOD1, whereby 
genetic knockdown of SOD1 with three independent SiRNA sequences provided a 
clear protection of at least 20% against viability lost induced by either etoposide (2.5 
μM) or doxorubicin (1 μM) in Jurkat cells (Figure 7). Clearly, an increase in O2
- 
level 
triggered by the diminution in SOD1 activity could grant tumour cells with a survival 
advantage against chemotherapeutic agents. However, whether this death-inhibitory 
effect is indeed a function of O2
-


















Figure 7: SiRNA-mediated downregulation of SOD1 protected against etoposide and 
doxorubicin induced cell death. 
Jurkat cells were treated with either 2.5 μM etoposide or 1 μM doxorubicin 48 hours after transfection 
with three individual sequences of SOD1-specific SiRNA (denoted as SiSOD1-A, B and C). Cells 
were subsequently harvested for MTT cell viability assay 18 hours after drug treatment. Silencing of 
SOD1 clearly protected against etoposide- or doxorubicin-induced cell death. Data shown are 
mean±SD of at least three independent experiments. 
 
1.8 S70 phosphorylation of Bcl-2 is required for the death-inhibitory activity 
of DDC 
Whereas the functional consequence(s) of multisite Bcl-2 phosphorylation at the FLD 
is still ambiguous (outlined in introductory chapter 3.4.2), it is clear that the 
phosphorylation of Bcl-2 specifically at S70 could confer protection against 
mitochondria targeting agents [137, 159]. Since tumour chemoresistance conferred by 
an elevated level of intracellular O2
-
 correlated strongly with an increase in S70 pBcl-
2, this places S70 pBcl-2 as the prime candidate in mediating the cytoprotective effect 
of DDC-induced O2
-
 in tumour cells.  
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To gain further insights on the potential intermediary role of S70 pBcl-2 in O2
-
-
induced chemoresistance, we transfected Jurkat cells with mutant Bcl-2 harbouring 
either a phosphomimetic (Serine to glutamate – S70E) or a non-phosphorytable 
(serine to alanine – S70A) point mutation at S70 and examined whether this would 
affect the protective effect of O2
- 
against etoposide-induced cell death. In agreement 
with the death-inhibitory role of S70 Bcl-2 phosphorylation, transfection of S70A-
Bcl-2 into Jurkat cells considerably dampened the protective effect of DDC against 
etoposide-induced cell death to a level comparable to that of the non-DDC pre-treated 
cells (Figure 8A). Conversely, introduction of the S70E-Bcl-2 mutants alone could 
protect the cells against etoposide-induced killing even in the absence of DDC pre-
treatment (Figure 8A). Interestingly, overexpression of wild type Bcl-2 also resulted 
in a significant increase in the level of S70 pBcl-2 (Figure 8B), and this provided 
considerable degree of protection against the cytotoxic effect of etoposide as well 
(Figure 8A). Of note, transfection of WT Bcl-2 or S70E mutants did not enhance the 
death-inhibitory effect of DDC despite a significantly greater level of S70 pBcl-2 in 
the cells (as compared to DDC-treated untransfected cells). This suggests that the 
protection conferred by S70 Bcl-2 phosphorylation was approaching saturation and 
the incomplete protection by S70 pBcl-2 implies that etoposide could be eliciting cell 
death via other non-mitochondria-related pathways as well.  
We demonstrated here that both O2
- 
(induced by either DDC or SOD1 silencing) and 
overexpression of S70E-Bcl-2 could further fortify the resistance of tumour cells 
against drug-induced apoptosis. This further establishes O2
- 
and S70 pBcl-2 as potent 
oncogenic factors that enhance survival capacity of tumour cells. More importantly, 
we have also identified, for the first time, a link between the pro-survival properties 
of O2
- 
and the phosphorylation of Bcl-2 at S70, whereby cells harbouring S70A Bcl-2 
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* *p < 0.05 
mutants are incapable of harnessing the survival benefits endowed by the O2
-
-inducer, 
DDC. Clearly, this establishes S70 pBcl-2 as an essential downstream effector of O2
-
-












Figure 8: S70E Bcl-2 mutants protected against etoposide-induced cell death while S70A 
abolished DDC-conferred protection against etoposide treatment.  
A. MTT cell viability assay of Jurkat cells transfected with either wild type pcDNA-Bcl-2, non-
phosphorylatable S70A Bcl-2 mutant, or phosphomimetic S70E Bcl-2 mutant. Here, cells were first 
transfected with Bcl-2 mutants for 24 hours followed by treatment with 2.5 μM etoposide for another 
18 hours before being harvested for MTT assay. 
B. Successful transfection of the Bcl-2 mutants was validated via western blot analysis. Sensitivity of 







1.9 S70 phosphorylation of Bcl-2 did not enhance its ability to sequester the 
pro-apoptotic protein, BAK 
While the phosphorylation of Bcl-2 at S70 is necessary for the death inhibitory 
properties of O2
-
, exactly how S70 pBcl-2 protects against drug-induced apoptosis 
remains a question. Since Bcl-2 is classically recognized for its ability to inhibit the 
mitochondria apoptotic pathway via the sequestration of pro-apoptotic Bcl-2 family 
members Bax and Bak, we tested if the phosphorylation of Bcl-2 at S70 could affect 
the interaction between Bcl-2 and its pro-apoptotic counterparts. With regards to this, 
we transfected Jurkat leukemic T cells with the S70 Bcl-2 phosphorylation mutants 
(S70A and S70E) and assayed for potential physical association between Bcl-2 and 
Bax/Bak via co-IP techniques. As shown in figure 9A, a constitutive level of 
interaction between Bcl-2 and Bak was clearly detected in Jurkat human T-leukemic 
cell line. The pro-apoptotic Bax protein, however, was undetectable not only in the 
immunoprecipitates but also in the whole cell lysates of Jurkat cells, a phenotype that 
has been attested by other studies as well [259]. Importantly, the interaction of Bak 
with S70E and S70A, respectively, were similar to that of WT Bcl-2 transfected cells 
(Figure 9A), suggesting that S70 phosphorylation of Bcl-2 does not influence the 
Bak-sequestering ability of Bcl-2. 
To validate our preceding findings, and to also determine if Bak-Bcl-2 interaction is 
affected by the exposure to death triggers, co-IP assays were performed on etoposide-
treated Jurkat cells with or without DDC pre-treatment. In line with our previous 
observations, DDC treatment did not alter the level of Bak-Bcl-2 interaction despite a 
marked increase in S70 pBcl-2 level (Figure 9B). Similarly, etoposide treatment did 
not alter the association between Bcl-2 and Bak as well (Figure 9B). It is interesting 
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however, that etoposide treatment resulted in a drastic decline in S70 pBcl-2 level 
whereas pre-treatment of DDC significantly restored the level of S70 pBcl-2 in 
etoposide-treated cells. It could be observed that S70 pBcl-2 levels, despite the lack 
of effect on Bcl-2-Bak interaction, clearly reflected the viability status of etoposide-
treated Jurkat cells (Figure 8A – untransfected cells). This, together with evidence 
presented in figure 8A, strongly suggest the existence of an antagonistic relationship 
between S70 pBcl-2 and the death-inducing properties of etoposide, though the 














Figure 9: S70 phosphorylation of Bcl-2 did not affect Bcl-2-Bak interaction.  
A. Co-IP assay with Bcl-2 as bait protein demonstrated that Bcl-2-Bak interaction in Jurkat cells was 
not affected by the introduction of the various Bcl-2 mutants, indicating that the ability of Bcl-2 to 
sequester Bak is independent from its phosphorylation status at S70. 
B. Jurkat cells were first pre-treated with 400 μM of DDC for one hour, followed by an additional 6 
hours of 2.5 μM etoposide before being harvested for co-IP analysis. Neither DDC nor etoposide 
treatment affected the interaction between Bcl-2 and Bak. Note that etopside treatment greatly reduced 












-induced S70 pBcl-2 upregulation is not a function of MAP kinases 
activation 
Regulation of phospho-proteins is achieved by the antagonistic balance between the 
kinases and the phosphatases.  In the context of Bcl-2, the most frequently implicated 
Bcl-2 kinases are the three major MAP kinases – JNK, ERK and p38 [151, 153-158], 
though there a small fraction of reports suggested the potential involvement of other 
kinases as well [159-161]. PP2A and PP1, on the other hand, are the main 
phosphatases known to counter the effects of these Bcl-2 kinases [163-165]. 
Owing to the stress-responsive nature of MAP kinases, ERK1/2, JNK1/2 and p38 
surfaces as the most promising candidates for the regulation of Bcl-2 phosphorylation 
in response to oxidative triggers. Thus, to decipher the mechanism(s) underlying O2
-
-
mediated increase in S70 pBcl-2, we assessed the activation statuses of JNK, ERK 
and p38 upon DDC treatment. Here, the phosphorylation statuses of these MAP 
kinases were employed as surrogate indicators of their respective activation. Upon 
DDC treatment, western blot analysis demonstrated that both ERK1 (~44 kDa) and 





This is so, as neither JNK1/2 nor p38 exhibited any 
noticeable response to DDC treatment while ERK, on the contrary, is phosphorylated 
(and hence activated) in parallel to that of S70 pBcl-2 level (Figure 10A).   
To verify that the observed increase in ERK1/2 activation has a causative effect rather 





-induced Bcl-2 phosphorylation. In this experiment, Jurkat cells were first pre-
treated for an hour with the general ERK inhibitor, PD98059, followed by an 
additional 4 hours of 400 μM DDC treatment before being harvested for western blot 
analysis. Results attained were disappointing, yet intriguing. Despite significant 
inhibition of ERK1/2 phosphorylation, the effect of PD98059 pre-treatment on O2
-
-
induced S70 Bcl-2 phosphorylation was, at best, minimal (Figure 10B). 
Consequently, no cause-and-effect relationship could be established between the 
activation of ERK1/2 and the upregulation of S70 pBcl-2 induced by O2
-
. It appears, 
as a matter of fact, that DDC-induced activation of ERK1/2 could just be a “bystander 
effect” independent from the regulatory effect of O2
- 




























Figure 10: DDC-induced upregulation of S70 pBcl-2 is not a function of MAP kinases activation.  
A. Jurkat cells were subjected to an incremental doses of DDC treatment for 4 hours and subsequently 
harvested for western blot analysis. DDC treatment induced the phosphorylation of ERK1 (44 kDa) 
and ERK2 (42 kDa) at thr202/tyr204 in a dose-dependent manner. 
B. Jurkat cells were first pre-treated with three different doses of general ERK1/2 inhibitor, PD98059, 
for an hour, followed by 4 additional hours of 400 μM DDC treatment. Subsequent western blot 











generated by pharmacological inhibition or genetic knockdown of 
SOD1 triggered a drop in PP2A activity 
The process governing the phosphorylation status of Bcl-2 is akin an eternal tug of 
war between the Bcl-2 kinases and phosphatases. As such, despite the lack of MAP 
kinases involvement in O2
-
-mediated upregulation of S70 pBcl-2, the increase in S70 
pBcl-2 could still be accounted by a decline in Bcl-2 phosphatases activity even if 
Bcl-2 kinases activity remain constant.  
Supported by numerous evidence implicating PP2A as the major Bcl-2-targeting 
phosphatase, we proceeded to investigate the potential involvement of PP2A as an 
intermediary player that links O2
- 
induction to the phosphorylation of Bcl-2 at S70. To 
this end, we studied the activity of PP2A in DDC-treated tumour cells using an 
absorbance-based serine/threonine phosphatase assay system whereby PP2A activity 
can be measured by detecting the rate in which phosphate groups are removed from 
synthetic phospho-peptides specific to PP2A. Through this assay, it was observed that 
DDC treatment brought about a considerable decline in PP2A activity in Jurkat T-
leukemic cells, while pre-treatment of cells with the O2
- 
scavenger, tiron, completely 
abrogated the observed decline in PP2A activity induced by DDC treatment (Figure 
11A). Also, similar results were obtained when the experiment was extended to two 
other adherent cell lines, MDA-231 and HK-1 cells (Figure 11A), thus providing 
indications that O2
-
 could suppress the activity of PP2A in tumour cells.    
Progressing forward from DDC-based experiments, SiRNA-mediated silencing of 
SOD1 was also employed to provide additional line of evidence to our findings. 
Indeed, a decline in PP2A activity comparable to that of DDC treatment was also 




* *p < 0.05 
activity of PP2A is clearly suppressed in a tumour environment with a heightened 
intracellular O2
- 
level, shedding lights that the inhibition of PP2A could be a key 


















Figure 11: PP2A activity declined upon pharmacological inhibition or genetic silencing of SOD1  
A. Jurkat, MDA231 and HK-1 cells were pre-treated with one hour of 5mM tiron before further 
treatment with 4 hours of 400 μM DDC. Cells were then harvested for PP2A activity assay as detailed 
in materials and methods. Treatment with 4 hours of DDC alone clearly triggered a drop in PP2A 
activity while pre-treatment of tiron restored PP2A activity to a level comparable to untreated cells. 
B. MDA231 and HK-1 cells were transfected with SOD1-specific SiRNA and harvested for PP2A 
activity assay 48 hours post-transfection. Genetic downregulation of SOD1 clearly suppressed the 
activity of PP2A in both cells. All data shown are mean±SD of three independent experiments. 
 
  







inhibited the interaction between Bcl-2 and the catalytic subunit of 
PP2A 
Notwithstanding the apparent suppression of PP2A activity in tumour cells with 
limited SOD1 activity, data acquired from PP2A activity assays is still far from 
conclusive in pinpointing Bcl-2 as the O2
-
-regulated target of PP2A. PP2A is a 
heterotrimeric enzyme consisting of an A-scaffolding subunit, a catalytic-C subunit, 
and a highly variable B-regulatory subunit, with the enzymatic specificity being 
largely determined by the substrate recognizing capability of the B-regulatory subunit 
[210-212]. In this regard, the synthetic phospho-peptide utilized in the PP2A assay 
serves only as a general sequence recognized by the catalytic core (A and C subunit) 
of all PP2A complexes and therefore does not carry information regarding substrate 
specificity. Consequently, information accrued from PP2A activity assays are not 
representative of Bcl-2 alone. 
Being mindful of the caveats associated with the serine/threonine phosphatase assay, 
we furthered our study by looking directly into a possible protein-protein interaction 
between Bcl-2 and the catalytic subunit of PP2A (PP2A-C). A series of co-IP studies 
were performed on three tumour cell lines (Jurkat, MDA-231 and Hela) upon DDC 
treatment (Figure 12A and 12B). Using Bcl-2 as the bait protein, a physical 
association between PP2A-C and Bcl-2 was detected in non-DDC-treated cells 
(Figure 12A and 12B). Upon DDC treatment, however, this observed interaction 
between PP2A-C and Bcl-2 was clearly disrupted across all the three assayed cell 
lines (Figure 12A and 12B). Importantly, the dissociation of Bcl-2 from PP2A-C was 
invariably accompanied with a parallel increase in S70 Bcl-2 phosphorylation in all 
three instances (Figure 12A and 12B). It is noteworthy that a physical interaction 
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between Bcl-2 and the catalytic subunit of PP1 (PP1-C) was also detected in Jurkat 
cells (Figure 12A). DDC treatment, however, did not affect PP1-Bcl-2 interaction, 
indicating that the inhibitory effect of O2
- 
is specific to PP2A. In addition to tumour 
cell lines, similar observations were also attained in primary lymphoma tissues 
(mantle cell lymphoma), thereby reaffirming that these findings are not mere artefacts 
from cell culture processes (Figure 12C). 
To further cross-validate our findings, we repeated the co-IP studies with PP2A-C, 
instead of Bcl-2, as the bait protein. Again, a similar protein complex between PP2A-
C and Bcl-2, which could also be inhibited by DDC treatment, was observed (Figure 
12D). Taken together, these data unequivocally implicates Bcl-2 as a target of PP2A 
and, more importantly, O2
- 
could augment the level of S70 pBcl-2 by inhibiting the 
interaction between PP2A and Bcl-2.  





















Figure 12: DDC inhibited the interaction between PP2A-C and Bcl-2  
A. Jurkat cells were treated with 4 hours of 400 μM DDC and harvested for co-IP assay using Bcl-2 as 
bait protein. PP2A-C and PP1-C were clearly co-immunoprecipitated with Bcl-2. DDC treatment 
inhibited the interaction between Bcl-2 and PP2A-C but not PP1-C. 
B. MDA231 and HK-1 cells were treated with 4 hours of 400 μM DDC and harvested for co-IP assay 
using Bcl-2 as bait protein. DDC treatment inhibited the interaction between Bcl-2 and PP2A-C in 
these cell lines as well.  
C. Primary lymphoma tumour (later diagnosed as mantle cell lymphoma) was surgically excised from 
patient donors from National University Hospital Singapore (NUHS). Lymphoma tissues were 
processed and purified into single cell suspension and subsequently treated with 4 hours of 400 μM 
DDC before harvested for co-IP assay. Interaction between PP2A-C and Bcl-2 was clearly inhibited by 
DDC treatment as well. 
D. Observations from A and B were cross-validated in Jurkat and MDA231 cells using PP2A-C as bait 
protein. An interaction between PP2A-C and Bcl-2 was clearly observed in both cell lines. This 










To provide further evidence on the disruptive effect of O2
- 
production on the 
interaction between PP2A-C and Bcl-2, confocal imaging studies were carried out on 
DDC-treated Jurkat (Figure 13A) and MDA-231 (Figure 13B) cells. While the co-
localization of PP2A-C and Bcl-2 was obvious in untreated cells, this phenomenon 
was markedly abrogated upon DDC treatment, as indicated by the decline in yellow 
fluorescence observed in DDC-treated tumour cells (Figure 13C). Likewise, confocal 
imaging experiments performed with the silencing of SOD1 via three independent 
sequences of SIRNA yielded a similar verdict as that attained from DDC-mediated 
inhibition of SOD1 (Figure 14A and 14B). Indeed, data here is in great concordance 
with previous co-IP experiments, lending further credence to our hypothesis that O2
- 
could upregulate the level of S70 pBcl-2 by inhibiting the dephosphorylation process 



















































Figure 13: DDC inhibited the co-localization of PP2A-C and Bcl-2  
A & B. Confocal fluorescence imaging studies of Jurkat and MDA cells treated with 4 hours of 400 
μM DDC. Primary antibody recognizing PP2A-C was stained via Alexafluor-488-conjugated 
secondary antibody (green) while Bcl-2 was stained using Alexafluor-568-conjugated secondary 
antibody (red). Co-localization of Bcl-2 and PP2A-C is depicted by yellow punctates (red arrows). 
DDC-treated cells exhibited a diminished level of co-localization between Bcl-2 and PP2A-C. 
C. An enlarged view of a single selected cell from panel A and panel B for greater clarity and 













































































Figure 14: SiRNA-mediated silencing of SOD1 inhibited the co-localization of PP2A-C and Bcl-2  
A. SiRNA specific for SOD1 were transfected into Jurkat cells via electroporation techniques and 
confocal imaging studies were performed 48 hours post transfection. PP2A-C was stained via 
Alexafluor-488-conjugated secondary antibody (green) while Bcl-2 was stained using Alexafluor-568-
conjugated secondary antibody (red). A total of three different SiRNA sequences were employed for 
the knockdown of SOD1, all of which interrupted with the co-localization of Bcl-2 and PP2A-C.  
B. An enlarged view of a single selected cell from panel A for greater clarity and resolution. Images 

















2.5 Mitochondrial translocation of PP2A-C was inhibited in tumour cells 
with heightened intracellular O2
-
 level 
Although there are certain instances where Bcl-2 was reported to be found in the ER 
and the nucleus [131], majority of this oncoprotein is known to reside at the OMM 
[130]. Since PP2A-C was shown to co-localize with Bcl-2 at the cell periphery 
(Figure 12C), it is deducible that the phosphatase would be targeted to the 
mitochondria where majority of Bcl-2 resides. Thus, to assess if PP2A-C could also 
be localized to the OMM together with Bcl-2, proteinase K protection assay was 
performed.  
In this assay, mitochondria were first isolated from either Jurkat or MDA-231 cells 
before being further incubated with two selected concentrations of proteinase K 
(Figure 15A) for 25 minutes. The concentrations of proteinase K in used were just 
suffice to digest the proteins that are exposed at the OMM but not those that are 
sheltered behind it. Here, western blot analysis showed that PP2A-C was clearly 
detected in the mitochondria, while treatment with proteinase K resulted in the 
digestion of both PP2A-C and Bcl-2 but not SOD2 (matrix protein) and Cytochrome 
c oxidase Va (COX Va; inner membrane protein). As a control, treatment of 
proteinase K together with Triton-X100 resulted in the complete digestion of all 
mitochondria proteins that were released from the mitochondria by the permeabilizing 
surfactant. Data here not only supports our imaging studies demonstrating the co-
localization of Bcl-2 and PP2A-C, but is further indicative that the two proteins are 
localized at the OMM. 
Furthering from this, we next asked the question if O2
- 
induction could lead to the 
delocalization of PP2A-C from the mitochondria. By employing differential 
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centrifugation mitochondrial fractionation techniques, we demonstrated that the level 
of PP2A-C was clearly diminished in the mitochondrial fraction of DDC-treated 
Jurkat and MDA-231 cells, while the converse is true for the level of mitochondrial 
S70 pBcl-2 (Figure 15B and 15C). Also, scavenging of O2
- 
via tiron pre-treatment 
completely reversed the level of both S70 pBcl-2 and PP2A-C in the mitochondria of 
DDC-treated cells (Figure 15B and 15C), thus confirming O2
- 
as the inhibitor of 
PP2A-C mitochondrial translocation. Notably, such changes in mitochondrial PP2A-
C level was also echoed by PP2A activity assay performed on mitochondria fractions 
attained from DDC-treated Jurkat cells, whereby a great decline in PP2A activity was 
detected only in the mitochondria fractions but not the cytosolic fractions (statistically 
insignificant) of DDC-treated cells (Figure 15D).  
Taken together, our data suggest that O2
-
-induced upregulation of S70 pBcl-2 is 
mediated by its inhibitory effect on PP2A-C mitochondrial translocation and 

























Figure 15: DDC treatment inhibited mitochondrial translocation of PP2A-C  
A. Proteinase K was used to determine the membrane localization of PP2A-C at the mitochondria. 
Mitochondria isolated from either MDA231 or Jurkat cells were incubated with indicated doses of 
proteinase K for 25 minutes for the digestion of mitochondrial proteins that are not protected by lipid 
membranes. Both Bcl-2 and PP2A-C, but not SOD2 and COX Va, were digested by proteinase K 
treatment. As a control, complete lysis of isolated mitochondria by tritonX-100 treatment resulted in 
the digestion of matrix (SOD2) and IMM (Cox Va) proteins by proteinase K. 
B & C. Mitochondria fractionation assay was performed on Jurkat or MDA231 cells treated with 
400μM DDC alone (4 hours) or pre-treated with 5 mM tiron prior to DDC treatment. Western blot 
analysis performed on the resultant mitochondria/cytosolic fractions indicated a decline in 
mitochondrial PP2A-C upon DDC treatment. SOD1 was employed as a cytosolic protein marker while 
prohibitin, an IMM protein, served as a mitochondrial protein marker. 
D. PP2A activity assay was performed on mitochondria/cytosolic fractions of Jurkat cells treated with 
either 400μM DDC alone or pre-treated with tiron prior to DDC treatment. DDC treatment resulted in 
a significant decline in mitochondrial PP2A activity, which could in turn be restored by tiron pre-
treatment. All data are presented as mean±SD of three independent experiments.  
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augmented the level of S70 pBcl-2 by inhibiting the holoenzyme 
assembly of B56δ-containing PP2A (PP2AB56δ) 
3.1 The B56δ regulatory subunit of PP2A is responsible for the substrate 
recognition of Bcl-2 in Jurkat and MDA-231 cells  
Given that PP2A functions mostly as heterotrimeric enzymes, it is therefore important 
to assess if the inhibitory effect of O2
- 
on PP2A could also affect the enzymatic 
assembly of other PP2A subunits as well. In order to achieve this goal, however, it 
would be necessary to first identify the precise B regulatory subunit that interacts 
with Bcl-2 before further studies could be executed.  
B’/B56 subunits are notoriously documented for their functional redundancy amongst 
subfamily members [260, 261], as well as their tissue- and developmental phase-
specific expression in mammalian system [210, 215, 217, 218, 262, 263]. Therefore, 
in spite of existing evidence implicating B56α as the regulatory subunit responsible 
for PP2A-mediated dephosphorylation of Bcl-2 [243], we sought to re-evaluate the 
involvement of PP2A-B56 subunits in our study. To that end, we proceeded to setting 
up a screen for potential interaction(s) between Bcl-2 and other members of the B56 
regulatory subfamily. 
Here, Jurkat and MDA-231 cells were respectively transfected with a series of HA-
tagged plasmids encoding for the five major B56 isoforms (α, β, γ1, δ and ε) and 
assayed for their respective interaction with Bcl-2. Intriguingly, co-IP assay revealed 
HA-B56δ as the only interacting partner of Bcl-2 in both Jurkat (Figure 16A) and 
MDA-231 (Figure 16B), instead of B56α as previously reported [243].  However, it 
could not be ascertain if HA-B56γ1 could interact with Bcl-2, since B56γ1 shares a 
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similar molecular weight as immunoglobulin heavy chain (IgG) and any potential 
interaction could have been masked by the strong signal stemming from the IgG 
heavy chain (Figure 16A and Figure 16B). Nevertheless, it is inferable that any 
interaction between Bcl-2 and HA-B56γ1 is unlikely, since HA-B56δ appeared as the 
only subunit that could enhance S70 dephosphorylation of Bcl-2 upon transfection 
(Figure 16A).  
The discordance between our findings with existing reports is not entirely surprising. 
A differential expression of B regulatory subunits across different mammalian tissues 
and developmental phases is known to exist [210, 215, 217, 218, 262, 263], as this 
would allow for a diverse regulation of heterotrimeric PP2A complexes throughout 
the course of mammalian tissue development. Similarly, our data suggests that B56 
subunits could also be dynamically regulated throughout the course of tumorigenesis, 
since PP2AB56α was shown by others to regulate the phosphorylation status of Bcl-2 
in REH precursor B cells [243], while we on the other hand, demonstrated that 
PP2AB56δ targets Bcl-2 for dephosphorylation in more mature and aggressive cancer 

















Figure 16: HA-B56δ interacts with Bcl-2.  
A & B. Jurkat and MDA231 cells were both transfected with HA-tagged B56 family members (α, β, 
γ1, δ, and ε isoforms) and subsequently harvested for co-IP assay 24 hours post-transfection. HA-B56δ 
was clearly co-immunoprecipitated with Bcl-2 in both cell lines. Red asterisk (*) on panel B denotes a 












inhibited the binding of the AC catalytic core, but not B56δ, to Bcl-2 
Progressing from our previous findings, we next investigated if O2
- 
induction could 
affect the binding of B56δ-containing PP2A (PP2AB56δ) to its substrate, Bcl-2. 
Interestingly, co-IP assay performed on Jurkat T-leukemic cells using PP2A-C as bait 
protein demonstrated that DDC treatment not only interrupted the binding of PP2A-C 
to Bcl-2, but also resulted in the dissociation of B56δ from the catalytic subunit as 
well (Figure 17A). On the other hand, PP2A-A remains attached to PP2A-C even in 
the presence of O2
- 
induction (Figure 17A).  Clearly, this suggests that the inhibitory 
effect of O2
- 
is not only limited to the interaction between Bcl-2 and PP2A-C, but also 
affected the binding of B56δ to the intact AC core.  
In addition, co-IP assays performed with Bcl-2 as bait provided further backings to 
these findings (Figure 17B). In concordance with previous data showing an 
interaction between Bcl-2 and HA-tagged B56δ (Figure 16A and 16B), a robust 
interaction between Bcl-2 and endogenous B56δ was also detected in both Jurkat and 
MDA231 cells (Figure 17B). More importantly, DDC-mediated O2
- 
induction affected 
only the interaction between Bcl-2 and PP2A-A but not B56δ (Figure 17B), thus 



















Figure 17: DDC treatment inhibited the interaction of PP2A-C with the B56δ regulatory subunit. 
A. Co-IP assay using PP2A-C as bait protein was performed on Jurkat cells treated with 400 μM DDC 
for 4 hours. DDC treatment inhibited the interaction of PP2A-C with B56δ, but not with PP2A-A. 
PP2A-A has a molecular weight of ~65 kDa and was detected just above the strong protein smear 
originating from IgG heavy chain.  
B. Observations from panel A were cross-validated with co-IP assay using Bcl-2 as bait. DDC 





3.3 DDC treatment did not affect the co-localization of B56δ and Bcl-2 
Besides co-IP assays, the redox insensitivity of the Bcl-2-B56δ complex was also 
reinforced by confocal imaging studies demonstrating a strong co-localization of Bcl-
2 and B56δ that was largely unaffected by DDC treatment (Figure 18A and 18B). 
This phenomenon is in stark contrast with the redox behaviour of the Bcl-2-PP2A-C 
complex as previously demonstrated (Figure 13A). Taken together, our data clearly 
suggests that O2
- 
induction could inhibit the recruitment of the AC catalytic core to 















Figure 18: Co-localization of B56δ and Bcl-2 was not affected by DDC treatment.   
A. Confocal imaging studies was performed on DDC-treated Jurkat cells. Primary antibody against 
B56δ was detected via Alexafluor-488-conjugated secondary antibody (green) while primary antibody 
against Bcl-2 was detected using Alexafluor-568-conjugated secondary antibody (red). Co-localization 
(depicted as yellow signal) was obvious in both DDC-treated and untreated cells. 
B. An enlarged view of a single selected cell from panel A for greater clarity and resolution. Images 





3.4 SiRNA-mediated knockdown of SOD1 inhibited the interaction of Bcl-2 
with PP2A-C but not with B56δ 
In further support of our findings attained from the pharmacological inhibition of 
SOD1, induction of O2
- 
via SiRNA-mediated downregulation of SOD1 also yielded a 
similar inhibitory effect on the interaction between Bcl-2 and the PP2A subunits. 
Silencing of SOD1 resulted in a simultaneous decreased in the interaction of PP2A-C 
with both Bcl-2 and B56δ respectively, and this was observed in all the three SiRNA 
sequences employed (Figure 19A). Conversely, the interaction between Bcl-2 and 
B56δ remained constant despite a marked decline in Bcl-2-PP2A-C interaction upon 
silencing of SOD1 (Figure 19B). Of note, any decline in the interaction between 
PP2A-C and Bcl-2 is invariably accompanied by an increase in S70 pBcl-2 level 
irrespective of the SiRNA sequences in used (Figure 19A and 19B). These findings 
yet again suggest that O2
-
-mediated enhancement of S70 pBcl-2 level is contributed 




































Figure 19: Silencing of SOD1 inhibited PP2A-C-B56δ interaction, but not the interaction 
between Bcl-2 and B56δ.   
A. Jurkat cells were transfected with three different SOD1-specific SiRNA sequences via 
electroporation techniques and harvested for co-IP analysis 48 post-transfection. The level of Bcl-2 and 
B56δ that were co-immunoprecipiated with PP2A-C was clearly reduced upon SOD1 silencing.  
B. Observations from panel A were cross-validated with Bcl-2 as bait protein. Interaction between Bcl-
2 and B56δ was completely unaffected by the silencing of SOD1 even though the binding of PP2A-C 








 inhibited mitochondrial localization of PP2A-AC catalytic core 
It is widely recognized that the B regulatory subunits of PP2A not only confer 
substrate specificity but also determine the subcellular localization of heterotrimeric 
PP2A [212, 215]. Since O2
- could inhibit the ability of B56δ in recruiting the AC core 
to the mitochondria resident protein, Bcl-2, we investigated the effect of O2
- 
induction 
on the mitochondrial localization status of the three PP2A holoenzyme subunits 
involved in the dephosphorylation of Bcl-2. In this regard, the induction of O2
- 
was 
achieved via SiRNA-mediated knockdown of SOD1. 
Successful downregulation of SOD1 with three independent SiRNA sequences 
invariably triggered a significant decline in the mitochondrial localization of both 
catalytic core members, PP2A-A and PP2A-C (Figure 20). Also, consistent with the 
function of PP2A as a Bcl-2 phosphatase, delocalization of the AC catalytic core from 
the mitochondria is consistently associated with an increase in S70 pBcl-2 level 
(Figure 20). Importantly, B56δ remains confined at the mitochondria despite the 
diminishing level of mitochondrial PP2A-C and PP2A-A. This indicates that O2
-
-
mediated inhibition of PP2AB56δ involved the dissociation of the AC catalytic core 















Figure 20: SiRNA-mediated knockdown of SOD1 inhibited mitochondrial translocation of PP2A-
A and PP2A-C, but not B56δ.   
Mitochondrial fractionation assay was performed on Jurkat cells transfected with three different 
SOD1-specific SiRNA sequences via electroporation techniques. The level of mitochondrial PP2A-C 
and PP2A-A was clearly reduced upon genetic silencing of SOD1 in Jurkat cells. The OMM protein, 


















 as the missing link between O2
-
 and the inhibition of PP2A 
4.1 DDC treatment of tumour cells was accompanied by a drop in 
intracellular nitric oxide (NO) level 
Notwithstanding conclusive evidence demonstrating the inhibitory effect of O2
- 
on 
PP2AB56δ-mediated dephosphorylation of Bcl-2, the precise cellular target of O2
- 
in 
this novel molecular pathway remains uncertain. As detailed previously, O2
-
 anions 
do not readily react with most biological molecules (refer to introductory chapter 1.1) 
[1]. With this in mind, it is unlikely that the inhibitory effect of O2
-
 on PP2A stems 
from a direct reaction between PP2A and the radical itself. As such, a more plausible 
mechanism would be via an intermediary conversion of O2
-
 into a more reactive 
species which could then react with PP2AB56δ via other forms of oxidative 
modifications. In this study, since O2
-
 production was induced by preventing the 
dismutation of O2
-
 to H2O2 (by downregulating SOD1 activity), the involvement of 
H2O2 and hydroxyl radical (OH∙) is therefore unlikely. A logical alternative would 
thus be the reaction of O2
-
 with NO and the subsequent formation of ONOO
-
, a highly 
reactive molecule which could allow for the nitrosative modification of PP2AB56δ. 
The first and simplest way to verify this hypothesis would be to measure the 
intracellular production of ONOO
- 
upon DDC treatment. However, owing to the 
limited availability of reliable detection methods for ONOO
-
, we resorted to 
measuring the level of intracellular NO as a surrogate indicator of ONOO
-
 production 
upon DDC treatment. The experiment was performed on the basis that ONOO
-
 
production would necessitate the initial reaction of O2
- 
with NO and therefore, a drop 
in intracellular NO level would be inevitable if ONOO
- 
is produced upon DDC 
treatment. True to this aspect, a decline in the fluorescent level of the NO-sensitive 
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probe, DAF-FM, was clearly detected upon DDC treatment in both Jurkat and MDA-
231 cells (Figure 21), while pre-treatment with the O2
- 
scavenger, tiron, entirely 
abrogated the drop in NO in induced by DDC in both cell lines. Data here is 










Figure 21: DDC treatment resulted in a decline in intracellular NO level.   
Intracellular NO was measured in Jurkat and MDA231 using the NO-sensitive probe DAF-FM 
following 4 hours of DDC treatment. Cells loaded with DAF-FM were subsequently analysed via flow 
cytometry. DDC treatment resulted in a decline in cellular NO level, while pre-treatment with one hour 
of 5 mM tiron prevented the decline in intracellular NO induced by DDC. Data were analysed using 












is necessary for DDC-induced S70 Bcl-2 phosphorylation 
Taking into account that DDC treatment is accompanied by a parallel production in 
intracellular ONOO
-
, we next investigated whether ONOO
-
 could be responsible for 
the increase in S70 pBcl-2 induced by a heightened O2
- 
level in tumour cells.  To 
achieve this goal, we employed a ferric porphyrin complex (FeTPPS) that could 
catalyse the rapid isomerization of ONOO
- 
to its stable nitrate form (NO3
-
) and tested 
whether the removal of ONOO
- 
via FeTPPS pre-treatment could interfere with DDC-
induced upregulation of S70 pBcl-2 in Jurkat cells. While pre-treatment of cells with 
50 μM FeTPPS resulted in a slight decrease in DDC-induced S70 pBcl-2, pre-
treatment with 100μM FeTPPS significantly abated DDC-induced S70 pBcl-2 in 
Jurkat T-leukemic cells (Figure 22). It is deducible from these data that ONOO
-
 is a 
potential effector molecule that bridges O2
- 







Figure 22: FeTPPS pre-treatment blocked DDC-induced upregulation of S70 pBcl-2   
Jurkat cells were pre-treated with increasing doses of FeTPPS followed by 4 hours of 400 μM DDC 
treatment. Pre-treatment with 100 μM of FeTPPS (a catalyst of ONOO- degradation) completely 






4.3 Low doses of ONOO
- 
mirrored the effects of O2
- 
in promoting S70 pBcl-2 
and chemoresistance 
Building from the evidence that ONOO
- 
could be immediately downstream of O2
- 
amidst the process of DDC-induced S70 pBcl-2 upregulation, we tested if the direct 
addition of pure ONOO
-
 could also yield the same stimulatory effect on S70 pBcl-2 
as compared to DDC treatment. Jurkat T-leukemic cell line, our main model of study, 
was first treated with a range of ONOO
-
 doses (1-10 μM) for 1, 2, 3 and 4 hours and 
subsequently assayed for the level of S70 pBcl-2. As demonstrated in figure 18A, 
ONOO
- 
treatment led to a time- and dose-dependent increase in S70 pBcl-2 which 
was further sustained to at least 4 hours post-treatment (Figure 23A). Consistent with 
the notion of ONOO
-




-induced S70 pBcl-2 
peaked (2 hours of 10 μM ONOO-) earlier than that of DDC treatment (Figure 22A as 
compared to Figure 1A).   
Intriguingly, as we assessed the level of S70 pBcl-2 over a greater range of ONOO
- 
treatment doses, S70 pBcl-2 level diminishes upon ONOO
- 
treatment with 
concentrations greater than 20 μM (Figure 23B). This phenomenon is nonetheless 
within anticipation, for ONOO
- 
, like most ROS, is notorious for its biphasic 
behaviour in the regulation of cell death and proliferation. Low levels of ROS is 
known to create an intracellular milieu that signals cell survival [194-198], while a 
massive burst in intracellular ROS level often leads to uncontrolled oxidation of 
important molecules and is therefore detrimental to the cells [188-190]. Likewise, we 
demonstrate here that the increase in S70 pBcl-2 (Figure 23B) triggered by low 
concentration of ONOO
-
 (<20 μM) correlated well with an enhanced resistance 
against etoposide or doxorubicin-induced apoptosis (Figure 24A and 24B), while the 
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converse is true when the doses of ONOO
-
 goes beyond 20 μM (Figure 23B and 
24A). In fact, reports from others corroborated our observations as well. High levels 
of ONOO
-
 (>75 μM), besides being known for its apoptosis inducing capability [264, 
265], has also been recently shown to nitrate and activate the catalytic subunit of 
PP2A [266], hence possibly accounting for the observed decline in S70 pBcl-2 level 
upon high doses (50 and 100 μM) of ONOO- treatment (Figure 23B). 
Despite the biphasic nature of ONOO
-
, our data nonetheless demonstrated that 
ONOO
-
, at low doses, is supportive of a pro-survival tumour environment (Figure 









Figure 23: Low doses of ONOO
-
 induced the phosphorylation of Bcl-2 at S70.   
A. Jurkat cells were treated an incremental doses of pure ONOO
- 
(1, 2, 5, 10 μM) across four treatment 
time points (1, 2, 3, 4 hours) and subsequently harvested for western blot analysis. S70 pBcl-2 was 
clearly elevated in all treatment doses after 2 hours of ONOO
- 
treatment.  
B. Jurkat cells were treated with a greater range of ONOO
-
 doses at a treatment time point of 2 hours. 





















Figure 24: Low doses of ONOO
-
 protected against drug-induced cell death.   
A. Jurkat cells were pre-treated with an incremental doses of pure ONOO
- 
(5, 10, 20, 50, 100 μM) for 
an hour, followed by 2.5 μM etoposide for an additional 18 hours before cell viability was assessed via 
MTT assay. Pre-treatment of ONOO
- 
at doses lower than 20 μM significantly protected the cells 
against etoposide-induced cell death. Data presented are mean±SD of at least three independent 
experiments.  
B. Hela cells were pre-treated with 10 μM of ONOO- followed by treatment with a range of 
doxorubicin doses (1, 2, 5, and 10 μM) for an additional 18 hours. Cell viability was then assessed via 
crystal violet assay. Pre-treatment with 10 μM ONOO- clearly rescued Hela cells from the death 











treatment mimicked the inhibitory effect of SOD1 
downregulation on the interaction between B56δ and the AC catalytic core 





nevertheless exhibited a similar phenotype to that of O2
-
 in 
terms of its regulatory effects on S70 pBcl-2 level. True to this aspect, co-IP assay 
demonstrated that 10 μM ONOO- treatment completely mirrored the inhibitory effect 
of DDC by interfering with the holoenzyme assembly of PP2AB56δ in Jurkat cells 
(Figure 25A and 25B). Here, ONOO
- 
treatment interfered with complex formation 
between PP2A-C and Bcl-2, and also between PP2A-C and B56δ (Figure 25A and 
25B). However, the interaction between the core AC subunits, and also the interaction 
between B56δ and its substrate, Bcl-2, were unscathed by ONOO- treatment (Figure 
25A and 25B). Not limiting our study to a single cell line, similar observation was 
also observed with co-IP assay performed in Hela cervical carcinoma cells treated 
with either DDC or ONOO
-
 (Figure 25C). With such strong correlation between the 




 on PP2AB56δ holoenzyme assembly, and also 
the fact that ONOO
- 
production stems from the reaction between O2
- 
and NO, it can 
be inferred that ONOO
-
 is likely an effector molecule immediately downstream of O2
- 























 treatment inhibited the interaction of Bcl-2 with the AC catalytic core but not 
with the B56δ regulatory subunit. 
A. Co-IP assay was performed on Jurkat cells treated with 2 hours of 10 μM ONOO-. Using Bcl-2 as 
bait, it could be observed that ONOO
-
 treatment clearly impeded the interaction of Bcl-2 with the AC 
catalytic core of PP2A, while the interaction between Bcl-2 and B56δ remained intact.  
B. Co-IP assay performed in Jurkat cells using PP2A-C as bait protein indicated that the interaction 
between the AC core subunits remained intact upon 10 μM ONOO- but the physical association 
between PP2A-C and Bcl-2 as well as B56δ were both inhibited by ONOO- treatment.  
C. Hela cells were harvested for co-IP assay after treatment with either 400 μM of DDC (4 hours) or 
10 μM of ONOO-. Akin to Jurkat cells, the amount of B56δ and Bcl-2 that were co-precipitated with 















To provide further evidence that ONOO
- 
is downstream of O2
- 
in the inhibition of 
PP2AB56δ holoenzyme assembly, we evaluated if the elimination of ONOO
- 
via 
FeTPPS pre-treatment could block O2
-
-induced mitochondrial delocalization of AC 
core subunits. As shown previously, DDC treatment resulted in a decline in the 
mitochondrial levels of PP2A-A and PP2A-C which correlated with a reciprocal 
increase in their respective cytosolic levels, while the level of mitochondrial B56δ 
remained constant (Figure 26). Importantly, abatement of intracellular ONOO
- 
level 
via FeTPPS pre-treatment restored mitochondrial levels of both PP2A-A and PP2A-C 
in DDC-treated cells (Figure 26), suggesting that ONOO
-
 production is necessary for 
O2
- 








Figure 26: Pre-treatment of FeTPPS blocked the inhibitory effect of DDC on the mitochondrial 
localization of PP2A-A and PP2A-C.  
Jurkat cells were pre-treated with 100 μM of FeTPPS for one hour, followed by 4 hours of DDC 
treatment before being harvested for mitochondria fractionation assay. SOD1 was employed as 






 inhibited PP2AB56δ holoenzyme assembly via ONOO
-
-mediated 
nitration of B56δ at tyrosine-289 (Y289) 
5.1 Bioinformatics analysis revealed a conserved tyrosine residue on PP2A-
B56 regulatory subunits that is prone to nitrative modification  
While ONOO
-
 has been identified as a downstream effector of O2
-
, the precise 
cellular target(s) of ONOO
-
 that leads to the inhibition of PP2AB56δ has yet been 
established. Taking into account the relatively broad enzymatic specificity of the AC 





an interruption of the core enzymatic activity would be translatable to a global 
deactivation of all PP2A-mediated processes. As such, in order for O2
-
-mediated 
inhibition of PP2A to be of greater specificity, a more promising inhibitory target 
would thus be the B56δ regulatory subunit instead of the AC enzymatic core.  
Based on this reasoning, we sought to examine if B56δ could be a potential target for 
nitrosative modification processes. The two most common forms of oxidative protein 
modifications mediated by ONOO
-
 is the S-nitrosylation of cysteine residues into S-
nitrocysteine and the nitration of tyrosine residues into 3-nitrotyrosine [1]. Therefore, 
to identify potential nitrosative modification sites on B56δ, we performed a multiple 
sequence analysis of various B56 isoforms (both mammalian and non-mammalian 
origin) and scrutinized for well conserved cysteine or tyrosine residues that could 
serve as candidate residue for further analysis. Interestingly, multiple sequence 
analysis identified a well conserved tyrosine residue (corresponding to Y289 of B56δ; 
Figure 22A) that not only falls within the A subunit binding domain of the B56 
subunits [267], but also serves as one of the interacting residue between the B56 
isoforms and the A-scaffolding subunit [211]. This tyrosine residue appeared as a 
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promising target for nitration-mediated inhibition of PP2AB56δ because any potential 
nitrative modification of this residue would potentially affect the interaction between 
the A and the B56 subunits.  
Serendipitously, further analysis of adjacent sequence revealed that this tyrosine 
residue is particularly prone to nitrative processes. Protein tyrosine nitration is a 
selective process, and studies have shown that the selectivity of this process is 
governed by a set of criteria which favour the underlying nitrative mechanisms [268]. 
Regarding this, Souza et al. laid out a set of five factors which could influence the 
nitration of a tyrosine residue [268], all of which were satisfied by the candidate 
tyrosine residue identified on PP2A-B56 subunits.  
The first criterion states that the presence of an acidic residue, such as glutamate, 
directly adjacent to the tyrosine residue would greatly enhance the tendency for 
nitration (Figure 27A; red arrow). Secondly, the tyrosine residue should be situated at 
an exposed surface that is accessible to nitrating agent (Figure 27B). Also, there 
should be a loop inducing residue (glycine/proline) within the vicinity of the tyrosine 
residue (Figure 27A; green arrow) and consequently, this tyrosine residue should be 
located on or close to a loop structure (Figure 27C). Lastly, there should not be any 
cysteine or lysine residues within +5 and -5 of the nitrated residue (Figure 27A). 
Notably, these criteria were also supported by a separate study on endogenously 
nitrated proteins in mouse brain using liquid chromatography tandem mass 
spectrometry (LC/LC-MS/MS) techniques, demonstrating that the same preference 
for tyrosine nitration also exists in vivo [269]. In addition, a sixth criterion was also 
specified in this in vivo study, whereby a positively charged arginine (R) or lysine (L) 
should be present within 10-15 residues upstream of the nitrated tyorine residue, a 
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criterion that was also satisfied by the candidate tyrosine residue identified in our 
study (Figure 27A; purple arrow). 
By fulfilling the criteria as a nitration prone tyrosine residue, Y289 of B56δ 
(B56δY289) appears to be a prime target for the nitrative-inhibition of PP2AB56δ. Also, 
the fact that Y289 serves as an interacting residue between B56δ and the A-
scaffolding subunit further accentuates it as a promising target for the inhibition of 
PP2A by O2
-
. This is so, for any potential nitration of B56δY289 induced by an 
elevated level of intracellular O2
-
 would likely affect the binding of the AC catalytic 
core to B56δ, with the decline in Bcl-2 phosphatase activity as an obvious 






















Figure 27: In silico identification of a nitration-labile tyrosine residue on B56 regulatory subunit 
family members. 
A. Multi-sequence alignment of the different B56 regulatory subunit isoforms from both mammalian 
and non-mammalian origin. The nitration-prone tyrosine residue (Y) identified in B56 family members 
is boxed in red. Blue arrows denote residues that were implicated in the interaction of B56 subunits 
with PP2A-A [211]. The criteria that predispose a tyrosine residue towards nitrative modification 
process are depicted by red, green and purple arrows [268, 269]. Red arrow denotes a glutamate 
residue (E) situated immediately adjacent to the tyrosine residue of interest. Green arrow denotes a 
loop-inducing glycine residue (G) within the vicinity of the boxed tyrosine residue while purple arrows 
indicate two positively charged residue, arginine (R) and lysine (K), located upstream of the nitration 
prone tyrosine residue. Note that cysteine (C) and lysine (K) are absent within +5 and -5 of the boxed 
tyrosine residue. Multi-sequence alignment analysis was performed via Jalview 2.7. 
B. Crystal structure of B56γ1 (PDB code: 2IAE) demonstrated that the nitration-prone tyrosine residue 
is located at the surface of the B56 regulatory subunits, thus making it accessible to nitrating agents. 
C. An enlarged view of the alpha-helix motif harbouring the tyrosine residue of interest. Figure 
showed that the tyrosine residue is located near a loop as well, satisfying one of the factors determining 





5.2 DDC treatment augmented the level of 3-nitrotyrosine (3-NT) in HA-
B56α and HA-B56δ 
Given the in silico discovery of a nitration prone tyrosine residue in all B56 subfamily 
members, we next examined if this finding could indeed be translated to an actual 
biological setting. Pertaining this, we transfected Jurkat cells with a series of HA-
tagged plasmids encoding for each of the five major B56 isoforms, and assessed the 
effect of DDC treatment on the level of 3-NT in these transfected proteins. More 
specifically, HA-tagged B56 isoforms were first enriched via immunoprecipitation 
techniques and subsequently probed for their respective tyrosine nitration status using 
an antibody against 3-NT residues. 
Intriguingly, although the nitration prone tyrosine residue is well conserved across all 
B56 isoforms (Figure 27A), 3-NT could only be detected in three out of the five B56 
isoforms tested – HA-B56α, HA-B56β and HA-B56δ (Figure 28). While it is evident 
that 3-NT was completely undetectable in HA-B56ε, tyrosine nitration status of HA-
B56γ1 remains uncertain, since any potential detection of nitrated HA-B56γ1 could 
have been obscured by the strong interfering signal originating from the IgG heavy 
chain (Figure 28). Interestingly, of the three 3-NT-containing isoforms, DDC 
treatment augmented tyrosine nitration level only in HA-B56α and HA-B56δ, but not 
in HA-B56β (Figure 28), suggesting that the presence of the nitration-prone tyrosine 
residue is not the lone factor governing the process of B56 tyrosine nitration. 
The varying sensitivity of B56 isoforms against DDC treatment is unlikely to be 
contributed by the subtle sequence variation in the flanking regions of the nitration 
prone tyrosine residue described in figure 27A, particularly when the polymorphic 
residues are mostly conservative in nature (Figure 27A). An alternative account for 
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this observed phenomenon would be the potential spatial difference in the subcellular 
distribution of these B56 isoforms, a key factor that could greatly influence their 
respective proximity to the source of O2
- 
production. Considering the low diffusion 
capacity of most reactive species, spatial regulation is critical for the specificity and 
the regulation of redox signalling processes. Therefore, taking into account that B56 
regulatory subunits are well documented for their role in targeting the core enzyme 
towards different subcellular location in the cell, it is plausible that the differential 
subcellular distribution of B56 subunits provided an added level of regulatory 
specificity to their respective susceptibility to nitrating agents. In fact, the specific 
nitration of only HA-B56α and HA-B56δ rather than a global nitration of all B56 
isoforms upon DDC treatment strongly argues in favour of O2
-
-mediated tyrosine 




Figure 28: DDC treatment induced tyrosine nitration in HA-B56α and HA-B56δ. 
Jurkat cells were transfected with HA-tagged B56 family members (α, β, γ1, δ, and ε isoforms) for 24 
hours, followed by 400 μM DDC treatment for 4 hours, and then harvested for further analysis. The 
transfected HA-B56 family members were immuneprecipitated using HA-specific primary antibody 
and subsequently assessed for their respective tyrosine nitration statuses via anti-3-nitrotyrosine (3-NT) 




5.3 3-NT level was elevated in endogenous B56δ upon DDC and ONOO- 
treatment 
Given that 3-NT was clearly detected in HA-tagged B56δ subunits, we next 
investigated if DDC or ONOO
-
 treatment could also trigger an increase in the tyrosine 
nitration of endogenous B56δ in both Jurkat and Hela cells. Consistent with our 
previous findings, both DDC and ONOO
- treatment augmented the level of B56δ 
tyrosine nitration in the two tested cell lines (Figure 29A). Importantly, the increase 
in B56δ tyrosine nitration triggered by DDC and ONOO- was always paralleled by a 
decline in B56δ-PP2A-C interaction, whereas the interaction between B56δ and Bcl-2 
remained constant despite the redox alterations of B56δ (Figure 29A).  An increase in 
S70 pBcl-2 was also consistently observed upon DDC and ONOO
-
 treatment (Figure 
29A). From these data, it is evident that the level of B56δ tyrosine nitration is 
inversely correlated to the interaction between Bcl-2 and PP2A-C, thus suggesting 
that O2
-
-mediated inhibition of PP2A holoenzyme assembly could be a function of 
B56δ tyrosine nitration. Indeed, in further support of ONOO- being downstream of 
O2
-
-induced B56δ tyrosine nitration, we also demonstrated that FeTPPS pre-treatment 
thwarted the increase in DDC-induced B56δ tyrosine nitration, and by doing so, 
restored the ability of B56δ in recruiting PP2A-C for the S70 dephosphorylation of 
























Figure 29: Endogenous B56δ is tyrosine nitrated upon DDC and ONOO- treatment. 
A. Jurkat and Hela cells were treated with either 400 μM DDC (4 hours) or 10 μM ONOO- (2 hours) 
and harvested for co-IP analysis. B56δ was immunoprecipitated and the level of 3-NT was assessed. 
The levels of PP2A-C and Bcl-2 that were co-immunoprecipitated with B56δ were also assessed. DDC 
and ONOO
-
 induced tyrosine nitration of B56δ and this was inversely related to the binding of B56δ 
with PP2A-C. 
B. Jurkat cells were pre-treated with 100 μM FeTPPS before treatment with 400 μM DDC. After 
which, cells were harvested for co-IP analysis using B56δ as bait. FeTPPS pre-treatment reversed 






5.4 SOD1 knockdown induced B56δ tyrosine nitration and inhibited B56δ-
mediated recruitment of PP2A-C to Bcl-2  
Since pharmacological inhibition of SOD1 led to the increased in B56δ tyrosine 
nitration, we next asked the question if SiRNA-mediated downregulation of SOD1 
could actuate the same effect as well. To that end, B56δ was immunoprecipitated 
upon SOD1 knockdown in Jurkat cells and subsequently assayed for 3-NT levels via 
western blot analysis. Corroborating our previous observations using DDC/ONOO
-
 as 
triggers, the level of 3-NT detected in B56δ was greatly enhanced by the respective 
silencing of SOD1 with two different sequence of SiRNA (Figure 30A). Moreover, 
the observed increased in B56δ tyrosine nitration corresponded well with a 
simultaneous induction of S70 pBcl-2 as well as a converse diminution in the 
interaction of B56δ with PP2A-C (Figure 30A).  
In addition to western blot assays, confocal fluorescence imaging technique was also 
employed to evaluate the level of tyrosine-nitrated B56δ subunit in SOD1-silenced 
Jurkat cells. In great agreement with the observations from our western blot studies, 
co-localization signal of B56δ and 3-NT was greatly enhanced upon successful 
silencing of SOD1 in Jurkat cells (Figure 31A and Figure 31B; red arrows), thus 
indicating that a greater portion of B56δ is tyrosine nitrated upon the downregulation 















Figure 30: SOD1 knockdown induced B56δ tyrosine nitration and inhibited B56δ-PP2A-C 
complex formation. 
Jurkat cells were transfected with two independent sequences of SOD1-targeted SiRNAs and then 
harvested for co-IP analysis 48 hours post-transfection. B56δ was immuneprecipitated and the co-
precipitated levels of 3-NT, PP2A-C and Bcl-2 were assessed. Here, SOD1 knockdown triggered a 




















































Figure 31: Increased co-localization of B56δ and 3-NT levels upon SOD1 knockdown.   
A. Confocal imaging studies was performed on SOD1-downregulated Jurkat cells. Primary antibody 
against 3-NT was stained with Alexafluor-488-conjugated secondary antibody (green) while B56δ was 
detected using Alexafluor-568-conjugated secondary antibody (red). SOD1 knockdown enhanced the 
co-localization of 3-NT emitted green signal with the red signal originating from B56δ. 
B. An enlarged view of a single selected cell from panel A for greater clarity and resolution. Images 
were analysed using Olympus Fluoview 3.0 viewer.  





5.5 Inhibition of NOX by diphenyliodium (DPI) abrogated the inhibitory 
effect of SOD1 knockdown on PP2AB56δ  
In further attempt to validate the role of O2
-
 in the tyrosine nitration of B56δ, we 
evaluated if DPI, a known inhibitor of the O2
-
-producing NOX complex, could 
abrogate the rise in B56δ tyrosine nitration observed in SOD1-silenced Jurkat cells. 
With respect to this, Jurkat cells were first treated with 2.5 μM DPI at 24 hours post-
transfection and subsequently incubated with DPI for an additional 24 hours before 
being harvested for further analysis. The treatment strategy was chosen on the basis 
that O2
- 
production ought to be inhibited prior to the effective silencing period of 
SOD1 (36-48 hours) so that any accumulation of intracellular O2
- 
could be entirely 
prevented during the period in which SOD1 is downregulated. Indeed, by adopting 
this treatment approach, O2
- 
production in SOD1-silenced Jurkat cells were 
successfully quenched to a level comparable to untransfected cells, as judged by the 
level of intracellular O2
- 
detected via lucigenin-based chemiluminescence assay 
(Figure 32B).  
More importantly, DPI-mediated quenching of intracellular O2
- 
production completely 
prevented the increase in B56δ tyrosine nitration in SOD1-silenced cells (Figure 
32A). Concurrently, DPI treatment also restored the ability of B56δ in binding PP2A-
C in SOD1-silenced cells and as a result, S70 phosphorylation of Bcl-2 was 
suppressed in parallel as well (Figure 32A). These data not only suggests that O2
- 
is 
crucial in the inhibitory effect of SOD1 silencing on PP2AB56δ holoenzyme assembly, 
but also provided further evidence that tyrosine nitrated B56δ subunits are incapable 



















Figure 32: Pre-treatment with DPI blocked the effect of SOD1 knockdown on B56δ tyrosine 
nitration and B56δ-PP2A-C interaction.   
A. 24 hours after SiRNA transfection, Jurkat cells were treated with 2.5 μM of DPI for an additional 24 
hours before being harvested for co-IP analysis. DPI treatment nullified the effect of SOD1 knockdown 
in Jurkat cells. 
B. Lucigenin chemiluminescence assay measuring intracellular O2
- 
level upon 24 hours of 2.5 μM DPI 
treatment in SOD1-knockdowned Jurkat cells. DPI treatment successfully restored intracellular O2
-
 in 
SOD1-downregualted Jurkat cells to a level comparable to that of untransfected cells. Intracellular O2
- 
level is positively correlated with B56δ tyrosine nitration status but negatively correlated with the 





5.6 Scavenging of O2
- 
via bSOD1 treatment potentiated PP2AB56δ mediated 
dephosphorylation of Bcl-2 at S70 
If an accumulation of intracellular O2
-
 induced by SOD1 downregulation could inhibit 
the holoenzyme assembly of PP2AB56δ by inducing the tyrosine nitration of B56δ, the 
converse effect would be expected if tumour cells are provided with an artificial boost 
in the dismutation rate of intracellular O2
-
 to H2O2. Advancing from this concept, we 
evaluated if the treatment of bSOD1 could elicit an opposing response to that of 
SOD1 knockdown.  
True to this aspect, treatment of Jurkat T-leukemic cells with 1,000 Units/ml bSOD1 
for 16 hours significantly reduced the level tyrosine-nitrated B56δ subunits (Figure 
33). Concomitantly, and increased in the binding of B56δ to PP2A-C was also 
observed, a phenomenon which is in turn translatable to a drop in S70 pBcl-2 level 
(Figure 33). Evidently, the level of both B56δ tyrosine nitration and S70 pBcl-2 
exhibited an inverse relationship with the O2
- 
scavenging capacity of Jurkat cells, thus 
further supporting the notion of B56δ tyrosine nitration being involved in O2
-
-induced 























Figure 33: bSOD1 treatment reduced B56δ tyrosine nitration and enhanced the interaction 
between PP2A-C and B56δ.  
Jurkat cells treated with 16 hours of 1,000 Units/ml bSOD1 were harvested for co-IP assay with B56δ 
as bait protein. bSOD1 was detected as a lower molecular weight band just below human SOD1 as 






production also stimulated the phosphorylation of tau, 
but not pRb, and Raf 
If B56δ is indeed targeted by O2
-
 for the inhibition of PP2AB56δ, the 
dephosphorylation of other known PP2AB56δ substrates would be equally affected by 
an elevated level of intracellular O2
- 
as well. As such, we examined if the induction of 
O2
- 
production via DDC treatment could also enhance the phosphorylation of other 
PP2AB56δ substrates.  
To date, two other proteins have been described as targets of PP2AB56δ. They are 
namely, the mitotic regulatory protein, Cdc25C [270], and the microtubule binding 
protein, tau [271]. However, owing to the limited commercial availability of primary 
antibodies specific for phospho-Cdc25C, we resorted to studying the phosphorylation 
status of tau protein as the only alternative substrate of PP2AB56δ. Indeed, in support 
of B56δ as an inhibitory target of O2
-
, the level of S202/T205 phospho-tau, the 
phosphorylation site under the regulation of PP2AB56δ [271], was markedly increased 
in a dose-dependent manner upon DDC treatment in Jurkat cells (Figure 34). In 
contrast, the phosphorylation status of two other non-B56 regulated substrates of 
PP2A, pRb (regulated by PP2APR70) and Raf1 (regulated by PP2AB55α/δ) were not 
affected by DDC treatment [235, 272].  
In addition, in attempt to determine if the activity of PP2AB56γ1 could be affected by 
DDC treatment as well, the expression status of p53 was also assessed. PP2AB56γ1 is 
known to dephosphorylate p53 at T55 and given that T55 phosphorylation of p53 is 
known to enhance its degradation [238], a decline in p53 level upon DDC treatment 
would be expected if PP2AB56γ1 could indeed be inhibited by O2
-
. Indeed, a marked 
decline in p53 levels was evident across the entire range of DDC doses used, 
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suggesting that PP2AB56γ1 is likely an inhibitory target of O2
- 
as well. In fact, 
PP2AB56γ1 appeared to be even more sensitive to the inhibitory effect of O2
-
, since a 
decline in p53 expression was detected at DDC doses as low as 50 μM.  
Taken together, data here is indicative of PP2AB56δ and PP2AB56γ1 as likely inhibitory 
targets of O2
-
, while non-B56-containing PP2A heterotrimers are spared from the 









Figure 34: DDC treatment induced the phosphorylation tau protein  
The phosphorylation status of various PP2A substrates were assessed in Jurkat cells treated with an 
incremental doses of DDC for 4 hours. Phosphorylation of tau protein (an alternative substrate of 








5.8 Nitration status of B56δY289 is positively correlated with the level of S70 
pBcl-2 in Jurkat cells 
Thus far, we have provided concrete evidence demonstrating an increased in B56δ 
tyrosine nitration in response to DDC/ONOO
- 
treatment in tumour cells. Moreover, 
B56δ tyrosine nitration corresponded not only with an increase in S70 pBcl-2 level, 
but also with the inability of B56δ in binding the AC catalytic core. Although these 
observations are phenotypic of what would have been expected from the nitration of 
B56δY289, there are nonetheless insufficient evidence to pinpoint B56δY289 as the 
precise residue that was nitrated in this instances. 
Therefore, to further investigate the nitration status of B56δY289 in an O2
- 
dominated 
intracellular environment, we employed a custom-made primary antibody that could 
specifically recognize Y289-nitrated B56δ proteins to evaluate if B56δY289 is indeed 
nitrated in our study. To that end, a 19 amino acids peptide containing nitrated 
B56δY289 residue (3NO2-Y289) and the corresponding flanking sequence of B56δ 
(Figure 35A) was utilized for the immunization of two rabbits over a period of 70 
days. The antisera obtained were then purified using a two-step affinity purification 
strategy whereby the first affinity column contains the non-nitrated peptides as 
affinity ligand and the flowthrough would be channelled through a second affinity 
column using 3NO2-Y289-containing peptides. This ensures that antibodies eluted 
from the second column would be specific for Y289-nitrated B56δ proteins but not its 
non-nitrated counterparts.  
Using this 3NO22-Y289 specific antibody, we detected a distinct protein band just 
underneath the 75 kDa protein marker, a position that corresponded well with the 
69.9 kDa molecular mass of B56δ subunit (Figure 35B), indicating that B56δY289 is 
131 
 
indeed nitrated in endogenous B56δ of Jurkat T-leukemic cells. More importantly, the 
intensity of 3NO22-Y289 paralleled the level of S70 pbcl-2 which increased in 
conjunction with the treatment of DDC, ONOO
-
 and also the silencing of SOD1 
(Figure 35B). In addition, pre-incubation of Jurkat cells with FeTPPS abrogated 
DDC-induced B56δY289 nitration but 16 hours of bSOD1 pre-treatment neither 
affected the nitration of B56δY289 nor the upregulation of S70 pBcl-2 induced by 
ONOO
- 





in the regulation of S70 Bcl-2 phosphorylation.  
Of note, two weaker protein bands were also detected at the region between the crisp 
3NO22-Y289 band and the 50 kDa protein marker. Though the exact identity of these 
bands is not entirely clear, a blastp analysis with the epitope peptide sequence 
retrieved B56γ1 (52.6 kDa) as the closest matching candidate with a sequence 
identity of 90%, while the three other B56 isoforms, B56α (56.2 kDa), B56β (57.4 
kDa) and B56ε (54.7 kDa), came in close with a percentage identity of 80%, 80% and 
75% respectively (Figure 35C). Taking into account the lowest molecular weight, as 
well as the highest epitope similarity amongst the B56 isoforms, B56γ1 appeared as 
the best candidate to account for the protein band closest to the 50 kDa protein 
marker. On the other hand, the relatively similar molecular weight and sequence 
identity amongst the other three B56 isoforms implies that either one of these 
isoforms could potentially account for the band located in the middle. However, since 
an increase in 3-NT level was previously detected in HA-B56α upon DDC treatment 
(Figure 28), this places B56α as the most plausible candidate to account for the 

































Figure 35: B56δY289 nitration is positively correlated with intracellular O2
- 
and S70 pBcl-2 levels. 
A. The amino acid sequence of the peptide employed for the immunization of rabbits. The nitrated 
tyrosine residue is denoted by an asterisk (*). 
B. Primary antibodies raised from the peptide depicted in panel A detected a distinct band that 
corresponded well with the molecular weight of B56δ in Jurkat cells. Two other protein bands with 
lower molecular weights were detected at a lower intensity as well. The intensities of these protein 
bands positively correlated with the level of S70 pBcl-2. 
C. Blastp analysis of the peptide sequence from panel A indicated that the peptide used for 
immunization shares a certain degree of similarity with other B56 family members as well.  
 
 
5.9 Site-directed mutagenesis studies confirmed the regulatory role of 
B56δY289 nitration in O2
-
-induced upregulation of S70 pBcl-2 
The strong correlation between 3NO2-Y289 and S70 pBcl-2 level is obvious, though 
a causal relationship between these two parameters has yet been established. To 
address this, we sought to examine whether O2
-
-induced upregulation of S70 pBcl-2 
could be affected if B56δY289 nitration is impeded by site-directed mutagenesis of 
B56δY289 to a non-nitratable phenylalanine residue (Figure 36A).  
Using the Quikchange II site-directed mutagenesis kit, primers designed to harbour 
the desired mutation (refer to materials and methods for primers sequences) were first 
PCR-amplified using the HA-B56δ-containing plasmids as template and subsequently 
verified via DNA agarose gel electrophoresis. Here, a total of 7 plasmid clones were 
generated using a variety of PCR conditions, with clone 6 and clone 7 exhibiting the 
highest yield of PCR-amplification products that co-migrated with the wild type 
plasmid (Figure 36B). These two plasmid clones were then selected for further 
purification and subsequently verified via sequencing procedures. Sequencing results 
validated the successful incorporation of the intended mutation (adenine to thymine) 
in both plasmid clones without any aberration mutations being detected across the 
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entire length of the B56δ insert (Figure 36C), thus confirming the successful synthesis 
of a plasmid clone encoding for HA-B56δ harbouring the Y289F mutation (Y289F-
B56δ).  
Furthering from here, we transfected either wild type HA-B56δ (WT-B56δ) or 
Y289F-B56δ into Jurkat T-leukemic cells and evaluated their respective effect on S70 
pBcl-2 levels in DDC-treated cells. Whereas the introduction of WT-B56δ resulted 
only in a modest delay in DDC-induced S70 Bcl-2 phosphorylation (Figure 37), the 
enforced expression of Y289F-B56δ completely abolished the agonistic effect of 
DDC on S70 phosphorylation of Bcl-2 (Figure 37). Despite the role of PP2AB56δ as a 
Bcl-2 phosphatase, overexpression of WT-B56δ alone was clearly insufficient in 
overcoming the positive effect of DDC on the level of S70 pBcl-2 and complete 
abrogation of DDC-induced S70 Bcl-2 phosphorylation could only be achieved when 
the nitration of B56δY289 was impeded. Clearly, B56δY289 nitration is imperative for 
O2
-























Figure 36: Site-directed mutagenesis of B56δY289 to a phenylalanine residue. 
A. Figure depicts the tyrosine residue on B56δ that was substituted to a phenylalanine residue (Y289F 
mutation).  
B. The various plasmid clones generated via PCR-based site-directed mutagenesis were validated by 
DNA gel electrophoresis. Clone 6 and clone 7 showed greatest yields of PCR-amplification products 
that co-migrated with the parental plasmid and were subsequently selected for further purification and 
validation via sequencing procedures. 
C. Sequencing results of clone 6 and clone 7 plasmids indicated successful mutation of an adenine 
nucleotide to a thymine nucleotide (red arrow), thereby converting a tyrosine residue (TAC) to a 















Figure 37: Substitution of B56δY289 to a non-nitratable phenylalanine residue abrogated DDC-
induced phosphorylation of Bcl-2 at S70. 
Jurkat cells were transfected with either WT-B56δ or Y289F-B56δ for 24 hours followed by 400 μM 
DDC treatment for an additional 4 or 8 hours. After which, cells were harvested and S70 pBcl-2 status 
was assessed via western blot analysis.  
 
 
5.10 Y289F-B56δ transfection restored the interaction between B56δ and 
PP2A-C in DDC-treated Jurkat cells 
Since O2
-
 augmented the level of S70 pBcl-2 by inhibiting the interaction between 
B56δ and PP2A-C, we next investigated if the Y289F mutants could also reverse the 
inhibitory effect of O2
- 
on the physical association of B56δ with PP2A-C. Thus, we 
transiently transfected Jurkat T-leukemic cells with either WT-B56δ or Y289F-B56δ 
and evaluated the effect(s) of DDC treatment on the respective interaction status of 
these transfected B56δ subunits with PP2A-C.  
Here, it could be observed that the enforced expression of either WT-B56δ or Y289F-
B56δ resulted in a decline in S70 pBcl-2 level as compared to empty vector-
transfected cells (Figure 38), indicating that these transfected proteins are functionally 
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intact. More importantly, Y289F mutation entirely blocked the susceptibility of B56δ 
to DDC-induced tyrosine nitration (Figure 38A), which in turn correlated strongly 
with the inability of DDC to induce S70 phosphorylation of Bcl-2 upon Y289F-B56δ 
transfection (Figure 38A). Moreover, the inhibitory effect of DDC on B56δ-PP2A-C 
interaction was also abrogated by the introduction of Y289F-B56δ mutants (Figure 
38A). In further support to the findings using DDC as trigger, Y289F-B56δ 
transfection also exerted a similar countering effect on ONOO
-
-mediated inhibition of 
PP2AB56δ (Figure 38B). Undoubtedly, these data confirms B56δ
Y289
 nitration as a 
critical step for O2
-
-mediated inhibition of both PP2AB56δ holoenzyme assembly and 
the Bcl-2 phosphatase activity that accompanies it.  
It is noteworthy that the basal 3-NT level of Y289F-B56δ is relatively similar to that 
of WT-B56δ in non-DDC-treated Jurkat cells. This is indicative of a constitutive 
presence of other 3-NT residue(s) that is non-Y289-related. The exact role of these 
Y289-independent 3-NT residue(s) is uncertain. However, it could be concluded that 
these nitro-tyrosine residues are barely, if at all, responsive to DDC or ONOO
-
 
treatment, as could be inferred from the similar 3-NT levels detected on Y289F-B56δ 
in both untreated and DDC/ONOO
-






















Figure 38: Y289F substitution abrogated DDC- and ONOO
-
-induced B56δ tyrosine nitration and 
restored the binding B56δ to PP2A-C. 
A & B. Jurkat cells were transfected with either WT-B56δ or Y289F-B56δ for 24 hours and then 
followed by 8 hours of 400 μM DDC treatment (panel A) or 4 hours of 10 μM ONOO- treatment 
(panel B). Transfected WT or mutant B56δ subunits were then immuneprecipitated using anti-HA 
antibodies and assessed for their respective nitration status. Co-immunoprecipitation status of PP2A-C 






5.11 Y289F-B56δ transfection restored the co-localization status of Bcl-2 and 
PP2A-C in DDC-treated Jurkat cells 
Besides co-IP assays, confocal imaging techniques were also employed to provide an 
additional line of evidence to our findings.  Immunofluorescence staining of Jurkat 
cells using anti-3-NT and anti-HA antibodies showed an enhanced co-localization of 
HA-B56δ and 3-NT upon DDC treatment in WT-B56δ-transfected cells (Figure 39A 
and 39B). In Y289F-B56δ-transfected cells, however, no increase in co-localization 
signal between Y289F-B56δ and 3-NT could be detected upon DDC treatment 
(Figure 39A and 39B). This data is in great agreement with our previous findings 




Extending from these findings, we next questioned if Y289F-B56δ transfection could 
also affect the inhibitory effect of O2
-
 induction on the co-localization of PP2A-C and 
Bcl-2. Thus, immunofluorescence staining using Bcl-2 and PP2A-C antibodies was 
also performed in Jurkat cells transfected with either WT-B56δ or Y289F-B56δ. 
Subsequent fluorescence imaging study demonstrated a strong co-localization of 
PP2A-C and Bcl-2 that was invariably observed in all non-DDC-treated cells 
irrespective of the transfected plasmid  (Figure 40A and 40B). Upon DDC treatment 
however, co-localization signal of Bcl-2 and PP2A-C was clearly diminished in both 
pCEP4- and WT-B56δ-transfected cells, but not in cells transfected with Y289F-
B56δ (Figure 40A and 40B). This indicates that DDC could not disrupt the co-
localization of PP2A-C and Bcl-2 upon the introduction of Y289F-B56δ, thus lending 
further credence to our hypothesis that the nitration of B56δY289 is necessary for O2
-
-
mediated inhibition of PP2AB56δ. 
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Figure 39: Y289F mutation abolished the co-localization of 3-NT and HA-B56δ upon DDC 
treatment.  
A. Jurkat cells transfected with either WT-B56δ or Y289F-B56δ were treated with 8 hours of 400 μM 
DDC and subsequently harvested for confocal imaging studies. 3-NT was stained via Alexafluor-488-
conjugated secondary antibody (green) while HA-tagged B56δ proteins (WT or Y289F) were stained 
using Alexafluor-568-conjugated secondary antibody (red).  
B. An enlarged view of a single selected cell from panel A for greater clarity and resolution. Images 


































Figure 40: Transfection of Y289F-B56δ preserved the co-localization status of PP2A-C and Bcl-2 
upon DDC treatment.  
A. Jurkat cells transfected with either WT-B56δ or Y289F-B56δ were treated with 8 hours of 400 μM 
DDC and subsequently harvested for confocal imaging studies. PP2A-C was stained via Alexafluor-
488-conjugated secondary antibody (green) while Bcl-2 were stained using Alexafluor-568-conjugated 
secondary antibody (red).  
B. An enlarged view of a single selected cell from panel A for greater clarity and resolution. Images 































5.12 Y289F-B56δ transfection abolished the death-inhibitory effect of DDC in 
Jurkat T-leukemic cells 
With concrete evidence demonstrating the critical role of B56δY289 nitration in O2
-
-
mediated upregulation of S70 pBcl-2, we next questioned if this is indeed translatable 
to the level of O2
-
-induced chemoresistance. Thus, in our endeavour to establish 
B56δY289 nitration as an important regulatory step amidst the death-inhibitory 
pathways orchestrated by O2
-
, we tested if Y289F-B56δ transfection could nullify the 
protective effect of DDC against various death-inducing agents.  
As demonstrated previously, DDC-conferred chemoresistance was evident in both 
untranfected and empty vector-transfected Jurkat cells treated with either etoposide 
(Figure 41A) or doxorubicin (Figure 41B). Whereas the overexpression of WT-B56δ 
slightly dwindled the protective effect of DDC against etoposide- or doxorubicin-
induced cell death (Figure 41A and 41B), enforced expression of the non-nitratable 
Y289F mutant completely abolished the death-inhibitory effect of DDC regardless of 
the death trigger (Figure 41A and 41B). Clearly, B56δY289 nitration is a key 
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Figure 41: Y289F-B56δ transfection abolished the protective effect of DDC against drug-induced 
cell death.  
A & B. WT-B56δ- or Y289F-B56δ-trasnfected Jurkat cells were first pre-treated with one hour of 400 
μM DDC before treatment with either 2.5 μM etoposide (panel A) or 1 μM doxorubicin (panel B) for 
another 18 hours. After which, cell viability was assessed via MTT assay. Data presented are 






6 Clinical relevance of SOD1 downregulation in primary lymphoma 
biopsy samples 
6.1 An inverse relationship exists between SOD1 and S70 pBcl-2 in primary 
lymphoma cells   
We have provided concrete evidence demonstrating that the expression of SOD1 is 
inversely correlated with the level of S70 pBcl-2 in a variety of tumour cell lines. 
This was further shown to be a function of an augmented level of intracellular O2
-
 
which triggered a series of signalling events that eventually lead to the nitrative 
inhibition of the Bcl-2 phosphatase, PP2AB56δ. More specifically, we delineated a 
molecular pathway demonstrating that O2
-
, by reacting with NO, formed ONOO
- 
which then triggered the nitration of B56δY289 and by doing so, impeded the 
recruitment PP2A-AC catalytic core to B56δ and Bcl-2. While these findings are 
supported by conclusive evidence from tumour cell line models, whether the same 
phenomenon could also be observed in vivo remains uncertain. 
Being mindful of this shortcoming, we sought to analyse the expression levels of 
relevant key proteins in a total of ten clinical lymphoma biopsies in pursuit of 
potential clinical evidence that could further substantiate our findings. Of the ten 
lymphoma biopsies accrued, three samples were clinically diagnosed as B cell 
lymphomas (P3, P4 and P5), two pairs of which were follicular lymphomas (P1 and 
P2) and Hodgkin’s lymphoma (P6 and P7) respectively, and the three remaining 
biopsies were respectively diagnosed as precursor T-lymphoblastic leukemia (P8), 
reactive lymphoid hyperplasia (P9) and mantle cell lymphoma (P10).  
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Corroborating our findings from in vitro cell culture studies, western blot analysis 
revealed an apparent regulatory link between S70 pBcl-2 and SOD1, whereby S70 
pBcl-2 levels tend to be elevated in primary lymphoma tumours that are low or 
entirely devoid of SOD1 (Figure 42A). The converse also holds true in tumours with 
high SOD1 levels, with the exceptions of P1 and P3 where a decent level of S70 
pBcl-2 could also be observed despite the high expression of SOD1 (Figure 42A).  
However, these two exceptions could be accounted, at least in part, by the lack of 
B56δ expression in both P1 and P3, suggesting that B56δ is involved in the 
dephosphorylation of S70 pBcl-2 not only in tumour cells lines, but also in primary 
lymphoma cells (Figure 42A). Of note, no correlation could be established between 
the levels of S70 pBcl-2 with either SOD2 or phospho-ERK1/2 (Figure 42A), 
suggesting the independence of these two factors from the regulation of S70 Bcl-2 
phosphorylation. 
Interestingly, it appears that a potential functional redundancy could also exist 
between B56δ and B56α (or possibly other B56 subunits as well) in the 
dephosphorylation process of S70 pBcl-2. This is indicated by the fact that S70 pBcl-
2 levels are lower in both P1 and P3 as compared to P2 and P4 despite the complete 
absence of B56δ (Figure 42A), indicating that other B56 isoforms could possibly 
assume the role of S70 Bcl-2 dephosphorylation in the absence of B56δ. Nonetheless, 
owing to the extremely heterogeneous nature of most, if not all, primary tumours, any 
postulations from these data is still a far cry from being conclusive, for any potential 
inter-tumour difference in S70 pBcl-2 levels could well be contributed by the 
differing Bcl-2 kinase activity amongst tumour samples as well. A greater sample size 
of lymphoma biopsies would allow for more conclusive interpretation in the future.  
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Figure 42: SOD1 expression is inversely correlated with the level of S70 pBcl-2 in primary 
lymphoma tissues. 
A. Clinical lymphoma biopsies were attained from patient donors from National University Hospital 
Singapore and processed as described in materials and methods. Lymphoma biopsies accrued were 
arbitrarily numbered as P1-P10 and the clinical diagnosis of these samples are: P1 – Low grade 
follicular lymphoma, P2 – Third grade follicular lymphoma, P3 – Low grade B cell lymphoma, P4 – 
Large B cell lymphoma, P5 – Diffused large B cell lymphoma, P6 – Classical Hodgkin’s lymphoma, 
P7 – Hodgkin’s lymphoma, P8 – Precursor T-lymphoblastic leukemia, P9 – Reactive lymphoid 
hyperplasia and P10 – Mantle cell lymphoma. Lymphoma biopsies denoted with an asterisk (*) were 
derived from tumours that were sufficiently large for further analysis via co-IP assay.  
B. Lysates from lymphoma biopsies denoted with * were subjected to further analysis via co-IP assay. 
B56δ were immunoprecipitated from the samples and assessed for their respective nitration status. The 





6.2 Primary lymphoma tumours expressing high level of S70 pBcl-2 
harboured B56δ that are tyrosine nitrated 
Of the ten clinical lymphoma samples tested, five (denoted with *) were derived from 
tumours that were sufficiently large for further experimental analysis via co-IP assay. 
Via the immunoprecipitation of B56δ, we asked the question if B56δ could also be 
tyrosine nitrated in primary lymphoma tumours, and if so, do the tyrosine nitration 
statuses correlate with the respective levels of S70 pBcl-2 in these tumours as well.  
As was previously demonstrated in tumour cell lines, a robust interaction between 
B56δ and Bcl-2 was also detected across all the five primary lymphomas biopsies that 
were tested (Figure 42B), thus implicating PP2AB56δ as the Bcl-2 phosphatase even in 
primary lymphoma tumours. Moreover, B56δ tyrosine nitration was also detected in 
tumour biopsies derived from patients with reactive lymphoid hyperplasia (P9) and 
mantle cell lymphoma (P10), and to a lesser extent in tumours from B cell lymphoma 
(P4) and classical Hodgkin’s lymphoma (P6) (Figure 42B). Importantly, the highly 
nitrated B56δ in P9 and P10 interacted poorly with PP2A-C (Figure 42B), and this 
correlated well with a heightened level of S70 pBcl-2 as well as an inversely low 
level of SOD1 in these tumours (Figure 42A). The converse is also true in both 
biopsy samples derived from Hodgkin’s lymphomas (P6 and P7).  
While these observations are strongly supportive of our findings from in vitro cell 
lines, there was nonetheless an exception, as the same correlation could not be 
established in P4, a large B cell lymphoma. Given a scarce, if at all detectable, level 
of SOD1 (Figure 42A), as well as the inability of B56δ in binding PP2A-C (Figure 
42B), B56δ would have been expected to be highly tyrosine nitrated in P4. This, 
however, was clearly not the case (Figure 42B). It appears that B56δ tyrosine 
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nitration might not be as critical in the regulation of S70 pBcl-2 in P4 (B cell 
lymphoma). Whether this phenomenon is due to a greater regulatory influence by 
B56α or other B56 regulatory subunits in B cell lymphomas is uncertain. In spite of 
the lone exception of a B cell lymphoma biopsy, our data, both in vivo and in vitro, is 
nonetheless in great favour of B56δY289 nitration as a central element in the redox 





1 ROS as intricate regulators of cell death 
1.1  S70 pBcl-2 as a key player in O2
-
-mediated chemoresistance 
ROS-governed cellular processes are highly intricate in nature, often involving a 
well-orchestrated series of events that necessitate the tight regulation of various 
important parameters. Factors such as the type of radical(s), the subcellular location 
in which the radical(s) are produced, and also the local concentration of the radical(s) 
involved could well influence the outcome of ROS-mediated signalling events.  
Likewise, ROS-dependent cell fate processes demand a delicate balance of different 
intracellular ROS species, deregulation of which would lead to uncontrolled cell 
proliferation and hence cancer. Indeed, a large body of evidence has demonstrated 
that tumours cells frequently exhibit a constitutively elevated level of ROS (in 
particularly O2
-
) [179, 200, 202, 273-275] as a result of dysregulated cellular 
antioxidant machineries, endowing these malignant cells with a greater metastatic 
[202, 273, 274] and survival potential [179, 198, 199, 201]. Although much effort 
have been channelled into elucidating the oncogenic potential of O2
- 
anions, precisely 
how this radical species exerts its pro-survival influence in tumour cells remains 
elusive.  
Here, we described a novel mechanism whereby an elevated level of intracellular O2
- 
induced by either pharmacological inhibition or genetic knockdown of SOD1 could 
promote tumour chemoresistance by augmenting the phosphorylation (and activation) 





react more readily with NO to form ONOO
-
. This we demonstrated, led to the 
inhibitory nitration of the Bcl-2 phosphatase, PP2AB56δ, and the consequential 
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increase in S70 pBcl-2 level. More specifically, we identified a nitration-prone 
tyrosine residue on the B56δ regulatory subunit of PP2A (B56δY289) which served as 
an interacting site between B56δ and the A scaffolding subunit of PP2A. The 
nitration of which impeded the association between the catalytic core and the B56δ-
Bcl-2 complex as well as inhibited the recruitment of the AC core to the 
mitochondria. As a result, the dephosphorylation of Bcl-2 at S70 is inhibited, and the 
accumulation of phosphorylation-activated Bcl-2 ensues. Via these findings, we 
reveal a novel strategy in which tumour cells could harness the pro-survival 
properties of O2
-
 in order to achieve a hardier phenotype (summarized in figure G; 





- – Killers or protectors?  
The regulatory role of ROS in cell death and proliferation processes is akin a double-
edged sword. While a mild pro-oxidant state dominated by O2
- 
anions is known to 
create an intracellular milieu that favours cell survival [179, 198-200, 202], excessive 
production of intracellular ROS has been shown to trigger cell death via the oxidative 
activation of various death executionary pathways [188-193]. In line with this, our 
work highlighted the existence of a dynamic interplay amongst the various ROS in 
the regulation of cell death processes. We showed that a tilt in cellular redox 
equilibrium in favour of O2
-
 anions augmented the formation of ONOO
- 
via the 
radical fusion of O2
-
 and NO, with the resultant ONOO
- 
being just sufficient for the 
nitrative modification of nitration-labile tyrosine residues which then triggered a 
cascade of pro-survival signalling events in the cell. However, a delicate balance in 
the levels of these reactive species appeared to be obligatory for the proper execution 
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of these pro-survival events. Low or moderate level of ONOO
- 
would only affect 
nitration-sensitive targets, but higher level of ONOO
- 
would result in the 
indiscriminatory nitration of less reactive targets as well. Thus, more is not always 
better, as exemplified by the deleterious effect of ONOO
- 
when introduced at high 
concentrations in Jurkat cells (Figure 24A). Therefore, in order for tumour cells to 
harness the pro-survival properties O2
-
, a tightly regulated level of intracellular NO 
would be necessary, as the downregulation of SOD1 in tumours with a heightened 
basal level of intracellular NO could well result in the massive formation of ONOO
-
, 
thereby tilting its role from a protector, over to a killer.  




 that kills? And what is not? 
Notwithstanding the extensive research on ROS-modulated death signalling events, 
the critical threshold that parts the death-inhibitory and the death-inducing effects of a 
reactive species remains elusive to date. This, in part, is contributed by the fact that 
the cellular concentration of ROS is not the sole determining factor of its biological 
activity, for it is also dependent on other factors such as the tumour 
microenvironment, the local concentration of ROS, and even the spatial and temporal 
distribution of the ROS involved. Likewise, the effective ONOO
-
 concentrations that 
govern its biological activity would likely differ in an intra- and inter-tumour manner, 
making it impractical to lay a “one size fits all” numerical value on the critical 
ONOO
-
 concentrations that determine its death-regulatory properties. 
In addition, efforts into delineating the critical ROS level that separates its pro-death 
and pro-survival properties is further complicated by a lack of experimental means in 
measuring the exact intracellular concentration of ROS. More often than not, radicals 
are indirectly detected via semi-quantitative methods such as redox-sensitive 
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luminescence/fluorescence probes or electron paramagnetic resonance (EPR) spin 
trapping techniques, rendering it difficult to put an absolute figure on the amount of 
detected ROS even if an important finding emerges. In the case of ONOO
-
, finding 
the exact intracellular concentration that renders it a pro-survival molecule would be 
even tougher, if at all possible, since research into identifying a specific probe for 
ONOO
-
 has yet been successful thus far. Clearly, a breakthrough from conventional 
ROS detection strategies would be crucial for a deeper understanding of this 
conundrum that has been troubling researchers for the past few decades.  
 
1.3  SOD1 – are they tumour suppressors? 
If O2
-
 anion is an oncogenic factor, that would imply SOD1 is a tumour suppressor. 
Indeed, given that the oppression of SOD1 activity led to an augmented level of 
intracellular O2
-
 that promoted chemoresistance in tumour cells, it would not be 
surprising if the antioxidant enzyme shares the task of other tumour suppressors in 
subduing neoplastic behaviours as well. On one hand, expression of SOD1 could 
assist in protecting genome integrity by reducing oxidative DNA damage, while on 
the other, keeps PP2AB56δ activated for the suppression of anti-apoptotic Bcl-2.  
While SOD1 may appear as a plausible tumour suppressor, studies attempting to 
elucidate the role of this antioxidant protein in tumorigenesis have not been entirely 
conclusive to date. Evidence accrued thus far is generally in favour of SOD1 as a 
tumour suppressor, though there are some reports indicating otherwise as well (Table 
2 and Table 3). In support of a tumour suppressive role, overexpression of SOD1 was 
shown to either promote apoptosis or sensitize against drug-induced apoptosis in 
melanoma, glioma, and neuroblastoma cells [198, 205, 206], while SOD1 knockdown 
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enhanced cell survival in lung epithelial and M14 melanoma cells (Table 2) [199, 
276]. However, contradictory to these findings, opposing observations were also 
reported when SOD1 activity or expression level was manipulated in other tumour 
cell lines such as ovarian carcinoma, lung carcinoma and leukemia cells (Table 2) 
[277-279], rendering it difficult to achieve a definitive conclusion regarding the 
tumour suppressive role of SOD1. 
Results attained from in vivo murine studies have not been straight forward as well. 
Overexpression of SOD1 was demonstrated to suppress the growth of glioma tumours 
grafted on nude mice (Table 3) [206]. In addition, administration of recombinant 
SOD1 (rec-SOD1) not only inhibited the metastatic potential of Meth A sarcoma cells 
that have been injected intravenously into BALB/C mice [280], but also sensitizes 
these tumours to adriamycin treatment (table 3) [281]. While these evidence clearly 
point towards SOD1 as a tumour suppressor, a separate experiment performed with 
colorectal carcinoma cells using a similar tumour inoculation approach paradoxically 
showed that rec-SOD1 administration potently enhanced the metastatic infiltration of 
these tumours into the liver of CDF1 mice [282].  
In the case of studies performed with primary human tumour biopsies, results attained 
were more inclined towards the idea of SOD1 as a tumour suppressor (Table 4). Of 
the nine studies carried out to date, SOD1 was either absent or lowly expressed in 
total of seven instances, and this encompassed biopsies procured from a wide range of 
tumours – colorectal cancer, renal cell carcinoma, pancreatic cancer, prostate cancer 
as well as lung cancer [283-289]. Although there was little information regarding the 
prognostic potential of SOD1 in these tumours, the fact that such a great variety of 
tumours invariably resorted into the suppression of this antioxidant enzyme during 
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the course of carcinogenesis nonetheless serves as an important indicator of SOD1 as 
a tumour suppressor. While seven out of nine studies may be suggestive of an SOD1-
mediated tumour suppressive role, the remaining two reports presented conflicting 
observations. In a huge study of 163 colorectal carcinoma biopsies, Janssen et al. 
reported that SOD1 expression is not significantly altered in colorectal tumour 
biopsies in relative to normal tissues [290]. In the other study, it was reported an 
elevated level of total SOD (both SOD1 and SOD2) activity in malignant breast 
tissues [291], as opposed to what would have been expected from SOD1 as a tumour 
suppressor. However, it should also be noted that SOD1 specific activity was only 
determined in three (out of fourteen) patient samples and SOD1 expression status was 
not investigated in this study as well [291].  
The inconsistent role of SOD1 in the process of tumorigenesis could, at least in part, 
be contributed by the intricate nature of ROS-modulated signalling pathways. As 
mentioned in preceding section, the functioning of O2
- 
as a death-regulator is highly 
dependent on the redox environment at the point in which the radical is produced. 
While SOD1 may function as a tumour suppressor by keeping cellular O2
- 
below its 
oncogenic level under typical circumstances, tumours that have evolved with a 
heightened basal level of intracellular NO could well be benefiting from the 
expression of SOD1, since the suppression of SOD1 activity would likely lead to a 
catastrophic production of ONOO
- 
in these tumours. Notably, cellular NO levels are 
often left out from the equation when studies are designed specifically for the 
investigation of SOD1, rendering it even tougher to achieve a sound interpretation of 
these findings. As such, it would be tough, if at all possible, to label SOD1 as a bona 
fide tumour suppressor (or an oncogene), since the tumour suppressive role of this 
antioxidant enzyme is likely context dependent.   
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Increases DNA fragmentation and 
apoptosis. 
[279] 
     
 
Table 2: In vitro cell culture studies investigating the role of SOD1 in carcinogenesis. TS: tumour 
suppressor, Onco: oncogene. 
 
 
In Vivo Mouse models 
Verdict Experimental Model Outcome(s) Ref 
TS 
SOD1-overexpressing glioma cells grafted on 
nude mice 
Supressed tumour growth. [206] 
TS 






Meth A sarcoma-inoculated-mice co-
administered with rec-SOD1 and Adriamycin 
Synergistic therapeutic effect 
with Adriamycin  
[281] 
Onco 
Colon carcinoma inoculated-mice administered 
with rec-SOD1 
Promoted metastatic nodules 
formation 
[282] 
     
 
Table 3: In vivo mice models investigating the role of SOD1 in carcinogenesis. TS: tumour 
suppressor, Onco: oncogene. Rec-SOD1: recombinant SOD1. 
158 
 







Low  60 cases – but not associated with poor prognosis [283] 
    
 Indifferent 






25 cases – 14 clear cell variant, 4 granular cell variant, 
and 7 mixed variant. All low in SOD1 
[284] 
    
 Low 36 cases – Variants unknown. Generally low in SOD1 [285] 
Prostatic 
carcinoma 
Low 31 cases – Lower SOD1 compared to benign glands [286] 
    
 Low 
27 cases – Lower in SOD1 expression but no significant 





10 cases – Lower SOD1 compared to normal pancreatic 
tissues. Also lower in chronic pancreatitis 
[288] 
Lung cancer Low 






14 cases – Generally high in SOD activity but 
expression was not determined 
[291] 
      
 
Table 4: SOD1 specific activity of expression status in various human tumours. 
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2 S70 pBcl-2 – How it is regulated, and how it regulates 
2.1  Redox regulation of Bcl-2 phosphorylation 
Little is known on the susceptibility of S70 Bcl-2 phosphorylation to the regulatory 
influence of ROS. Indications that the phosphorylation of Bcl-2 at S70 could 
potentially be redox-regulated came largely from indirect evidence demonstrating the 
redox-regulation of known Bcl-2 kinases and phosphatases [241, 244-249]. 
Herein, we describe for the first time that Bcl-2 phosphorylation at S70 is amenable 
to the regulatory influence of ROS. While neither of the stress-activated MAP kinases 
were involved in the redox-regulation of S70 Bcl-2 phosphorylation (Figure 10A), we 
provided evidence that an elevated intracellular O2
- 
level induced by the 
downregulation of SOD1 activity could trigger a marked increase in S70 pBcl-2 by 
means of an inhibitory tyrosine nitration of the Bcl-2 phosphatase, PP2AB56δ.  
In addition, we further demonstrated that O2
-
-mediated induction of S70 pBcl-2 is a 
reversible process, as indicated by the decline in S70 pBcl-2 level upon bSOD1 
treatment (Figure 4D). This observation, however, begs the question of how exactly 
could a drop in intracellular O2
- 
elicit the reactivation of PP2AB56δ, since this would 
imply that B56δY289 nitration is a reversible process as well. Indeed, a key 
characteristic of all cellular regulatory signalling pathways is reversibility. In the 
context of Bcl-2 phosphorylation, reversibility is achieved by the antagonistic effect 
of the Bcl-2 kinases and phosphatases. With respect to the tyrosine nitration of B56δ, 
however, the mechanism(s) involved in countering protein nitration remains poorly 
understood. No “denitrase” enzyme has been identified to date, although there are 
number of studies suggesting the presence of a “denitrase” activity that exhibits the 
selectivity and specificity of a regulatory enzyme [292-296]. In general, these studies 
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showed that protein nitration can be a transient process as indicated by the rapid 
decline in detectable nitrated-protein even in the presence of proteasome inhibitors 
[292-296]. Moreover, it was further demonstrated that this “denitrase” activity is 
inducible in macrophages by lipopolysaccharide (LPS) [292-296] and the addition of 
lysates from LPS-treated macrophages to other untreated cells could enhance the 
denitration rate of a selective set of nitrated proteins [296]. Clearly, these evidence 
suggest the presence of a yet to be identified “denitrase” enzyme. However, whether 
this purported “denitrase” activity is responsible for the denitration (and thus 
reactivation) of PP2AB56δ upon the upregulation of SOD1 activity is still uncertain and 
requires further validation. 
 
2.2  Potential source(s) of O2
- 
and NO responsible for the induction of S70 
pBcl-2 
Through the downregulation of SOD1 activity, we demonstrated that the resultant 
intracellular O2
-
 that accumulated could react with NO for the formation of ONOO
-
, 
the actual effector molecule that was responsible for the induction of S70 pBcl-2. 
However, it should be noted that SOD1 acts only as a scavenger of cytosolic O2
-
, and 
its inhibition could only lead to an elevated level of intracellular O2
- 
if a constitutive 
source of cytosolic O2
- 
exists in the cell. Similarly, SOD1 inhibition would not be able 
to elicit a rise in intracellular ONOO
- 
in the absence of NO as well. Therefore, this 
brings our attention to the potential sources of both cytosolic O2
- 
and NO that could 




2.2.1  NADPH Oxidase (NOX) complex as a major contributor of cytosolic O2
-
 
The NOX enzyme, together with its regulatory subunits, is one of the major producers 
of cytosolic O2
- 
in the cell. The NOX2 (gp91
phox
) catalytic enzyme was first 
discovered in phagocytes, by which it catalyses the transfers of electrons from 
NADPH to molecular oxygen for the massive formation of O2
- 
in response to 
invading pathogens [297, 298]. Subsequently, six other homologs of NOX2 (as 
detailed in chapter 1.1.2) were identified in a variety of other tissues where they 
contribute to a mild constitutive level of ROS for various regulatory and signalling 
purposes [297, 298].  
Interestingly, the NOX enzymes have also been implicated in cancer cell growth and 
proliferation processes. NOX1-derived O2
- 
production was first associated with a 
transformed tumorigenic phenotype in NIH3T3 mouse embryonic fibroblast cells [24, 
299], while subsequent evidence demonstrating the overexpression of different NOX 
isoforms in a variety of tumours [299-302] lend further support to an oncogenic role 
for NOX-derived ROS. Based on these findings, it is compelling that the NOX 
enzymes could be one of the major contributors of cytosolic O2
- 
responsible for the 
pro-survival effects of SOD1 downregulation. Indeed, the observation that DPI, a 
general NOX inhibitor, could impede the positive effect of SOD1 knockdown on S70 
pBcl-2 (Figure 32A) provided further indication that NOX-derived O2
- 
plays a crucial 
role in the anti-apoptotic effect of SOD1 downregulation. However, given that DPI is 
a general inhibitor that affects the activity of all NOX isoforms, it is still unclear 
which NOX isoform(s) is actually involved in our study.  
It is worth mentioning that the subcellular localization of different NOX isoforms is 
also known to be spatially regulated according to their signalling functions [29-32]. In 
smooth muscles for instance, NOX1 is targeted to caveolaes on the cell surface while 
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NOX4 is confined at focal adhesions in the cell [303]. While the precise function of 
caveolae-targeted NOX1 is unclear, NOX4 was suggested to be involved in 
cytoskeletal remodelling events in smooth muscle [303]. Such differential localization 
of NOX enzymes would allow for a localized increase in O2
- 
level, which in turn 
limits the oxidization processes to relevant molecules within the vicinity of the NOX 
complexes. Transferring this concept to the redox-regulation of PP2A, the spatial 
regulation of NOX enzymes could also account for the differing susceptibility of 
various B56 isoforms towards the nitrative environment generated by DDC treatment 
in Jurkat cells (Figure 28). This is particularly so if HA-B56α and HA-B56δ (both of 
which were tyrosine nitrated upon DDC treatment) could both localized to subcellular 
region where the NOX enzyme congregates, thereby providing an added level of 
selectivity to the redox-regulation of B56 regulatory subunits. While these reasoning 
may appear compelling, additional co-localization studies would nonetheless be 
necessary to further validate this hypothesis. 
 




Although this may sound ironic, research suggests that the mitochondria ETC could 
indeed be a significant contributor to the pool of cytosolic O2
-
. About 0.1-0.2% of 
molecular oxygen is incompletely reduced to O2
- 
anions in the mitochondria during 
oxidative phosphorylation [5-7]. Mitochondrial complex I [8-10] and complex III 
[10-12] are the two main sites along the ETC in which O2
- 
anions are formed, 
although several studies have implicated other electron transport enzymes as 
contributors of mitochondrial O2
- 





generated from complex I and complex III leaks out into the matrix [8, 9, 304] 
and the mitochondrial intermembrane space [11, 12], respectively. While the inner 





released into the mitochondrial intermembrane space (IMS) is capable of leaking 
out into the cytosol via the voltage-dependent anion channels (VDAC) residing in the 
outer  mitochondrial membrane (OMM) [305, 306]. Notably, O2
- 
from the 
mitochondrial IMS are reportedly dismutated to H2O2 by cytosolic SOD1 instead of 
the SOD2 enzymes residing in the mitochondrial matrix [82, 83], shedding 
indications that the mitochondria could potentially be significant sources of O2
- 
for 
the induction of S70 pBcl-2 in SOD1-downregulated cells. Evidence demonstrating 
that B56δ co-localizes with Bcl-2 at the OMM (Figure 15A, 18A and 20) further 
accentuates the possibility of mitochondria-derived O2
- 
being involved, at least 
partially, in the inhibitory nitration of mitochondrial B56δ. If the mitochondria are 
indeed significant sources of cytosolic O2
-
, and given the spatial proximity between 
B56δ and the mitochondria, it would be comprehensible why B56δ appeared as one 
of the B56 regulatory isoforms that was preferentially nitrated when SOD1 was 
inhibited in Jurkat cells (Figure 28). 
 
2.2.3  Nitric Oxide Synthases (NOS) as the main source of cellular NO 
Without a constitutive source of cellular NO, redox regulation of PP2AB56δ would not 
be possible in spite of an elevated level of O2
-
. Indeed, a basal level of NO was 
consistently observed across our model cell lines in study, as indicated by the decline 
in cellular NO levels upon the inhibition of SOD1 in Jurkat and MDA231 cells 
(Figure 21). With regards to this constitutive level of intracellular NO, the NOS 
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enzymes, being the only family of enzymes recognized for their role in the production 
of NO, appears to be the most plausible source of NO in these cells [1, 52]. 
Three NOS isoforms has been identified to date – endothelial NOS (eNOS), neuronal 
NOS (nNOS) and inducible NOS (iNOS), all of which produce NO from L-arginine, 
NADPH, and molecular oxygen. As their name implies, eNOS and nNOS are 
predominantly found in endothelial cells and neuronal cells respectively, while iNOS, 
on the other hand, is transcriptionally inducible (by inflammatory cytokines, 
endotoxins, oxidative stress etc.) in a variety of different tissues [52]. Although it is 
uncertain which NOS isoform(s) is involved in the supply of NO necessary for the 
anti-apoptotic effect of SOD1 downregulation in tumour cells, iNOS appears to be the 
prime candidate for this role. This is so, for iNOS is notorious for its ubiquitous 
expression in a variety of malignancies, including those originating from the prostate 
[54], pancreas [55], breast [56, 307], colon [57, 308], and even the oesophagus [309]. 
The role of iNOS in the regulation of cell death and tumour progression has been 
ambiguous. Whereas there are existing studies showing that the transduction of 
antisense iNOS impedes tumour growth [310] and the enforced expression of iNOS 
enhances tumour survival and proliferation [308, 311, 312], there are other groups 
which have reported otherwise as well [313, 314]. Such discordance, as could be 
expected from the biphasic nature of most ROS, might be contributed by the 
difference in tumour environment as well as cellular sensitivity to NO. This is 
exemplified by studies showing that iNOS could only enhanced tumour growth when 
present at a moderate level [315], but when expressed in high levels in tumour cells, 
iNOS impeded tumour growth and triggered apoptosis [314, 315]. In fact, these 
observations are in line with our findings, for a colossal expression of iNOS in SOD1 
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downregulated cells would likely lead to an overwhelming production of ONOO
- 
that 
would be deleterious to the cells as well. Based on these findings, a moderate 
expression of iNOS would therefore be a critical criterion to be fulfilled before 
tumour cells could harness the pro-survival effects of O2
-
 endowed by the 
downregulation of SOD1.  
 
2.3  The death-regulatory role of S70 pBcl-2 
2.3.1  Revisiting the conundrum of Bcl-2 phosphorylation – to kill? Or not to 
kill? 
While it is indisputable that the phosphorylation of Bcl-2 at its FLD (residue T69, 
S70 and S87) influences the death-regulatory activity of Bcl-2, the functional 
outcome associated with the phosphorylation of these residues is still clouded by 
controversy. Reports in support of a pro-apoptotic phenotype showed that multisite 
phosphorylation of Bcl-2 at residue T69, S70 and S87 inactivates the anti-apoptotic 
properties of the oncoprotein [151, 153, 166, 167]. However, there is a large body of 
evidence suggesting otherwise as well (Table 5) [136, 137, 159, 170-172].  
Although there is no definitive conclusion to the functional role of Bcl-2 
phosphorylation at the FLD, it appears that the functional consequence is highly 
dependent on the type of trigger, the residue(s) being phosphorylated, as well as the 
regulatory kinases/phosphatases involved in the phosphorylation process. For 
instance, the inactivation of Bcl-2 by multisite phosphorylation at its FLD appears to 
be invariably mediated by JNK1 activation [151, 153, 166]. On the other hand, 
functional activation of Bcl-2 by FLD phosphorylation (both mono and multisite) is 
associated with other regulators such as PKC [137, 159], ERK1/2 [158, 170], and also 
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the inhibition of PP2A [164, 171]. Consistent to this notion, we have also 
demonstrated that S70 phosphorylation of Bcl-2 induced by O2
-
 enhanced the anti-
apoptotic activity Bcl-2, and this was a function PP2AB56δ inhibition but not JNK1/2 
activation.  
In addition, given that the phosphorylation of Bcl-2 at S70 alone has been pre-
dominantly documented to be pro-survival (Table 5), the conundrum associated with 
Bcl-2 phosphorylation appears to be related only to multisite (residue T69, S70 and 
S87) phosphorylation of Bcl-2. A total of seven studies indicated that Bcl-2 is 
positively regulated by its phosphorylation at S70 [136, 137, 158, 164, 170, 171, 
243], although there was one study that presented itself as an exception [169]. 
However, it is noteworthy that this lone report describing the deactivation of Bcl-2 by 
S70 phosphorylation did not control for the phosphorylation status of other known 
phosphorylation sites (T69 and S87) despite employing a chemotherapeutic trigger 
(taxol) well recognized for its ability to elicit the hyperphosphorylation of Bcl-2 [151, 
173]. Therefore, the inactivation of Bcl-2 reported in this study could have possibly 
involved the phosphorylation of other phosphoregulatory sites as well. 
Indeed, consistent with the idea of S70 pBcl-2 as a pro-survival factor, we 
demonstrated that O2
-
-induced phosphorylation of Bcl-2 was specific to S70, but not 
T69 and S87 (Figure 1A), and this enhanced the death-inhibitory properties of Bcl-2 
against various chemotherapeutic agents. Moreover, expression of phosphomimetic 
S70E Bcl-2 mutant clearly protected against drug-induced cell death (Figure 8A), 
lending further support to the notion of S70 phosphorylation as a positive regulator of 
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2.3.2  S70 pBcl-2 – How does it protects?  
In this study, we have provided concrete evidence demonstrating that O2
- 
could 
enhance the survival capacity of tumours cells via the upregulation of S70 pBcl-2. 
However, exactly how S70 Bcl-2 phosphorylation drives chemoresistance is still 
poorly understood. Despite existing evidence suggesting that S70 Bcl-2 
phosphorylation could inhibit death execution by stabilizing the dimerization of Bax 
and Bcl-2 [158], the same death-inhibitory mechanism may not be relevant in our 
study, since Bax expression is negligible in Jurkat human T-leukemic cells [259]. 
Whereas Bak was significantly expressed in Jurkat cells, S70 phosphorylation of Bcl-
2 did not enhance complex formation between Bcl-2 and Bak (Figure 9A and 9B), 
indicating the lack of Bak involvement in the pro-survival effect S70 pBcl-2 as well.  
Apart from Bax, p53 has also been recently implicated in the anti-apoptotic effect of 
S70 phosphorylation of Bcl-2. p53, a transcription factor well documented for its 
tumour suppressive properties, has recently been shown to possess a direct 
apoptogenic role at the mitochondria independent of its transcriptional activity [316-
320]. With respect to the latter role of p53, it was demonstrated that the tumour 
suppressor can be directly targeted to the mitochondria, where it binds Bcl-2 and 
releases Bax to engage the mitochondrial apoptotic machinery [317-319]. 
Subsequently, S70 phosphorylation of Bcl-2 was shown to disrupt complex formation 
between Bcl-2 and p53, thus enabling Bcl-2 to bind Bax and prevent Bax-mediated 
MOMP [318, 319]. Although it has yet been determined whether Bcl-2 could interact 
with p53 in our study, the significance of this interaction, if any, would still be 
questionable. This is so, for the protection conferred by S70 phosphorylation of Bcl-2 
(via the displacement of p53 from Bcl-2) ultimately involves the binding of Bcl-2 to 
Bax, a pro-apoptotic factor that is absent in Jurkat cells. Also, Jurkat T-leukemic cells 
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are known to express a mutant form of p53 [321-323] and it is uncertain if this would 
affect its mitochondrial apoptogenic activity as well. Nevertheless, the involvement 
p53 in the protective role of S70 pBcl-2 could not be entirely ruled out, particular 
when p53 has also been described to induce apoptosis independent of Bax activation 
[324-326]. Clearly, further investigations would be necessary to elucidate the death-




3 A new facet in the anti-apoptotic activity of Bcl-2 
Bcl-2 is an oncoprotein traditionally recognized for its death-inhibitory activity via 
Bax/Bak sequestration at the mitochondria. However, recent evidence demonstrated 
that the anti-apoptotic activity of Bcl-2 is not solely a function of its ability to 
neutralize Bax/Bak. Bcl-2, when overexpressed, could generate an O2
-
-dominated that 
enhance the survival capacity of tumour cells [200]. Later, an interaction between 
Bcl-2 and the Vα subunit of cytochrome c oxidase (COX Vα) was identified, and this 
was shown to bestow Bcl-2 with the ability to enhance respiration dependent O2
- 
by-
production from the mitochondria [208, 209], thereby contributing to the pro-survival 
milieu in the cells. 
In these studies, the mechanistic aspect of how Bcl-2-mediated pro-oxidant state 
boost the survival of tumour cells was left unaddressed, and this, we demonstrated, is 
contributed by the positive regulatory effect of O2
- 
on the level of mitochondrial S70 
pBcl-2 in tumour cells. Interestingly, given that Bcl-2 itself is a pro-oxidant, and the 
fact that the oncoprotein is activated by O2
-
, it is conceivable that the anti-apoptotic 
activity of Bcl-2 could in fact be modulated by a self-regulatory loop which allows 
for its “autoactivation” (Figure G; page 186). Also, the premise of Bcl-2 
overexpression effectuating its own phosphorylation at S70 could, at least in part, 
account for the unusually high levels of S70 pBcl-2 that was detected in Jurkat cells 
transfected with wild type Bcl-2 (Figure 8B). In fact, such “autoregulatory loop” 
could well be an oncogenic strategy employed by Bcl-2 overexpressing tumours to 
maximize the death-inhibitory potential of the oncoprotein itself.  
Considering the dual role of Bcl-2 in the regulation of cellular redox status as well as 
the mitochondrial apoptotic machinery, efforts in delineating the post-translational 
regulation of Bcl-2 in response to intracellular redox alterations has proven to be a 
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major cornerstone in our understanding of ROS-mediated carcinogenesis. Our work 
in delineating the pathways involved in O2
-
-mediated induction of S70 pBcl-2 
provided important insights to our understanding of Bcl-2-conferred chemoresistance, 
revealing potential chemotherapeutic targets that could break the autoactivation cycle 





4 Inhibitory tyrosine nitration of B56 regulatory isoforms – potential 
implication(s) beyond the activation of Bcl-2 
4.1  Redox regulation of PP2AB56δ – implications on phospho-tau  
Despite a large pool of evidence demonstrating the potential regulation of PP2A in a 
ROS-dependent fashion [242, 327-329], no reports has addressed the mechanistic 
aspect underlying the redox-regulation of PP2A to date. With respect to this, we 
demonstrated in detail, a novel regulatory mechanism which allows for the redox-
regulation of B56-harboring-PP2A by O2
- 
anions (Figure 34). In this study, we 
showed that O2
-
-mediated nitration of B56δY289 interfered with catalytic core 
recruitment but not substrate recognition of Bcl-2. This resulted in a drop in Bcl-2 
phosphatase activity and the consequential accumulation of activated S70 pBcl-2. 
However, it is noteworthy that Bcl-2 is not the only substrate of PP2AB56δ, nor is 
B56δ the only B56 regulatory subunit being targeted by O2
-
. As such, O2
-
-mediated 
inhibition of PP2A heterotrimers harbouring the B56 regulatory subunits could have 
profound implications not only on the anti-apoptotic activity of Bcl-2 in tumour cells, 
but also on the various signalling pathways regulated by PP2AB56δ as well as its 
isomeric counterparts. 
In the context of PP2AB56δ regulated processes, the level of phosphorylated 
(S202/T205) tau protein, an alternative substrate of PP2AB56δ notorious for its 
pathological role in Alzheimer’s disease [271, 330, 331], also responded positively to 
DDC-mediated inhibition of SOD1 in Jurkat cells (Figure 34). This observation is 
also corroborated by a recent report describing an enhanced level of tau 
phosphorylation and amyloid plaque formation in SOD1-deficient mouse models 
[332]. Moreover, Alzheimer patients with high levels of phosphorylated tau proteins 
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were found to be low or deficient in SOD1 (but not SOD2) [332], further supporting a 
role of SOD1 deficiency in the pathology of Alzheimer disease. Although there is still 
insufficient evidence pinpointing the direct involvement of PP2AB56δ in these 
observations, these data nonetheless suggest that the nitrative inhibition of PP2AB56δ 
in response to increasing intracellular O2
- 
level could have potential ramifications on 
the pathological development of Alzheimer’s disease as well.  
 




Judging from the augmented level of tyrosine nitration detected in both B56α and 
B56γ1 upon exposure to an elevated level of intracellular O2
-
 (Figure 28 and 35B), it 
appeared that these two B56 isoforms could be regulated by nitrative-modification 
processes as well. Both PP2AB56α and PP2AB56γ1 are well documented for their 
regulatory roles in various important cell death and proliferation pathways [232, 238, 
239, 333]. Therefore, any nitrative inhibition of these regulatory subunits by O2
- 
would have profound impact in the context of carcinogenesis.  
PP2AB56α for instance, apart from its potential redundant role with PP2AB56δ in the 
regulation of S70 pBcl-2 [243], is also known to dephosphorylate (at Ser62) and 
enhance the proteasomal degradation of c-myc proteins [232]. Thus, if PP2AB56α 
could indeed be inhibited by nitrative modifications, an elevation of O2
-
 would lead to 
the accumulation of mitogenic c-myc proteins as well. Moreover, evidence 
demonstrating that c-myc could synergize with Bcl-2 in driving tumorigenesis further 
highlighted the role of O2
-
 as a potent oncogenic factor [138]. While c-myc 





 to promote neoplastic transformation of tumour cells, the 
involvement of c-myc proteins remains a conjecture at this juncture and further 
validation would be necessary.  
Besides PP2AB56α, PP2AB56γ1 is  also known to dephosphorylate several important 
regulatory molecules involved in cell fate decision processes, including the tumour 
suppressor p53 and the mitogenic MAP kinases, ERK1/2 [238, 239]. PP2AB56γ1-
mediated dephosphorylation at thr55 stabilizes p53 [238], while conversely, 
dephosphorylation of ERK1/2 inactivates their respective kinase activity [239]. 
Clearly, the action of PP2AB56γ1 on p53 and ERK1/2 is largely tumour suppressive in 
nature, and the inhibition of PP2AB56γ1 would lead to the activation of ERK1/2 [239] 
whilst subduing the expression of p53 [238]. Indeed, such phenotypes associated with 
PP2AB56γ1 inhibition was also observed in DDC-treated Jurkat cells, whereby SOD1 
inhibition brought about a decline in p53 levels (Figure 34) but a converse 
upregulation in ERK1/2 activation (Figure 10A). Given that B56γ1 also appeared to 
be tyrosine-nitrated in response to elevated level of intracellular O2
-
 (bottom most 
band of 3NO2-Y289 panel; Figure 35B), it is plausible that the effect of SOD1 
inhibition on p53 and ERK1/2 was mediated by O2
-
-dependent nitrative inhibition of 
PP2AB56γ1. 
Whereas the precise contribution of PP2AB56γ1 inhibition to the oncogenic properties 
of O2
-
 is still uncertain in our study, especially when p53 is mutated in Jurkat cells, 
these observations nevertheless underscore the immense potential of O2
- 
as an 
oncogenic factor, not only by activating Bcl-2, but also by activating other 




4.3  The fate of B56δ-dissociated PP2A-C 
Given that the phosphorylation status of other non-B56-regulated PP2A substrates 
were unaffected by SOD1 inhibition (Figure 34), it is deducible that the AC catalytic 
core itself was not an inhibitory target of O2
-
. However, PP2A activity assays 
performed on DDC-treated tumour cell suggested otherwise. The synthetic phospho-
peptides utilized in PP2A activity assays are recognizable by all intact AC catalytic 
core irrespective of the B regulatory subunits involved. Therefore, PP2A activity 
assays would not have detected any decline in overall PP2A activity if the AC core 
was just dissociated from B56δ but not directly inhibited by O2
-
 upon SOD1 
inhibition. Clearly, the fact that an overall decline in PP2A catalytic activity was 
detected upon SOD1 inhibition suggests that the AC catalytic core could somehow be 
affected by the elevated level of intracellular O2
- 
as well.  
True to this aspect, studies have shown that PP2A-C dissociated from its regulatory 
subunits are rapidly bound and muted by a chaperone protein, alpha4, so to avoid 
non-specific dephosphorylation processes catalysed by the broad specificity catalytic 
cores [334]. In addition, catalytic core subunits are extremely unstable when present 
in their respective monomeric form, for PP2A subunits that fails to assemble into 
heterotrimers are rapidly degraded via the ubiquitin-proteasomal pathway [220, 260, 
335]. Binding of PP2A-C to alpha4, therefore, also serves to stabilize and maintain a 
ready pool of catalytic subunits for subsequent dephosphorylation events, while any 
unbound catalytic subunits would be rapidly degraded [220, 260, 335]. For these 
reasons, PP2A-C dissociated from B56δ is unlikely to carry any remnants of 
phosphatase activity, hence accounting for the observed decline in overall PP2A 
activity upon SOD1 inhibition. 
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On a separate note, the regulatory nature of alpha4 on the stability of PP2A-C could 
also account for the minimal reciprocal increase in cytosolic PP2A-C despite a 
significant decline in the level of mitochondrial PP2A-C upon SOD1 inhibition 
(Figure 15B, 15C, 20, and 26). Studies in a variety of mammalian system (murine, 
primate and human) revealed that the interaction between alpha4 and PP2A-C is 
highly sensitive to fluctuations in surrounding temperature [334, 336]. Complex 
formation between alpha4 and PP2A-C greatly diminishes with the decline in 
surrounding temperature and this resulted in an enhanced degradation of monomeric 
PP2A-C in the absence of alpha4 binding [334]. Although such drastic temperature 
fluctuations are extremely unlikely in physiological settings, these findings are 
nonetheless of great significance to in vitro studies requiring prolonged incubation of 
cells/cell extracts in ice or any other low temperature environments. Mitochondrial 
isolation procedures for instance, often involve prolonged incubation of cells in ice-
chilled isolation buffer prior to homogenization procedures. Such drastic reduction in 
temperature would have likely disrupted the interaction between alpha4 and PP2A-C 
prior to homogenization procedures, thereby resulting in the rapid degradation of 
PP2A-C and an artefactual decline in monomeric PP2A-C that have dissociated from 
the B56 regulatory subunits. As such, an alternative mitochondrial isolation protocol 
devoid of ice-chilled experimental settings would be better suited to study the effect 
of SOD1 downregulation on the mitochondrial localization of PP2A-C. Alternatively, 
future inclusion of proteasome inhibitors such as MG-132 in mitochondrial isolation 







-mediated inhibition of PP2A – its relevance in a clinical setting   
5.1 Is PP2A a druggable target for anti-cancer therapy?  
We have demonstrated in this study that O2
-
-mediated inhibition of PP2AB56δ could 
enhance the resistance of tumour cells against chemotherapeutic agents by inducing 
the phosphorylation of Bcl-2 at S70. Thus, pharmacological activation of PP2AB56δ 
emerges as a sound strategy to overcome the oncogenic influence of O2
- 
on Bcl-2. 
Indeed, the concept of PP2A as a target for chemotherapeutic intervention is 
supported by a large pool of evidence demonstrating its suppressive effects on various 
neoplastic pathways (refer to introductory chapter 5.1 for more details). Evidence 
demonstrating that PP2A activity is frequently suppressed in a variety of tumours 
[228, 230, 231, 337-342] further support the idea of PP2A as a therapeutic target 
against cancer. The lingering question which remains to be answered, however, is the 
suitability of PP2A as a pharmacological target for chemotherapeutic intervention.  
Whereas many kinase inhibitors such as imatinib (Bcr/Abl inhibitor) and gefitinib 
(EGFR inhibitor) have already been approved for therapeutic use, there has yet been 
any phosphatase targeting compound being clinically approved for cancer therapy to 
date. In great contrast to the kinases, the chemotherapeutic potential of PP2A is very 
much unexplored despite its well documented role in countering the various 
oncogenic kinases. In part, this is due to the promiscuous nature of the PP2A catalytic 
core, since targeting the phosphatase activity of the core enzyme would likely affect 
other essential homeostatic pathways under the governance of PP2A as well. There 
are, nevertheless, several PP2A activating compounds that have exhibited promising 




5.1.1 Ceramide is a PP2A activator with potent anti-tumour activity 
Ceramide, a lipid product from the hydrolysis of sphingomyelins, is among the 
earliest PP2A activator [343] described for it apoptosis-inducing ability in various 
tumour models [243, 318, 344-347]. Several PP2A-dependent mechanisms have since 
been proposed for the death-inducing activity of ceramide, including the 
dephosphorylation and deactivation of the pro-survival Akt pathways [344], as well 
as the dephosphorylative-activation of the death associated protein kinase (DAPK) 
[347]. Importantly, PP2A-dependent S70 Bcl-2 dephosphorylation has also been 
implicated in the death-inducing activity of ceramide [164, 243], underscoring the 
potential of PP2A activation as a therapeutic strategy to overcome the pro-survival 
effect of both O2
-
 and Bcl-2.  
Despite its potent anti-tumour activity, the suitability of ceramide as a clinical 
therapeutic agent is questionable, particularly when the pharmacological target of the 
lipid molecule itself is multitude. Besides PP2A, ceramide is known to regulate 
several other transcription factors such as AP-1 and NF-κB [348, 349], and even 
paradoxically stimulating the mitogenic MAP kinase pathway in both transformed 
and untransformed cells [350, 351]. For these reasons, the use of ceramide as a 
therapeutic compound would likely be accompanied with a strings of unintended 
effects. Nevertheless, the discovery of ceramide as a PP2A activator with potent anti-
tumorigenic activity clearly highlighted the potential of PP2A induction as a 
therapeutic strategy against cancer, paving way for future development of more PP2A 




5.1.2 FTY720 as a novel PP2A activator with promising chemotherapeutic 
potential 
A more promising compound that was recently reported for its positive regulatory 
effect on PP2A is FTY720 (Fingolimod; Novartis), a synthetic analog of the 
antibiotic myriocin that shares significant structural similarity to sphingosine [352]. 
FTY720 was first discovered, and evaluated, for its immunomodulatory activity in 
multiple sclerosis patients and its recently completed phase III trial yielded very 
positive outcomes with minimal safety concerns [352-354]. Importantly, recent 
studies demonstrated that the therapeutic properties of FTY720 go beyond its 
beneficial effects in multiple sclerosis patients, as the compound was reported to 
possess potent anti-cancer properties as well [341, 342, 355, 356]. In particular, 
treatment of FTY720 induced marked apoptosis and greatly impaired the colony 
formation ability of Bcr/Abl-driven leukemic cell lines as well as primary chronic 
myelogenous leukemia cells [341, 356]. Moreover, in vivo studies showed that 
FTY720 could inhibit leukemogenesis without significant adverse effects on normal 
hematopoetic processes as well [341]. The anti-tumorigenic activity of FTY720 was 
attributed to its ability to augment/reactivate the catalytic activity of PP2A, 
particularly in Bcr/Abl-driven leukemic cell lines whereby the tumour suppressive 
function of PP2A is greatly oppressed by the overexpression of a PP2A inhibitory 
protein, SET [341]. Reactivation of PP2A was demonstrated to counter the kinase 
activity of Bcr/Abl in these leukemia cells by suppressing the phosphorylation (and 
activation) of MAP kinases, STAT5, Jak2, Akt as well as c-myc, all of which acted 
oncogenic drivers in these cells [341, 342]. Although the precise mechanism 
underlying the activation of PP2A by FTY720 is still uncertain, in vitro studies 
suggested that this sphingosine-like compound could directly bind to and activate the 
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PP2A dimeric core, thus allowing it to overcome the inhibitory effect of SET 
overexpression in these leukemic cells [356].  
Given the immense chemotherapeutic potential of FTY720 in treating Bcr/Abl-driven 
leukemia, it would be tempting to extend this therapeutic strategy to other types of 
tumours as well. In tumours lacking SOD1, or even in tumours overexpressing Bcl-2, 
for instance, activation of PP2A by FTY720 could likely negate the death-inhibitory 
effect of Bcl-2 by augmenting its dephosphorylation at S70, thereby sensitizing these 
tumours towards conventional cytotoxic agents such as etoposide and cisplastin. 
However, considering that FTY720 is still largely untested in other tumour types, 
there remains a shadow of uncertainty regarding the therapeutic potential of this 
compound in other malignancies, particularly when most, if not all, tumours are 
notoriously heterogeneous in nature. Indeed, even if FTY720 may appear as an 
appealing option to enhance the efficacy of existing arsenal of combinatory 
therapeutic strategies, much work is still to be done to better characterize and 
understand the anti-neoplastic properties of FTY720 in other tumour types before the 
compound could be clinically recognized for its therapeutic properties. 
 
5.2 Activating specific PP2A complexes as a novel chemotherapeutic strategy  
All PP2A activators discovered to date are incapable of discriminating between the 
PP2A heterotrimers harbouring different regulatory subunits. FTY720, for instance, 
acts by directly targeting the catalytic core of PP2A [356]. Owing to the broad 
specificity of PP2A catalytic core, it is of remote probability that these compounds 
would spare other PP2A-regulated physiological pathways if they were to be 
employed as anti-cancer agents. As such, targeting PP2A heterotrimers harbouring 
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specific regulatory subunits could potentially be a better strategy for the development 
of PP2A-targeting cancer drugs with greater specificity and less toxicity. In this 
regard, the specific reactivation of PP2AB56δ in tumours lacking SOD1 activity, or 
even in tumours overexpressing the Bcl-2 oncoprotein, would greatly sensitize these 
tumours against other conventional chemotherapeutic agents without affecting other 
essential PP2A pathways. A compound with such properties would therefore warrant 
the use of lower doses of cytotoxic agents without incurring additional 
pharmacological adverse effects to the existing regimen. The question remains 
whether is it feasible to design a compound that targets only specific PP2A 
complexes? 
While no pharmacological agent is known to selectively activate a particular PP2A 
heterotrimer, there are nonetheless some indirect evidence suggesting the possible 
regulation of PP2A in a B subunit-dependent manner. Recruitment of the B 
regulatory subunits to the catalytic core is highly regulated by the methylation and 
phosphorylation pattern on the C-terminal tail of PP2A-C [357-359]. Methylation of 
PP2A-C at Leu309 by S-adenosylmethionine-dependent leucine carboxyl transferase 
1 (LCMT-1) was demonstrated to facilitate the recruitment of B55 subfamily 
members to the core enzyme but not other B regulatory subunits [358]. 
Phosphorylation of PP2A-C at Tyr307, on the other hand, inhibits the binding of only 
B55, B56α, B56β and B56ε to the catalytic core [357]. Along similar lines, we also 
demonstrated that PP2A harbouring B56 subunit could be regulated by the selective 
tyrosine nitration of B56α, B56γ, and B56δ but not other B regulatory subunits. 
Together, these evidence suggest that B subunit-dependent regulation of PP2A is 
possible, shedding hopes on the possible identification of complex-specific PP2A 
targeting compounds. In fact, screening of compound libraries for molecules that 
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could selectively activate LCMT-1, or even compounds that could specifically bind to 
a particular PP2A complex, would be among the first step to the discovery of novel 
therapeutic agents that allows for complex-specific targeting of PP2A. Compounds of 
such nature would add great value to our existing arsenal of cancer drugs, paving way 
for more efficacious combination therapy strategies.  
 
5.3 Targeting intracellular O2
-
 as a novel therapeutic strategy against Bcl-2-
induced chemoresistance 
Supplementing to the large body of evidence supporting the role of O2
- 
in promoting 
tumour progression and chemoresistance, we demonstrated that the pro-survival 
properties of O2
- 
anions is a function of its inhibitory activity on PP2AB56δ, which in 
turn allows for the accumulation of S70 phosphorylation-activated Bcl-2 proteins. 
From these findings, it is evident that the simplest approach to curtail Bcl-2-induced 
chemoresistance would be to directly activate PP2AB56δ for the dephosphorylation of 
Bcl-2 at S70. Considering the lack of PP2AB56δ-specific compounds, however, an 
alternative and more feasible approach would thus be to exploit the dependence of 
Bcl-2 on O2
- 
anions for its phosphorylation and activation. 
Indeed, the idea of redox modulation as a chemotherapeutic strategy is supported by a 
substantial number of studies demonstrating that the suppression of intracellular O2
- 
levels could sensitize tumour cells against a variety of death triggers [198, 200, 207, 
360]. Notably, it was demonstrated that the anti-apoptotic effect of Bcl-2 could be 
bypassed via the pre-treatment of cells with DPI, a NOX inhibitor that could suppress 
the production of intracellular O2
- 
[200]. In another study, it was also shown that the 
combined exposure of glioblastoma cell lines to temozolomide (DNA methylating 
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agent) and tempol (an SOD mimetic) could produce a synergistic therapeutic effect in 
these cell lines, presumably due to an enhanced dismutation of O2
- 
to H2O2 by tempol 
[360].  
Although the involvement of S70 pBcl-2 was not addressed in these studies, the 
therapeutic outcomes from these treatment regimens are nonetheless in good 
agreement with our working hypothesis. A  more reduced intracellular redox state 
would release PP2AB56δ from the inhibitory shackles of O2
-
, thus allowing the 
phosphatase to facilitate death execution via the dephosphorylation of Bcl-2 at S70. 
True to this aspect, the importance of Bcl-2 dephosphorylation in chemo-intervention 
strategies was further highlighted by a recent study demonstrating the inability of 
ABT-737 (a BH3 mimetic that inhibits Bcl-2) to sensitize tumour cells against 
conventional anti-cancer drugs when Bcl-2 is present in its phosphorylated form 
[168]. Clearly, pharmacological strategies for the activation of PP2AB56δ, or more 
feasibly, the suppression of intracellular O2
- 
level, should be taken into great 
consideration for the future design and development of effective combination 
therapies. Indeed, considering the abundant availability of SOD1 mimetics that have 
yet been explored for their influence on the death-regulatory pathways [361-365], the 
potential of modulating intracellular O2
- 
level as a strategy for chemotherapeutic 
interventions is immense.  
 
5.4 SOD1, S70 pBcl-2 and B56δY289 nitration (nitro-B56δY289) – a potential 
prognostic signature for better cancer management and care 
Our study in a variety of cell lines (Figure 29A and 30) as well as a series of primary 
lymphoma biopsies (Figure 42A and 42B) revealed a marked inverse correlation 
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between the expression levels of SOD1 and the levels of both S70 pBcl-2 and B56δ 
nitration, and further analysis in tumour cell lines indicated that the nitration of B56δ 
was selectively targeted at the B56δY289 residue. This remarkable interrelationship 
between SOD1, S70 pBcl-2 and nitro-B56δY289 presents itself as a biological 
signature that could be potentially exploited for prognostic and therapeutic purposes. 
Indeed, given the strong negative relationship between S70 pBcl-2 and tumour 
chemosensitivity, the expression signature of SOD1, S70 pBcl-2 and nitro-B56δY289 
harbours great potential as a prognostic tool for the prediction of potential drug 
resistance, and more importantly, for the facilitation of therapeutic decision-making 
processes. For example, the detection of tumours with low SOD1 but high in S70 
pBcl-2 and nitro-B56δY289 would be indicative of a greater resistance against 
mitochondrial targeting drugs, thus warranting the selection of chemotherapeutic 
cocktails comprising anti-cancer agents that are less reliant on the mitochondria 
apoptotic pathway. Alternatively, if the use of redox modulators in therapeutic 
regimens is clinically-condoned in the future, the inclusion of a O2
-
 suppressor would 
then be a great strategy to bypass Bcl-2-induced chemoresistance in such tumours.  
Of note, the potential of S70 pBcl-2 as a prognostic marker for the prediction of 
tumour aggression and drug resistance appears to be supported by our clinical data of 
lymphoma biopsies as well (Figure 43A). Although the sample size of clinical 
biopsies may not suffice for a definitive conclusion, these data nonetheless provided 
some important clues regarding the role of S70 pBcl-2 in lymphoma tissues (Figure 
43A). With the exception of P5 (diffused B cell lymphoma), it appears that high S70 
pBcl-2 levels tend to be associated with higher grade tumours (P2 vs P1; P4 vs P3) or 
with aggressive tumours that are notorious for their recalcitrant phenotype (P10 – 
mantle cell lymphoma) [366]. While this observation is undoubtedly suggestive of an 
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association between S70 pBcl-2 and tumour aggressiveness, further studies with 
greater number of clinical samples would be necessary to validate these findings. 
Moreover, the evaluation of B56δY289 nitration in future clinical biopsy studies using 
3NO2-Y289 antibody will also be important for the further characterization of 
lymphoma biopsies. If successfully validated, our findings could provide a novel 
means for stratifying clinical lymphomas based on tumour aggressiveness and 
resistance to chemotherapy, paving way for potential marker-based chemotherapy and 






6 Conclusion  
 
Figure 43: Schematic summary of O2
-
-mediated pro-survival pathways.  
In tumours with downregulated expression of SOD1, dismutation of O2
-
 to H2O2 is inhibited. This 
results in the accumulation of O2
-
 and the increase reaction with NO for the formation of ONOO
-
. In 
turn, this triggers the nitration of B56δY289 and inhibits the recruitment of PP2A catalytic core to 
mitochondrial Bcl-2, leading to the accumulation of S70 phosphorylated Bcl-2 and the inhibition of 
apoptosis. Although the precise source(s) of intracellular O2
-
 driving this pathway remains uncertain 
(depicted by red dotted arrows), the NOX complexes and the mitochondrial respiratory machinery are 
nonetheless two plausible O2
-
 sources that could contribute to this pathway
 
(discussed in chapter 2.2). 
Note that Bcl-2 itself has been reported to enhance mitochondrial O2
-
 production by modulating the 
activity of complex IV/COX (depicted by blue arrow extending from Bcl-2) thus allowing for a 
potential auto-regulatory loop which allows for its self-activation (discussed in chapter 3) [208, 209]. 
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Evasion from apoptosis is a key mechanism by which tumour cells acquire resistance 
to therapeutic treatment. Understanding the underlying molecular circuitries of 
apoptotic evasion is therefore crucial to our endeavour in combatting cancer. In this 
regard, work over the years has demonstrated that the recalcitrant nature of various 
tumours against therapeutic agents is fuelled, at least in part, by a dysregulated redox 
milieu constituting an elevated level of O2
-
 anions [179, 198-200]. Subsequent studies 
showed that the tumorigenic behaviour of certain oncogenes such as Bcl-2 is partially 
dependent on an elevated level of intracellular O2
- 
as well [200].  
Extending from these findings, our work uncovered a novel link between O2
-
 and the 
phosphorylation-activated form of Bcl-2 (S70 pBcl-2) which could, at least in part, 
account for the death-inhibitory effects of O2
-
 in tumour cells. We demonstrated that 
intracellular O2
-
 induced by the downregulation of SOD1, enhanced the anti-apoptotic 
activity of Bcl-2 by promoting the phosphorylation of Bcl-2 at S70. Through the 
formation of ONOO
- 
(by reacting with NO), O2
- 
was shown to retard holoenzyme 
assembly of the Bcl-2 phosphatase PP2AB56δ via the selective inhibitory nitration of 
B56δY289, and by doing so, abetted chemoresistance by dint of the accumulation of 
S70 pBcl-2 (Figure E). By virtue of a downregulated expression of SOD1, tumour 
cells could therefore maximize the anti-apoptotic potential of Bcl-2 and 
consequentially, acquire a survival edge over its non-malignant counterparts.   
Our work in unravelling the workings of O2
-
-induced chemoresistance has provided 
important insights to our understanding of redox-driven oncogenesis. The 
identification of ONOO
-
, PP2AB56δ and S70 pBcl-2 as pivotal players in O2
-
-driven 
neoplastic processes not only reveals novel drug targets for anti-cancer therapy, but 
also carries prognostic potential for better patient management and care. If further 
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developed, these findings could even be of significant contribution to the 












1. Halliwell, B. and J.M.C. Gutteridge, Free radicals in biology and medicine. 
4th ed2007, Oxford ; New York: Oxford University Press. 851 p. 
2. Imlay, J.A., Pathways of oxidative damage. Annu Rev Microbiol, 2003. 57: p. 
395-418. 
3. Gardner, P.R. and I. Fridovich, Superoxide sensitivity of the Escherichia coli 
aconitase. J Biol Chem, 1991. 266(29): p. 19328-33. 
4. Liochev, S.I. and I. Fridovich, Modulation of the fumarases of Escherichia 
coli in response to oxidative stress. Arch Biochem Biophys, 1993. 301(2): p. 
379-84. 
5. Chance, B., H. Sies, and A. Boveris, Hydroperoxide metabolism in 
mammalian organs. Physiol Rev, 1979. 59(3): p. 527-605. 
6. Kudin, A.P., et al., Characterization of superoxide-producing sites in isolated 
brain mitochondria. J Biol Chem, 2004. 279(6): p. 4127-35. 
7. Cadenas, E., et al., Production of superoxide radicals and hydrogen peroxide 
by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from 
beef-heart mitochondria. Archives of Biochemistry and Biophysics, 1977. 
180(2): p. 248-257. 
8. Poyton, R.O., K.A. Ball, and P.R. Castello, Mitochondrial generation of free 
radicals and hypoxic signaling. Trends in Endocrinology &amp; Metabolism, 
2009. 20(7): p. 332-340. 
9. Grivennikova, V.G. and A.D. Vinogradov, Generation of superoxide by the 
mitochondrial Complex I. Biochimica et Biophysica Acta (BBA) - 
Bioenergetics, 2006. 1757(5–6): p. 553-561. 
10. St-Pierre, J., et al., Topology of superoxide production from different sites in 
the mitochondrial electron transport chain. J Biol Chem, 2002. 277(47): p. 
44784-90. 
11. Chen, Q., et al., Production of reactive oxygen species by mitochondria: 
central role of complex III. J Biol Chem, 2003. 278(38): p. 36027-31. 
12. Muller, F.L., Y. Liu, and H. Van Remmen, Complex III releases superoxide to 
both sides of the inner mitochondrial membrane. J Biol Chem, 2004. 279(47): 
p. 49064-73. 
13. Saborido, A., L. Soblechero, and A. Megias, Isolated respiring heart 
mitochondria release reactive oxygen species in states 4 and 3. Free Radic 
Res, 2005. 39(9): p. 921-31. 
14. Andreyev, A.Y., Y.E. Kushnareva, and A.A. Starkov, Mitochondrial 
metabolism of reactive oxygen species. Biochemistry (Moscow), 2005. 70(2): 
p. 200-214. 
15. Chan, P.C. and H.J. Bielski, Enzyme-catalyzed Free Radical Reactions with 
Nicotinamide Adenine Nucleotides. Journal of Biological Chemistry, 1974. 
249(4): p. 1317-1319. 
16. Chan, P.C. and B.H. Bielski, Glyceraldehyde-3-phosphate dehydrogenase-
catalyzed chain oxidation of reduced nicotinamide adenine dinucleotide by 




17. Starkov, A.A., et al., Mitochondrial α-ketoglutarate dehydrogenase complex 
generates reactive oxygen species. Journal of Neuroscience, 2004. 24(36): p. 
7779-7788. 
18. Tretter, L. and V. Adam-Vizi, Generation of reactive oxygen species in the 
reaction catalyzed by α-ketoglutarate dehydrogenase. Journal of 
Neuroscience, 2004. 24(36): p. 7771-7778. 
19. Banfi, B., et al., A Ca(2+)-activated NADPH oxidase in testis, spleen, and 
lymph nodes. J Biol Chem, 2001. 276(40): p. 37594-601. 
20. Edens, W.A., et al., Tyrosine cross-linking of extracellular matrix is catalyzed 
by Duox, a multidomain oxidase/peroxidase with homology to the phagocyte 
oxidase subunit gp91phox. J Cell Biol, 2001. 154(4): p. 879-91. 
21. Geiszt, M., et al., Identification of renox, an NAD(P)H oxidase in kidney. Proc 
Natl Acad Sci U S A, 2000. 97(14): p. 8010-4. 
22. Lambeth, J.D., et al., Novel homologs of gp91phox. Trends Biochem Sci, 
2000. 25(10): p. 459-61. 
23. Shiose, A., et al., A novel superoxide-producing NAD(P)H oxidase in kidney. 
J Biol Chem, 2001. 276(2): p. 1417-23. 
24. Suh, Y.A., et al., Cell transformation by the superoxide-generating oxidase 
Mox1. Nature, 1999. 401(6748): p. 79-82. 
25. Nunoi, H., et al., Two forms of autosomal chronic granulomatous disease lack 
distinct neutrophil cytosol factors. Science, 1988. 242(4883): p. 1298-1301. 
26. Kwong, C.H., et al., Regulation of the human neutrophil NADPH oxidase by 
rho-related G-proteins. Biochemistry, 1993. 32(21): p. 5711-5717. 
27. Volpp, B.D., W.M. Nauseef, and R.A. Clark, Two cytosolic neutrophil 
oxidase components absent in autosomal chronic granulomatous disease. 
Science, 1988. 242(4883): p. 1295-1297. 
28. Babior, B.M., J.D. Lambeth, and W. Nauseef, The neutrophil NADPH 
oxidase. Arch Biochem Biophys, 2002. 397(2): p. 342-4. 
29. Diaz, B. and S.A. Courtneidge, Redox signaling at invasive microdomains in 
cancer cells. Free Radic Biol Med, 2012. 52(2): p. 247-56. 
30. Terada, L.S., Specificity in reactive oxidant signaling: think globally, act 
locally. J Cell Biol, 2006. 174(5): p. 615-23. 
31. Ambasta, R.K., et al., Direct interaction of the novel Nox proteins with 
p22phox is required for the formation of a functionally active NADPH 
oxidase. J Biol Chem, 2004. 279(44): p. 45935-41. 
32. Ushio-Fukai, M., Localizing NADPH oxidase-derived ROS. Sci STKE, 2006. 
2006(349): p. re8. 
33. Fisher, A.B., Redox signaling across cell membranes. Antioxid Redox Signal, 
2009. 11(6): p. 1349-56. 
34. Hawkins, B.J., et al., Superoxide flux in endothelial cells via the chloride 
channel-3 mediates intracellular signaling. Mol Biol Cell, 2007. 18(6): p. 
2002-12. 
35. Harrison, R., Structure and function of xanthine oxidoreductase: where are we 
now? Free Radic Biol Med, 2002. 33(6): p. 774-97. 
36. Bray, R.C., The inorganic biochemistry of molybdoenzymes. Q Rev Biophys, 
1988. 21(3): p. 299-329. 
37. Takikawa, O., Biochemical and medical aspects of the indoleamine 2,3-
dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res 
Commun, 2005. 338(1): p. 12-9. 
191 
 
38. Brodie, A.E. and D.J. Reed, Reversible oxidation of glyceraldehyde 3-
phosphate dehydrogenase thiols in human lung carcinoma cells by hydrogen 
peroxide. Biochem Biophys Res Commun, 1987. 148(1): p. 120-5. 
39. Stadtman, E.R. and B.S. Berlett, Fenton chemistry revisited: amino acid 
oxidation. Basic Life Sci, 1988. 49: p. 131-6. 
40. Halliwell, B. and J.M. Gutteridge, Biologically relevant metal ion-dependent 
hydroxyl radical generation. An update. FEBS Lett, 1992. 307(1): p. 108-12. 
41. Halliwell, B. and J.M. Gutteridge, Oxygen toxicity, oxygen radicals, transition 
metals and disease. Biochem J, 1984. 219(1): p. 1-14. 
42. Pietrangeli, P. and B. Mondov  , Amine Oxidases and Tumors. 
NeuroToxicology, 2004. 25(1–2): p. 317-324. 
43. Denninger, J.W. and M.A. Marletta, Guanylate cyclase and the .NO/cGMP 
signaling pathway. Biochim Biophys Acta, 1999. 1411(2-3): p. 334-50. 
44. Ignarro, L.J., et al., Endothelium-derived relaxing factor produced and 
released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A, 1987. 
84(24): p. 9265-9269. 
45. Palmer, R.M.J., A.G. Ferrige, and S. Moncada, Nitric oxide release accounts 
for the biological activity of endothelium-derived relaxing factor. Nature, 
1987. 327(6122): p. 524-526. 
46. Stamler, J.S., S. Lamas, and F.C. Fang, Nitrosylation. the prototypic redox-
based signaling mechanism. Cell, 2001. 106(6): p. 675-83. 
47. Stamler, J.S., et al., S-nitrosylation of proteins with nitric oxide: synthesis and 
characterization of biologically active compounds. Proc Natl Acad Sci U S A, 
1992. 89(1): p. 444-8. 
48. Stamler, J.S., et al., S-nitrosylation of tissue-type plasminogen activator 
confers vasodilatory and antiplatelet properties on the enzyme. Proc Natl 
Acad Sci U S A, 1992. 89(17): p. 8087-91. 
49. Keszler, A., Y. Zhang, and N. Hogg, Reaction between nitric oxide, 
glutathione, and oxygen in the presence and absence of protein: How are S-
nitrosothiols formed? Free Radic Biol Med, 2010. 48(1): p. 55-64. 
50. Kwon, N.S., et al., L-citrulline production from L-arginine by macrophage 
nitric oxide synthase. The ureido oxygen derives from dioxygen. J Biol Chem, 
1990. 265(23): p. 13442-5. 
51. Nathan, C. and Q.W. Xie, Regulation of biosynthesis of nitric oxide. J Biol 
Chem, 1994. 269(19): p. 13725-8. 
52. Fukumura, D., S. Kashiwagi, and R.K. Jain, The role of nitric oxide in tumour 
progression. Nat Rev Cancer, 2006. 6(7): p. 521-34. 
53. Pasto, M., et al., Nasal polyp-derived superoxide anion: dose-dependent 
inhibition by nitric oxide and pathophysiological implications. Am J Respir 
Crit Care Med, 2001. 163(1): p. 145-51. 
54. Klotz, T., et al., Selective expression of inducible nitric oxide synthase in 
human prostate carcinoma. Cancer, 1998. 82(10): p. 1897-903. 
55. Vickers, S.M., et al., Association of increased immunostaining for inducible 
nitric oxide synthase and nitrotyrosine with fibroblast growth factor 
transformation in pancreatic cancer. Arch Surg, 1999. 134(3): p. 245-51. 
56. Tschugguel, W., et al., Expression of inducible nitric oxide synthase in human 




57. Cianchi, F., et al., Inducible nitric oxide synthase expression in human 
colorectal cancer: correlation with tumor angiogenesis. Am J Pathol, 2003. 
162(3): p. 793-801. 
58. Liaudet, L., G. Vassalli, and P. Pacher, Role of peroxynitrite in the redox 
regulation of cell signal transduction pathways. Front Biosci, 2009. 14: p. 
4809-14. 
59. Cuzzocrea, S., A.P. Caputi, and B. Zingarelli, Peroxynitrite-mediated DNA 
strand breakage activates poly (ADP-ribose) synthetase and causes cellular 
energy depletion in carrageenan-induced pleurisy. Immunology, 1998. 93(1): 
p. 96-101. 
60. Epe, B., et al., DNA damage by peroxynitrite characterized with DNA repair 
enzymes. Nucleic Acids Res, 1996. 24(21): p. 4105-10. 
61. Ferrante, R.J., et al., Increased 3-nitrotyrosine and oxidative damage in mice 
with a human copper/zinc superoxide dismutase mutation. Ann Neurol, 1997. 
42(3): p. 326-34. 
62. Radi, R., et al., Peroxynitrite-induced membrane lipid peroxidation: the 
cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys, 
1991. 288(2): p. 481-7. 
63. Smith, M.A., et al., Widespread peroxynitrite-mediated damage in Alzheimer's 
disease. J Neurosci, 1997. 17(8): p. 2653-7. 
64. Wu, G.S., J. Zhang, and N.A. Rao, Peroxynitrite and oxidative damage in 
experimental autoimmune uveitis. Invest Ophthalmol Vis Sci, 1997. 38(7): p. 
1333-9. 
65. Gow, A.J., et al., Effects of peroxynitrite-induced protein modifications on 
tyrosine phosphorylation and degradation. FEBS Lett, 1996. 385(1-2): p. 63-
6. 
66. Kong, S.K., et al., Peroxynitrite disables the tyrosine phosphorylation 
regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to 
phosphorylate nitrated cdc2(6-20)NH2 peptide. Proc Natl Acad Sci U S A, 
1996. 93(8): p. 3377-82. 
67. Mohr, S., J.S. Stamler, and B. Brune, Mechanism of covalent modification of 
glyceraldehyde-3-phosphate dehydrogenase at its active site thiol by nitric 
oxide, peroxynitrite and related nitrosating agents. FEBS Lett, 1994. 348(3): 
p. 223-7. 
68. Newman, D.K., et al., Nitration of PECAM-1 ITIM tyrosines abrogates 
phosphorylation and SHP-2 binding. Biochem Biophys Res Commun, 2002. 
296(5): p. 1171-9. 
69. Saeki, M. and S. Maeda, p130cas is a cellular target protein for tyrosine 
nitration induced by peroxynitrite. Neurosci Res, 1999. 33(4): p. 325-8. 
70. Viner, R.I., T.D. Williams, and C. Schoneich, Peroxynitrite modification of 
protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally 
important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. 
Biochemistry, 1999. 38(38): p. 12408-15. 
71. van der Vliet, A., et al., Formation of S-Nitrosothiols via Direct Nucleophilic 
Nitrosation of Thiols by Peroxynitrite with Elimination of Hydrogen Peroxide. 
Journal of Biological Chemistry, 1998. 273(46): p. 30255-30262. 
72. Pei, D.S., Y.F. Sun, and Y.J. Song, S-nitrosylation of PTEN Invovled in 
ischemic brain injury in rat hippocampal CA1 region. Neurochem Res, 2009. 
34(8): p. 1507-12. 
193 
 
73. Beckman, J.S., et al., Kinetics of superoxide dismutase- and iron-catalyzed 
nitration of phenolics by peroxynitrite. Arch Biochem Biophys, 1992. 298(2): 
p. 438-45. 
74. Radi, R., Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad 
Sci U S A, 2004. 101(12): p. 4003-8. 
75. Souza, J.M., G. Peluffo, and R. Radi, Protein tyrosine nitration--functional 
alteration or just a biomarker? Free Radic Biol Med, 2008. 45(4): p. 357-66. 
76. MacMillan-Crow, L.A., et al., Nitration and inactivation of manganese 
superoxide dismutase in chronic rejection of human renal allografts. 
Proceedings of the National Academy of Sciences, 1996. 93(21): p. 11853-
11858. 
77. Schmidt, P., et al., Specific Nitration at Tyrosine 430 Revealed by High 
Resolution Mass Spectrometry as Basis for Redox Regulation of Bovine 
Prostacyclin Synthase. Journal of Biological Chemistry, 2003. 278(15): p. 
12813-12819. 
78. el-Remessy, A.B., et al., Oxidative stress inactivates VEGF survival signaling 
in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci, 2005. 
118(Pt 1): p. 243-52. 
79. McCord, J.M. and I. Fridovich, Superoxide dismutase. An enzymic function 
for erythrocuprein (hemocuprein). J Biol Chem, 1969. 244(22): p. 6049-55. 
80. Crapo, J.D., et al., Copper,zinc superoxide dismutase is primarily a cytosolic 
protein in human cells. Proceedings of the National Academy of Sciences, 
1992. 89(21): p. 10405-10409. 
81. Weisiger, R.A. and I. Fridovich, Mitochondrial superoxide dismutase. Site of 
synthesis and intramitochondrial localization. Journal of Biological 
Chemistry, 1973. 248(13): p. 4793-4796. 
82. Okado-Matsumoto, A. and I. Fridovich, Subcellular distribution of superoxide 
dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem, 
2001. 276(42): p. 38388-93. 
83. Sturtz, L.A., et al., A fraction of yeast Cu,Zn-superoxide dismutase and its 
metallochaperone, CCS, localize to the intermembrane space of mitochondria. 
A physiological role for SOD1 in guarding against mitochondrial oxidative 
damage. J Biol Chem, 2001. 276(41): p. 38084-9. 
84. Wispe, J.R., et al., Synthesis and processing of the precursor for human 
mangano-superoxide dismutase. Biochimica et Biophysica Acta (BBA) - 
Protein Structure and Molecular Enzymology, 1989. 994(1): p. 30-36. 
85. Oury, T.D., et al., Immunocytochemical localization of extracellular 
superoxide dismutase in human lung. Laboratory Investigation, 1994. 70(6): 
p. 889-898. 
86. Marklund, S.L., Human copper-containing superoxide dismutase of high 
molecular weight. Proc Natl Acad Sci U S A, 1982. 79(24 I): p. 7634-7638. 
87. Fita, I. and M.G. Rossmann, The active center of catalase. J Mol Biol, 1985. 
185(1): p. 21-37. 
88. Reid, T.J., 3rd, et al., Structure and heme environment of beef liver catalase at 
2.5 A resolution. Proc Natl Acad Sci U S A, 1981. 78(8): p. 4767-71. 
89. Antunes, F., D. Han, and E. Cadenas, Relative contributions of heart 
mitochondria glutathione peroxidase and catalase to H(2)O(2) detoxification 
in in vivo conditions. Free Radic Biol Med, 2002. 33(9): p. 1260-7. 
90. Meister, A., Selective modification of glutathione metabolism. Science, 1983. 
220(4596): p. 472-7. 
194 
 
91. Meister, A., Glutathione metabolism and its selective modification. J Biol 
Chem, 1988. 263(33): p. 17205-8. 
92. Schafer, F.Q. and G.R. Buettner, Redox environment of the cell as viewed 
through the redox state of the glutathione disulfide/glutathione couple. Free 
Radic Biol Med, 2001. 30(11): p. 1191-212. 
93. Flohe, L., H. Budde, and B. Hofmann, Peroxiredoxins in antioxidant defense 
and redox regulation. Biofactors, 2003. 19(1-2): p. 3-10. 
94. Hofmann, B., H.J. Hecht, and L. Flohe, Peroxiredoxins. Biol Chem, 2002. 
383(3-4): p. 347-64. 
95. Rhee, S.G., et al., Peroxiredoxin, a novel family of peroxidases. IUBMB Life, 
2001. 52(1-2): p. 35-41. 
96. Seo, M.S., et al., Identification of a new type of mammalian peroxiredoxin that 
forms an intramolecular disulfide as a reaction intermediate. J Biol Chem, 
2000. 275(27): p. 20346-54. 
97. Rhee, S.G., H.Z. Chae, and K. Kim, Peroxiredoxins: a historical overview 
and speculative preview of novel mechanisms and emerging concepts in cell 
signaling. Free Radic Biol Med, 2005. 38(12): p. 1543-52. 
98. Holmgren, A. and M. Bjornstedt, Thioredoxin and thioredoxin reductase. 
Methods Enzymol, 1995. 252: p. 199-208. 
99. Chae, H.Z., S.J. Chung, and S.G. Rhee, Thioredoxin-dependent peroxide 
reductase from yeast. J Biol Chem, 1994. 269(44): p. 27670-8. 
100. Kerr, J.F., A.H. Wyllie, and A.R. Currie, Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 
1972. 26(4): p. 239-57. 
101. Wyllie, A.H., J.F. Kerr, and A.R. Currie, Cell death: the significance of 
apoptosis. Int Rev Cytol, 1980. 68: p. 251-306. 
102. Jacobson, M.D., M. Weil, and M.C. Raff, Programmed cell death in animal 
development. Cell, 1997. 88(3): p. 347-54. 
103. Osborne, B.A., Apoptosis and the maintenance of homoeostasis in the immune 
system. Curr Opin Immunol, 1996. 8(2): p. 245-54. 
104. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): 
p. 57-70. 
105. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. 
Cell, 2011. 144(5): p. 646-74. 
106. Alnemri, E.S., et al., Human ICE/CED-3 protease nomenclature. Cell, 1996. 
87(2): p. 171. 
107. Cohen, G.M., Caspases: the executioners of apoptosis. Biochem J, 1997. 326 
( Pt 1): p. 1-16. 
108. Hengartner, M.O., The biochemistry of apoptosis. Nature, 2000. 407(6805): p. 
770-6. 
109. Crawford, E.D. and J.A. Wells, Caspase substrates and cellular remodeling. 
Annu Rev Biochem, 2011. 80: p. 1055-87. 
110. Buendia, B., A. Santa-Maria, and J.C. Courvalin, Caspase-dependent 
proteolysis of integral and peripheral proteins of nuclear membranes and 
nuclear pore complex proteins during apoptosis. J Cell Sci, 1999. 112 ( Pt 
11): p. 1743-53. 
111. Rao, L., D. Perez, and E. White, Lamin proteolysis facilitates nuclear events 
during apoptosis. J Cell Biol, 1996. 135(6 Pt 1): p. 1441-55. 




113. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol Pathol, 
2007. 35(4): p. 495-516. 
114. Hsu, H., J. Xiong, and D.V. Goeddel, The TNF receptor 1-associated protein 
TRADD signals cell death and NF-kappa B activation. Cell, 1995. 81(4): p. 
495-504. 
115. Wajant, H., The Fas signaling pathway: more than a paradigm. Science, 
2002. 296(5573): p. 1635-6. 
116. Kischkel, F.C., et al., Cytotoxicity-dependent APO-1 (Fas/CD95)-associated 
proteins form a death-inducing signaling complex (DISC) with the receptor. 
EMBO J, 1995. 14(22): p. 5579-88. 
117. Ozoren, N. and W.S. El-Deiry, Defining characteristics of Types I and II 
apoptotic cells in response to TRAIL. Neoplasia, 2002. 4(6): p. 551-7. 
118. Scaffidi, C., et al., Two CD95 (APO-1/Fas) signaling pathways. EMBO J, 
1998. 17(6): p. 1675-87. 
119. Kroemer, G., L. Galluzzi, and C. Brenner, Mitochondrial membrane 
permeabilization in cell death. Physiol Rev, 2007. 87(1): p. 99-163. 
120. Chinnaiyan, A.M., The apoptosome: heart and soul of the cell death machine. 
Neoplasia, 1999. 1(1): p. 5-15. 
121. Li, P., et al., Cytochrome c and dATP-dependent formation of Apaf-1/caspase-
9 complex initiates an apoptotic protease cascade. Cell, 1997. 91(4): p. 479-
89. 
122. Cain, K., et al., Caspase activation involves the formation of the aposome, a 
large (approximately 700 kDa) caspase-activating complex. J Biol Chem, 
1999. 274(32): p. 22686-92. 
123. Stennicke, H.R., et al., Caspase-9 can be activated without proteolytic 
processing. J Biol Chem, 1999. 274(13): p. 8359-62. 
124. Schimmer, A.D., Inhibitor of apoptosis proteins: translating basic knowledge 
into clinical practice. Cancer Res, 2004. 64(20): p. 7183-90. 
125. van Loo, G., et al., The serine protease Omi/HtrA2 is released from 
mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP 
and induces enhanced caspase activity. Cell Death Differ, 2002. 9(1): p. 20-6. 
126. Adams, J.M. and S. Cory, The Bcl-2 protein family: arbiters of cell survival. 
Science, 1998. 281(5381): p. 1322-6. 
127. Gross, A., J.M. McDonnell, and S.J. Korsmeyer, BCL-2 family members and 
the mitochondria in apoptosis. Genes Dev, 1999. 13(15): p. 1899-911. 
128. Reed, J.C., Double identity for proteins of the Bcl-2 family. Nature, 1997. 
387(6635): p. 773-6. 
129. Cleary, M.L., S.D. Smith, and J. Sklar, Cloning and structural analysis of 
cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from 
the t(14;18) translocation. Cell, 1986. 47(1): p. 19-28. 
130. Nguyen, M., et al., Targeting of Bcl-2 to the mitochondrial outer membrane 
by a COOH-terminal signal anchor sequence. J Biol Chem, 1993. 268(34): p. 
25265-8. 
131. Lithgow, T., et al., The protein product of the oncogene bcl-2 is a component 
of the nuclear envelope, the endoplasmic reticulum, and the outer 
mitochondrial membrane. Cell Growth Differ, 1994. 5(4): p. 411-7. 
132. Petros, A.M., E.T. Olejniczak, and S.W. Fesik, Structural biology of the Bcl-2 
family of proteins. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research, 2004. 1644(2–3): p. 83-94. 
196 
 
133. Petros, A.M., et al., Solution structure of the antiapoptotic protein bcl-2. 
Proceedings of the National Academy of Sciences, 2001. 98(6): p. 3012-3017. 
134. Basu, A., S.A. You, and S. Haldar, Regulation of Bcl2 phosphorylation by 
stress response kinase pathway. Int J Oncol, 2000. 16(3): p. 497-500. 
135. Bassik, M.C., et al., Phosphorylation of BCL-2 regulates ER Ca2+ 
homeostasis and apoptosis. EMBO J, 2004. 23(5): p. 1207-16. 
136. Deng, X., et al., Mono- and multisite phosphorylation enhances Bcl2's 
antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl 
Acad Sci U S A, 2004. 101(1): p. 153-8. 
137. Ito, T., et al., Bcl-2 phosphorylation required for anti-apoptosis function. J 
Biol Chem, 1997. 272(18): p. 11671-3. 
138. Vaux, D.L., S. Cory, and J.M. Adams, Bcl-2 gene promotes haemopoietic cell 
survival and cooperates with c-myc to immortalize pre-B cells. Nature, 1988. 
335(6189): p. 440-2. 
139. Strasser, A., et al., Novel primitive lymphoid tumours induced in transgenic 
mice by cooperation between myc and bcl-2. Nature, 1990. 348(6299): p. 331-
3. 
140. Low, I.C., J. Kang, and S. Pervaiz, Bcl-2: a prime regulator of mitochondrial 
redox metabolism in cancer cells. Antioxid Redox Signal, 2011. 15(12): p. 
2975-87. 
141. Chipuk, J.E., et al., The BCL-2 family reunion. Mol Cell, 2010. 37(3): p. 299-
310. 
142. Mikhailov, V., et al., Association of Bax and Bak homo-oligomers in 
mitochondria. Bax requirement for Bak reorganization and cytochrome c 
release. J Biol Chem, 2003. 278(7): p. 5367-76. 
143. Kuwana, T., et al., Bid, Bax, and lipids cooperate to form supramolecular 
openings in the outer mitochondrial membrane. Cell, 2002. 111(3): p. 331-
342. 
144. Wei, M.C., et al., tBID, a membrane-targeted death ligand, oligomerizes BAK 
to release cytochrome c. Genes and Development, 2000. 14(16): p. 2060-
2071. 
145. Kuwana, T., et al., BH3 Domains of BH3-Only Proteins Differentially 
Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both 
Directly and Indirectly. Mol Cell, 2005. 17(4): p. 525-535. 
146. Letai, A., et al., Distinct BH3 domains either sensitize or activate 
mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer 
Cell, 2002. 2(3): p. 183-192. 
147. Uren, R.T., et al., Mitochondrial permeabilization relies on BH3 ligands 
engaging multiple prosurvival Bcl-2 relatives, not Bak. Journal of Cell 
Biology, 2007. 177(2): p. 277-287. 
148. Willis, S.N., et al., Apoptosis initiated when BH3 ligands engage multiple Bcl-
2 homologs, not Bax or Bak. Science, 2007. 315(5813): p. 856-859. 
149. Wei, M.C., et al., Proapoptotic BAX and BAK: a requisite gateway to 
mitochondrial dysfunction and death. Science, 2001. 292(5517): p. 727-30. 
150. Ojala, P.M., et al., The apoptotic v-cyclin-CDK6 complex phosphorylates and 
inactivates Bcl-2. Nat Cell Biol, 2000. 2(11): p. 819-25. 
151. Yamamoto, K., H. Ichijo, and S.J. Korsmeyer, BCL-2 is phosphorylated and 
inactivated by an ASK1/Jun N-terminal protein kinase pathway normally 
activated at G(2)/M. Mol Cell Biol, 1999. 19(12): p. 8469-78. 
197 
 
152. Nencioni, L., et al., Bcl-2 expression and p38MAPK activity in cells infected 
with influenza A virus: impact on virally induced apoptosis and viral 
replication. J Biol Chem, 2009. 284(23): p. 16004-15. 
153. Thomas, A., T. Giesler, and E. White, p53 mediates bcl-2 phosphorylation 
and apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene, 2000. 
19(46): p. 5259-69. 
154. De Chiara, G., et al., Bcl-2 Phosphorylation by p38 MAPK: identification of 
target sites and biologic consequences. J Biol Chem, 2006. 281(30): p. 21353-
61. 
155. Kang, Y.H. and S.J. Lee, The role of p38 MAPK and JNK in Arsenic trioxide-
induced mitochondrial cell death in human cervical cancer cells. J Cell 
Physiol, 2008. 217(1): p. 23-33. 
156. Wei, Y., et al., JNK1-mediated phosphorylation of Bcl-2 regulates starvation-
induced autophagy. Mol Cell, 2008. 30(6): p. 678-88. 
157. Liu, Y., et al., Activation of ERK-p53 and ERK-Mediated Phosphorylation of 
Bcl-2 Are Involved in Autophagic Cell Death Induced by the c-Met Inhibitor 
SU11274 in Human Lung Cancer A549 Cells. J Pharmacol Sci, 2012. 118(4): 
p. 423-32. 
158. Deng, X., et al., Survival function of ERK1/2 as IL-3-activated, staurosporine-
resistant Bcl2 kinases. Proc Natl Acad Sci U S A, 2000. 97(4): p. 1578-83. 
159. May, W.S., et al., Interleukin-3 and bryostatin-1 mediate 
hyperphosphorylation of BCL2 alpha in association with suppression of 
apoptosis. J Biol Chem, 1994. 269(43): p. 26865-70. 
160. Asnaghi, L., et al., Bcl-2 phosphorylation and apoptosis activated by damaged 
microtubules require mTOR and are regulated by Akt. Oncogene, 2004. 
23(34): p. 5781-91. 
161. Pathan, N., et al., Microtubule-targeting drugs induce bcl-2 phosphorylation 
and association with Pin1. Neoplasia, 2001. 3(6): p. 550-9. 
162. Boudny, V. and S. Nakano, Src tyrosine kinase augments taxotere-induced 
apoptosis through enhanced expression and phosphorylation of Bcl-2. Br J 
Cancer, 2002. 86(3): p. 463-9. 
163. Lin, S.S., et al., PP2A regulates BCL-2 phosphorylation and proteasome-
mediated degradation at the endoplasmic reticulum. J Biol Chem, 2006. 
281(32): p. 23003-12. 
164. Ruvolo, P.P., et al., Ceramide induces Bcl2 dephosphorylation via a 
mechanism involving mitochondrial PP2A. J Biol Chem, 1999. 274(29): p. 
20296-300. 
165. Brichese, L. and A. Valette, PP1 phosphatase is involved in Bcl-2 
dephosphorylation after prolonged mitotic arrest induced by paclitaxel. 
Biochemical and Biophysical Research Communications, 2002. 294(2): p. 
504-508. 
166. Srivastava, R.K., et al., Deletion of the loop region of Bcl-2 completely blocks 
paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A, 1999. 96(7): p. 3775-
80. 
167. Haldar, S., J. Chintapalli, and C.M. Croce, Taxol induces bcl-2 
phosphorylation and death of prostate cancer cells. Cancer Res, 1996. 56(6): 
p. 1253-5. 
168. Konopleva, M., et al., Mechanisms of apoptosis sensitivity and resistance to 
the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006. 
10(5): p. 375-88. 
198 
 
169. Shitashige, M., et al., Dissociation of Bax from a Bcl-2/Bax heterodimer 
triggered by phosphorylation of serine 70 of Bcl-2. J Biochem, 2001. 130(6): 
p. 741-8. 
170. Mai, H., et al., A functional role for nicotine in Bcl2 phosphorylation and 
suppression of apoptosis. J Biol Chem, 2003. 278(3): p. 1886-91. 
171. Ray, R.M., S. Bhattacharya, and L.R. Johnson, Protein phosphatase 2A 
regulates apoptosis in intestinal epithelial cells. J Biol Chem, 2005. 280(35): 
p. 31091-100. 
172. Ruvolo, P.P., X. Deng, and W.S. May, Phosphorylation of Bcl2 and 
regulation of apoptosis. Leukemia, 2001. 15(4): p. 515-22. 
173. Srivastava, R.K., et al., Involvement of microtubules in the regulation of Bcl2 
phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. 
Mol Cell Biol, 1998. 18(6): p. 3509-17. 
174. Fridlyand, L.E. and L.H. Philipson, Reactive species and early manifestation 
of insulin resistance in type 2 diabetes. Diabetes Obes Metab, 2006. 8(2): p. 
136-45. 
175. Hool, L.C., Reactive oxygen species in cardiac signalling: from mitochondria 
to plasma membrane ion channels. Clin Exp Pharmacol Physiol, 2006. 33(1-
2): p. 146-51. 
176. Larbi, A., J. Kempf, and G. Pawelec, Oxidative stress modulation and T cell 
activation. Exp Gerontol, 2007. 42(9): p. 852-8. 
177. Piccoli, C., et al., Role of reactive oxygen species as signal molecules in the 
pre-commitment phase of adult stem cells. Ital J Biochem, 2007. 56(4): p. 295-
301. 
178. Touyz, R.M., F. Tabet, and E.L. Schiffrin, Redox-dependent signalling by 
angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol 
Physiol, 2003. 30(11): p. 860-6. 
179. Pervaiz, S. and M.V. Clement, Superoxide anion: oncogenic reactive oxygen 
species? Int J Biochem Cell Biol, 2007. 39(7-8): p. 1297-304. 
180. Armstrong, A.W., et al., Angiogenesis and oxidative stress: common 
mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci, 2011. 
63(1): p. 1-9. 
181. Jomova, K., et al., Metals, oxidative stress and neurodegenerative disorders. 
Mol Cell Biochem, 2010. 345(1-2): p. 91-104. 
182. Park, J.G. and G.T. Oh, The role of peroxidases in the pathogenesis of 
atherosclerosis. BMB Rep, 2011. 44(8): p. 497-505. 
183. Taupin, P., A dual activity of ROS and oxidative stress on adult neurogenesis 
and Alzheimer's disease. Cent Nerv Syst Agents Med Chem, 2010. 10(1): p. 
16-21. 
184. Victor, V.M., et al., Oxidative stress and mitochondrial dysfunction in type 2 
diabetes. Curr Pharm Des, 2011. 17(36): p. 3947-58. 
185. Ushio-Fukai, M. and Y. Nakamura, Reactive oxygen species and 
angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett, 
2008. 266(1): p. 37-52. 
186. Pani, G., T. Galeotti, and P. Chiarugi, Metastasis: cancer cell's escape from 
oxidative stress. Cancer Metastasis Rev, 2010. 29(2): p. 351-78. 
187. Li, Z.Y., et al., Mitochondrial ROS generation for regulation of autophagic 
pathways in cancer. Biochem Biophys Res Commun, 2011. 414(1): p. 5-8. 
188. Saito, Y., et al., Turning point in apoptosis/necrosis induced by hydrogen 
peroxide. Free Radic Res, 2006. 40(6): p. 619-30. 
199 
 
189. Takeda, M., et al., Hydrogen peroxide induces necrosis, apoptosis, oncosis 
and apoptotic oncosis of mouse terminal proximal straight tubule cells. 
Nephron, 1999. 81(2): p. 234-8. 
190. Teramoto, S., et al., Hydrogen peroxide-induced apoptosis and necrosis in 
human lung fibroblasts: protective roles of glutathione. Jpn J Pharmacol, 
1999. 79(1): p. 33-40. 
191. Ahmad, K.A., et al., Hydrogen peroxide-mediated cytosolic acidification is a 
signal for mitochondrial translocation of Bax during drug-induced apoptosis 
of tumor cells. Cancer Res, 2004. 64(21): p. 7867-78. 
192. Inoshita, S., et al., Phosphorylation and inactivation of myeloid cell leukemia 
1 by JNK in response to oxidative stress. J Biol Chem, 2002. 277(46): p. 
43730-4. 
193. Schroeter, H., et al., c-Jun N-terminal kinase (JNK)-mediated modulation of 
brain mitochondria function: New target proteins for JNK signalling in 
mitochondrion-dependent apoptosis. Biochemical Journal, 2003. 372(2): p. 
359-369. 
194. Naughton, R., et al., Bcr-Abl-mediated redox regulation of the PI3K/AKT 
pathway. Leukemia, 2009. 23(8): p. 1432-1440. 
195. Leslie, N.R., et al., Redox regulation of PI 3-kinase signalling via inactivation 
of PTEN. EMBO Journal, 2003. 22(20): p. 5501-5510. 
196. Shibanuma, M., T. Kuroki, and K. Nose, Induction of DNA replication and 
expression of proto-oncogene c-myc and c-fos in quiescent Balb/3T3 cells by 
xanthine/xanthine oxidase. Oncogene, 1988. 3(1): p. 17-21. 
197. Burdon, R.H., Superoxide and hydrogen peroxide in relation to mammalian 
cell proliferation. Free Radical Biology and Medicine, 1995. 18(4): p. 775-
794. 
198. Pervaiz, S., et al., Superoxide anion inhibits drug-induced tumor cell death. 
FEBS Lett, 1999. 459(3): p. 343-8. 
199. Clement, M.V. and I. Stamenkovic, Superoxide anion is a natural inhibitor of 
FAS-mediated cell death. EMBO J, 1996. 15(2): p. 216-25. 
200. Clement, M.V., J.L. Hirpara, and S. Pervaiz, Decrease in intracellular 
superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-
induced apoptosis independent of the mitochondria. Cell Death Differ, 2003. 
10(11): p. 1273-85. 
201. Clément, M.V. and S. Pervaiz, Intracellular superoxide and hydrogen 
peroxide concentrations: A critical balance that determines survival or death. 
Redox Report, 2001. 6(4): p. 211-214. 
202. Zhu, P., et al., Angiopoietin-like 4 Protein Elevates the Prosurvival 
Intracellular O2−:H2O2 Ratio and Confers Anoikis Resistance to Tumors. 
Cancer Cell, 2011. 19(3): p. 401-415. 
203. Clement, M.V., A. Ponton, and S. Pervaiz, Apoptosis induced by hydrogen 
peroxide is mediated by decreased superoxide anion concentration and 
reduction of intracellular milieu. FEBS Lett, 1998. 440(1-2): p. 13-8. 
204. Hirpara, J.L., M.V. Clement, and S. Pervaiz, Intracellular acidification 
triggered by mitochondrial-derived hydrogen peroxide is an effector 
mechanism for drug-induced apoptosis in tumor cells. J Biol Chem, 2001. 
276(1): p. 514-21. 
205. Barbosa, L.F., et al., Increased SOD1 association with chromatin, DNA 
damage, p53 activation, and apoptosis in a cellular model of SOD1-linked 
200 
 
ALS. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 
2010. 1802(5): p. 462-471. 
206. Zhang, Y., et al., Overexpression of copper zinc superoxide dismutase 
suppresses human glioma cell growth. Cancer Res, 2002. 62(4): p. 1205-1212. 
207. Lin, K.I., et al., Decreased intracellular superoxide levels activate Sindbis 
virus-induced apoptosis. J Biol Chem, 1999. 274(19): p. 13650-5. 
208. Chen, Z.X. and S. Pervaiz, Bcl-2 induces pro-oxidant state by engaging 
mitochondrial respiration in tumor cells. Cell Death Differ, 2007. 14(9): p. 
1617-27. 
209. Chen, Z.X. and S. Pervaiz, Involvement of cytochrome c oxidase subunits Va 
and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death 
Differ, 2010. 17(3): p. 408-20. 
210. Virshup, D.M. and S. Shenolikar, From promiscuity to precision: protein 
phosphatases get a makeover. Mol Cell, 2009. 33(5): p. 537-45. 
211. Xu, Y., et al., Structure of the protein phosphatase 2A holoenzyme. Cell, 2006. 
127(6): p. 1239-51. 
212. Eichhorn, P.J., M.P. Creyghton, and R. Bernards, Protein phosphatase 2A 
regulatory subunits and cancer. Biochim Biophys Acta, 2009. 1795(1): p. 1-
15. 
213. Stone, S.R., J. Hofsteenge, and B.A. Hemmings, Molecular cloning of cDNAs 
encoding two isoforms of the catalytic subunit of protein phosphatase 2A. 
Biochemistry, 1987. 26(23): p. 7215-20. 
214. Hemmings, B.A., et al., alpha- and beta-forms of the 65-kDa subunit of 
protein phosphatase 2A have a similar 39 amino acid repeating structure. 
Biochemistry, 1990. 29(13): p. 3166-73. 
215. McCright, B., et al., The B56 family of protein phosphatase 2A (PP2A) 
regulatory subunits encodes differentiation-induced phosphoproteins that 
target PP2A to both nucleus and cytoplasm. J Biol Chem, 1996. 271(36): p. 
22081-9. 
216. Yang, J. and C. Phiel, Functions of B56-containing PP2As in major 
developmental and cancer signaling pathways. Life Sci, 2011. 87(23-26): p. 
659-66. 
217. Moreno, C.S., et al., WD40 repeat proteins striatin and S/G(2) nuclear 
autoantigen are members of a novel family of calmodulin-binding proteins 
that associate with protein phosphatase 2A. J Biol Chem, 2000. 275(8): p. 
5257-63. 
218. Stark, M.J., Yeast protein serine/threonine phosphatases: multiple roles and 
diverse regulation. Yeast, 1996. 12(16): p. 1647-75. 
219. Götz, J., et al., Delayed embryonic lethality in mice lacking protein 
phosphatase 2A catalytic subunit Cα. Proc Natl Acad Sci U S A, 1998. 
95(21): p. 12370-12375. 
220. Strack, S., J.T. Cribbs, and L. Gomez, Critical role for protein phosphatase 
2A heterotrimers in mammalian cell survival. J Biol Chem, 2004. 279(46): p. 
47732-9. 
221. Janssens, V. and J. Goris, Protein phosphatase 2A: a highly regulated family 
of serine/threonine phosphatases implicated in cell growth and signalling. 
Biochem J, 2001. 353(Pt 3): p. 417-39. 
222. Wurzenberger, C. and D.W. Gerlich, Phosphatases: providing safe passage 
through mitotic exit. Nat Rev Mol Cell Biol, 2011. 12(8): p. 469-82. 
201 
 
223. Collins, E. and A.T. Sim, Regulation of neuronal PP1 and PP2A during 
development. Methods Mol Biol, 1998. 93: p. 79-102. 
224. Basu, S., PP2A in the regulation of cell motility and invasion. Curr Protein 
Pept Sci, 2011. 12(1): p. 3-11. 
225. Suganuma, M., et al., Okadaic acid: an additional non-phorbol-12-
tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci U S A, 
1988. 85(6): p. 1768-71. 
226. Pallas, D.C., et al., Polyoma small and middle T antigens and SV40 small t 
antigen form stable complexes with protein phosphatase 2A. Cell, 1990. 
60(1): p. 167-76. 
227. Campbell, K.S., et al., Identification of regions in polyomavirus middle T and 
small t antigens important for association with protein phosphatase 2A. J 
Virol, 1995. 69(6): p. 3721-8. 
228. Wang, S.S., et al., Alterations of the PPP2R1B gene in human lung and colon 
cancer. Science, 1998. 282(5387): p. 284-7. 
229. Campbell, I.G. and T. Manolitsas, Absence of PPP2R1B gene alterations in 
primary ovarian cancers. Oncogene, 1999. 18(46): p. 6367-9. 
230. Takagi, Y., et al., Alterations of the PPP2R1B gene located at 11q23 in 
human colorectal cancers. Gut, 2000. 47(2): p. 268-71. 
231. Calin, G.A., et al., Low frequency of alterations of the alpha (PPP2R1A) and 
beta (PPP2R1B) isoforms of the subunit A of the serine-threonine 
phosphatase 2A in human neoplasms. Oncogene, 2000. 19(9): p. 1191-5. 
232. Arnold, H.K. and R.C. Sears, Protein phosphatase 2A regulatory subunit 
B56alpha associates with c-myc and negatively regulates c-myc 
accumulation. Mol Cell Biol, 2006. 26(7): p. 2832-44. 
233. Felsher, D.W. and J.M. Bishop, Reversible Tumorigenesis by MYC in 
Hematopoietic Lineages. Mol Cell, 1999. 4(2): p. 199-207. 
234. Pelengaris, S., et al., Reversible Activation of c-Myc in Skin: Induction of a 
Complex Neoplastic Phenotype by a Single Oncogenic Lesion. Mol Cell, 
1999. 3(5): p. 565-577. 
235. Magenta, A., et al., Protein phosphatase 2A subunit PR70 interacts with pRb 
and mediates its dephosphorylation. Mol Cell Biol, 2008. 28(2): p. 873-82. 
236. Cobrinik, D., Pocket proteins and cell cycle control. 2005. 24(17): p. 2796-
2809. 
237. Mittnacht, S., The retinoblastoma protein—from bench to bedside. European 
Journal of Cell Biology, 2005. 84(2–3): p. 97-107. 
238. Li, H.H., et al., A specific PP2A regulatory subunit, B56gamma, mediates 
DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J, 2007. 
26(2): p. 402-11. 
239. Letourneux, C., G. Rocher, and F. Porteu, B56-containing PP2A 
dephosphorylate ERK and their activity is controlled by the early gene IEX-1 
and ERK. EMBO J, 2006. 25(4): p. 727-38. 
240. Pearson, G., et al., Mitogen-activated protein (MAP) kinase pathways: 
regulation and physiological functions. Endocr Rev, 2001. 22(2): p. 153-83. 
241. Foley, T.D., J.J. Armstrong, and B.R. Kupchak, Identification and H2O2 
sensitivity of the major constitutive MAPK phosphatase from rat brain. 
Biochem Biophys Res Commun, 2004. 315(3): p. 568-74. 
242. Chen, L., L. Liu, and S. Huang, Cadmium activates the mitogen-activated 
protein kinase (MAPK) pathway via induction of reactive oxygen species and 
202 
 
inhibition of protein phosphatases 2A and 5. Free Radic Biol Med, 2008. 
45(7): p. 1035-44. 
243. Ruvolo, P.P., et al., A functional role for the B56 alpha-subunit of protein 
phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation 
status and function. J Biol Chem, 2002. 277(25): p. 22847-52. 
244. Acharya, A., et al., Redox regulation in cancer: a double-edged sword with 
therapeutic potential. Oxid Med Cell Longev, 2010. 3(1): p. 23-34. 
245. Hsu, W.H., et al., Berberine induces apoptosis in SW620 human colonic 
carcinoma cells through generation of reactive oxygen species and activation 
of JNK/p38 MAPK and FasL. Arch Toxicol, 2007. 81(10): p. 719-28. 
246. Kim, M.H., et al., Acetylcholine inhibits long-term hypoxia-induced apoptosis 
by suppressing the oxidative stress-mediated MAPKs activation as well as 
regulation of Bcl-2, c-IAPs, and caspase-3 in mouse embryonic stem cells. 
Apoptosis, 2008. 13(2): p. 295-304. 
247. Kuo, P.L., et al., Involvement of reactive oxygen species/c-Jun NH(2)-terminal 
kinase pathway in kotomolide A induces apoptosis in human breast cancer 
cells. Toxicol Appl Pharmacol, 2008. 229(2): p. 215-26. 
248. Shim, H.Y., et al., Acacetin-induced apoptosis of human breast cancer MCF-7 
cells involves caspase cascade, mitochondria-mediated death signaling and 
SAPK/JNK1/2-c-Jun activation. Mol Cells, 2007. 24(1): p. 95-104. 
249. Kim, H.S., et al., Constitutive induction of p-Erk1/2 accompanied by reduced 
activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen 
species during cellular senescence. J Biol Chem, 2003. 278(39): p. 37497-
510. 
250. Banker, D.E., et al., Measurement of spontaneous and therapeutic agent-
induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. 
Blood, 1997. 89(1): p. 243-55. 
251. Campos, L., et al., Expression of apoptosis-controlling proteins in acute 
leukemia cells. Leuk Lymphoma, 1999. 33(5-6): p. 499-509. 
252. Lickliter, J.D., et al., HA14-1 selectively induces apoptosis in Bcl-2-
overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced 
cell death. Leukemia, 2003. 17(11): p. 2074-80. 
253. Skinnider, B.F., et al., Bcl-6 and Bcl-2 protein expression in diffuse large B-
cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 
chromosomal abnormalities. Hum Pathol, 1999. 30(7): p. 803-8. 
254. Huang, S.T. and J.A. Cidlowski, Phosphorylation status modulates Bcl-2 
function during glucocorticoid-induced apoptosis in T lymphocytes. FASEB J, 
2002. 16(8): p. 825-32. 
255. Wright, V.P., et al., Superoxide scavengers augment contractile but not 
energetic responses to hypoxia in rat diaphragm. Journal of Applied 
Physiology, 2005. 98(5): p. 1753-1760. 
256. Tilly, J.L. and K.I. Tilly, Inhibitors of oxidative stress mimic the ability of 
follicle-stimulating hormone to suppress apoptosis in cultured rat ovarian 
follicles. Endocrinology, 1995. 136(1): p. 242-52. 
257. Davies, C.M., et al., Reactive nitrogen and oxygen species in interleukin-1-
mediated DNA damage associated with osteoarthritis. Osteoarthritis 
Cartilage, 2008. 16(5): p. 624-30. 
258. Low, I.C., Z.X. Chen, and S. Pervaiz, Bcl-2 modulates resveratrol-induced 
ROS production by regulating mitochondrial respiration in tumor cells. 
Antioxid Redox Signal, 2010. 13(6): p. 807-19. 
203 
 
259. Karpinich, N.O., et al., The course of etoposide-induced apoptosis in Jurkat 
cells lacking p53 and Bax. J Cell Physiol, 2006. 208(1): p. 55-63. 
260. Li, X., et al., B56-associated protein phosphatase 2A is required for survival 
and protects from apoptosis in Drosophila melanogaster. Mol Cell Biol, 
2002. 22(11): p. 3674-84. 
261. Chen, F., et al., Multiple protein phosphatases are required for mitosis in 
Drosophila. Curr Biol, 2007. 17(4): p. 293-303. 
262. Csortos, C., et al., High complexity in the expression of the B' subunit of 
protein phosphatase 2A0. Evidence for the existence of at least seven novel 
isoforms. J Biol Chem, 1996. 271(5): p. 2578-88. 
263. McCright, B. and D.M. Virshup, Identification of a new family of protein 
phosphatase 2A regulatory subunits. J Biol Chem, 1995. 270(44): p. 26123-8. 
264. Lin, K.T., et al., Peroxynitrite induces apoptosis of HL-60 cells by activation 
of a caspase-3 family protease. Am J Physiol, 1998. 274(4 Pt 1): p. C855-60. 
265. Sandoval, M., et al., Peroxynitrite-induced apoptosis in T84 and RAW 264.7 
cells: attenuation by L-ascorbic acid. Free Radic Biol Med, 1997. 22(3): p. 
489-95. 
266. Wu, F. and J.X. Wilson, Peroxynitrite-dependent activation of protein 
phosphatase type 2A mediates microvascular endothelial barrier dysfunction. 
Cardiovasc Res, 2009. 81(1): p. 38-45. 
267. Li, X. and D.M. Virshup, Two conserved domains in regulatory B subunits 
mediate binding to the A subunit of protein phosphatase 2A. Eur J Biochem, 
2002. 269(2): p. 546-52. 
268. Souza, J.M., et al., Factors determining the selectivity of protein tyrosine 
nitration. Arch Biochem Biophys, 1999. 371(2): p. 169-78. 
269. Sacksteder, C.A., et al., Endogenously nitrated proteins in mouse brain: links 
to neurodegenerative disease. Biochemistry, 2006. 45(26): p. 8009-22. 
270. Forester, C.M., et al., Control of mitotic exit by PP2A regulation of Cdc25C 
and Cdk1. Proc Natl Acad Sci U S A, 2007. 104(50): p. 19867-72. 
271. Louis, J.V., et al., Mice lacking phosphatase PP2A subunit PR61/B'delta 
(Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 
and GSK3beta. Proc Natl Acad Sci U S A, 2011. 108(17): p. 6957-62. 
272. Adams, D.G., et al., Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by 
protein serine/threonine phosphatase 2A holoenzymes. J Biol Chem, 2005. 
280(52): p. 42644-54. 
273. Giannoni, E., et al., Redox regulation of anoikis resistance of metastatic 
prostate cancer cells: key role for Src and EGFR-mediated pro-survival 
signals. Oncogene, 2009. 28(20): p. 2074-86. 
274. Chiarugi, P. and E. Giannoni, Anchorage-dependent cell growth: tyrosine 
kinases and phosphatases meet redox regulation. Antioxid Redox Signal, 
2005. 7(5-6): p. 578-92. 
275. Irani, K. and P.J. Goldschmidt-Clermont, Ras, superoxide and signal 
transduction. Biochem Pharmacol, 1998. 55(9): p. 1339-46. 
276. Narayanan, A., et al., Alteration in superoxide dismutase 1 causes oxidative 
stress and p38 MAPK activation following RVFV infection. PLoS One, 2011. 
6(5): p. e20354. 
277. Somwar, R., et al., Superoxide dismutase 1 (SOD1) is a target for a small 
molecule identified in a screen for inhibitors of the growth of lung 
adenocarcinoma cell lines. Proceedings of the National Academy of Sciences, 
2011. 108(39): p. 16375-16380. 
204 
 
278. Brown, D.P., et al., Targeting superoxide dismutase 1 to overcome cisplatin 
resistance in human ovarian cancer. Cancer Chemother Pharmacol, 2009. 
63(4): p. 723-30. 
279. Huang, P., et al., Superoxide dismutase as a target for the selective killing of 
cancer cells. Nature, 2000. 407(6802): p. 390-395. 
280. Yoshizaki, N., et al., Suppressive effect of recombinant human Cu, Zn-
superoxide dismutase on lung metastasis of murine tumor cells. International 
Journal of Cancer, 1994. 57(2): p. 287-292. 
281. Kogawa, K., et al., Enhanced inhibition of experimental metastasis by the 
combination chemotherapy of Cu-Zn SOD and adriamycin. Clinical and 
Experimental Metastasis, 1999. 17(3): p. 239-244. 
282. Nonaka, Y., et al., Effect of reactive oxygen intermediates on the in vitro 
invasive capacity of tumor cells and liver metastasis in mice. International 
Journal of Cancer, 1993. 54(6): p. 983-986. 
283. Van Driel, B.E.M., et al., Expression of CuZn- and Mn-Superoxide Dismutase 
in Human Colorectal Neoplasms. Free Radical Biology and Medicine, 1997. 
23(3): p. 435-444. 
284. Oberley, T.D., et al., Immunogold analysis of antioxidant enzymes in human 
renal cell carcinoma. Virchows Archiv, 1994. 424(2): p. 155-164. 
285. Oberley, T.D., J.M. Sempf, and L.W. Oberley, Immunogold analysis of 
antioxidant enzymes in common renal cancers. Histology and Histopathology, 
1996. 11(1): p. 153-160. 
286. Baker, A.M., L.W. Oberley, and M.B. Cohen, Expression of antioxidant 
enzymes in human prostatic adenocarcinoma. Prostate, 1997. 32(4): p. 229-
233. 
287. Bostwick, D.G., et al., Antioxidant enzyme expression and reactive oxygen 
species damage in prostatic intraepithelial neoplasia and cancer. Cancer, 
2000. 89(1): p. 123-134. 
288. Cullen, J.J., F.A. Mitros, and L.W. Oberley, Expression of antioxidant 
enzymes in diseases of the human pancreas: Another link between chronic 
pancreatitis and pancreatic cancer. Pancreas, 2003. 26(1): p. 23-27. 
289. Coursin, D.B., et al., An immunohistochemical analysis of antioxidant and 
glutathione S-transferase enzyme levels in normal and neoplastic human lung. 
Histology and Histopathology, 1996. 11(4): p. 851-860. 
290. Janssen, A.M.L., et al., Superoxide dismutases in relation to the overall 
survival of colorectal cancer patients. Br J Cancer, 1998. 78(8): p. 1051-1057. 
291. Bianchi, M.S., N.O. Bianchi, and A.D. Bolzán, Superoxide dismutase activity 
and superoxide dismutase-1 gene methylation in normal and tumoral human 
breast tissues. Cancer Genetics and Cytogenetics, 1992. 59(1): p. 26-29. 
292. Gorg, B., et al., Reversible inhibition of mammalian glutamine synthetase by 
tyrosine nitration. FEBS Lett, 2007. 581(1): p. 84-90. 
293. Kamisaki, Y., et al., An activity in rat tissues that modifies nitrotyrosine-
containing proteins. Proc Natl Acad Sci U S A, 1998. 95(20): p. 11584-9. 
294. Smallwood, H.S., et al., Identification of a denitrase activity against 
calmodulin in activated macrophages using high-field liquid chromatography-
-FTICR mass spectrometry. Biochemistry, 2007. 46(37): p. 10498-505. 
295. Irie, Y., et al., Histone H1.2 is a substrate for denitrase, an activity that 
reduces nitrotyrosine immunoreactivity in proteins. Proc Natl Acad Sci U S 
A, 2003. 100(10): p. 5634-9. 
205 
 
296. Kang, M. and H.I. Akbarali, Denitration of L-type calcium channel. FEBS 
Lett, 2008. 582(20): p. 3033-6. 
297. Lambeth, J.D., NOX enzymes and the biology of reactive oxygen. Nat Rev 
Immunol, 2004. 4(3): p. 181-9. 
298. Bae, Y.S., et al., Regulation of reactive oxygen species generation in cell 
signaling. Mol Cells, 2011. 32(6): p. 491-509. 
299. Perner, A., et al., Superoxide production and expression of NAD(P)H oxidases 
by transformed and primary human colonic epithelial cells. Gut, 2003. 52(2): 
p. 231-6. 
300. Brar, S.S., et al., NOX5 NAD(P)H oxidase regulates growth and apoptosis in 
DU 145 prostate cancer cells. Am J Physiol Cell Physiol, 2003. 285(2): p. 
C353-69. 
301. Brar, S.S., et al., An NAD(P)H oxidase regulates growth and transcription in 
melanoma cells. Am J Physiol Cell Physiol, 2002. 282(6): p. C1212-24. 
302. Geiszt, M., et al., NAD(P)H oxidase 1, a product of differentiated colon 
epithelial cells, can partially replace glycoprotein 91phox in the regulated 
production of superoxide by phagocytes. J Immunol, 2003. 171(1): p. 299-
306. 
303. Hilenski, L.L., et al., Distinct subcellular localizations of Nox1 and Nox4 in 
vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2004. 24(4): p. 
677-83. 
304. Brand, M.D., The sites and topology of mitochondrial superoxide production. 
Exp Gerontol, 2010. 45(7-8): p. 466-72. 
305. Madesh, M. and G. Hajnóczky, VDAC-dependent permeabilization of the 
outer mitochondrial membrane by superoxide induces rapid and massive 
cytochrome c release. J Cell Biol, 2001. 155(6): p. 1003-1016. 
306. Han, D., et al., Voltage-dependent anion channels control the release of the 
superoxide anion from mitochondria to cytosol. J Biol Chem, 2003. 278(8): p. 
5557-63. 
307. Vakkala, M., et al., Inducible nitric oxide synthase expression, apoptosis, and 
angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res, 
2000. 6(6): p. 2408-16. 
308. Ambs, S., et al., Relationship between p53 mutations and inducible nitric 
oxide synthase expression in human colorectal cancer. J Natl Cancer Inst, 
1999. 91(1): p. 86-8. 
309. Tanaka, H., et al., Frequent expression of inducible nitric oxide synthase in 
esophageal squamous cell carcinomas. Int J Oncol, 1999. 14(6): p. 1069-73. 
310. Yamaguchi, S., et al., Glioma tumourgenicity is decreased by iNOS knockout: 
experimental studies using the C6 striatal implantation glioma model. Br J 
Neurosurg, 2002. 16(6): p. 567-72. 
311. Jenkins, D.C., et al., Roles of nitric oxide in tumor growth. Proc Natl Acad Sci 
U S A, 1995. 92(10): p. 4392-6. 
312. Barreiro Arcos, M.L., et al., Inducible nitric oxide synthase-mediated 
proliferation of a T lymphoma cell line. Nitric Oxide, 2003. 8(2): p. 111-8. 
313. Shi, Q., et al., Direct correlation between nitric oxide synthase II inducibility 
and metastatic ability of UV-2237 murine fibrosarcoma cells carrying mutant 
p53. Cancer Res, 1999. 59(9): p. 2072-5. 
314. Le, X., et al., Nitric oxide synthase II suppresses the growth and metastasis of 
human cancer regardless of its up-regulation of protumor factors. Proc Natl 
Acad Sci U S A, 2005. 102(24): p. 8758-63. 
206 
 
315. Wang, B., et al., A novel model system for studying the double-edged roles of 
nitric oxide production in pancreatic cancer growth and metastasis. 
Oncogene, 2003. 22(12): p. 1771-82. 
316. Marchenko, N.D., A. Zaika, and U.M. Moll, Death signal-induced 
localization of p53 protein to mitochondria. A potential role in apoptotic 
signaling. J Biol Chem, 2000. 275(21): p. 16202-12. 
317. Mihara, M., et al., p53 has a direct apoptogenic role at the mitochondria. Mol 
Cell, 2003. 11(3): p. 577-90. 
318. Deng, X., F. Gao, and W.S. May, Protein phosphatase 2A inactivates Bcl2's 
antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 
binding. Blood, 2009. 113(2): p. 422-8. 
319. Deng, X., et al., Bcl2's flexible loop domain regulates p53 binding and 
survival. Mol Cell Biol, 2006. 26(12): p. 4421-34. 
320. Chipuk, J.E., et al., Direct activation of Bax by p53 mediates mitochondrial 
membrane permeabilization and apoptosis. Science, 2004. 303(5660): p. 
1010-4. 
321. Cheng, J. and M. Haas, Frequent mutations in the p53 tumor suppressor gene 
in human leukemia T-cell lines. Mol Cell Biol, 1990. 10(10): p. 5502-9. 
322. Laumann, R., M. Jucker, and H. Tesch, Point mutations in the conserved 
regions of the p53 tumour suppressor gene do not account for the 
transforming process in the Jurkat acute lymphoblastic leukemia T-cells. 
Leukemia, 1992. 6(3): p. 227-8. 
323. Pan, Y. and D.S. Haines, The pathway regulating MDM2 protein degradation 
can be altered in human leukemic cells. Cancer Res, 1999. 59(9): p. 2064-7. 
324. Knudson, C.M., et al., Bax-deficient mice with lymphoid hyperplasia and male 
germ cell death. Science, 1995. 270(5233): p. 96-9. 
325. Li, P.F., R. Dietz, and R. von Harsdorf, p53 regulates mitochondrial 
membrane potential through reactive oxygen species and induces cytochrome 
c-independent apoptosis blocked by Bcl-2. EMBO J, 1999. 18(21): p. 6027-
36. 
326. Reinke, V. and G. Lozano, The p53 targets mdm2 and Fas are not required as 
mediators of apoptosis in vivo. Oncogene, 1997. 15(13): p. 1527-34. 
327. Chen, L., et al., Hydrogen peroxide-induced neuronal apoptosis is associated 
with inhibition of protein phosphatase 2A and 5, leading to activation of 
MAPK pathway. Int J Biochem Cell Biol, 2009. 41(6): p. 1284-95. 
328. Han, X., et al., Curcumin inhibits protein phosphatases 2A and 5, leading to 
activation of mitogen-activated protein kinases and death in tumor cells. 
Carcinogenesis, 2012. 33(4): p. 868-75. 
329. Zhang, Y., et al., Protein phosphatases 2A as well as reactive oxygen species 
involved in tributyltin-induced apoptosis in mouse livers. Environ Toxicol, 
2012. 
330. Grundke-Iqbal, I., et al., Abnormal phosphorylation of the microtubule-
associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl 
Acad Sci U S A, 1986. 83(13): p. 4913-7. 
331. Oddo, S., et al., Abeta immunotherapy leads to clearance of early, but not 
late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004. 
43(3): p. 321-32. 
332. Murakami, K., et al., SOD1 (copper/zinc superoxide dismutase) deficiency 
drives amyloid beta protein oligomerization and memory loss in mouse model 
of Alzheimer disease. J Biol Chem, 2011. 286(52): p. 44557-68. 
207 
 
333. Okamoto, K., et al., p53-dependent association between cyclin G and the B' 
subunit of protein phosphatase 2A. Mol Cell Biol, 1996. 16(11): p. 6593-602. 
334. Kong, M., et al., Alpha4 is an essential regulator of PP2A phosphatase 
activity. Mol Cell, 2009. 36(1): p. 51-60. 
335. Trockenbacher, A., et al., MID1, mutated in Opitz syndrome, encodes an 
ubiquitin ligase that targets phosphatase 2A for degradation. Nat Genet, 
2001. 29(3): p. 287-94. 
336. Prickett, T.D. and D.L. Brautigan, Overlapping binding sites in protein 
phosphatase 2A for association with regulatory A and alpha-4 (mTap42) 
subunits. J Biol Chem, 2004. 279(37): p. 38912-20. 
337. Ruediger, R., H.T. Pham, and G. Walter, Alterations in protein phosphatase 
2A subunit interaction in human carcinomas of the lung and colon with 
mutations in the A beta subunit gene. Oncogene, 2001. 20(15): p. 1892-9. 
338. Ruediger, R., H.T. Pham, and G. Walter, Disruption of protein phosphatase 
2A subunit interaction in human cancers with mutations in the A alpha 
subunit gene. Oncogene, 2001. 20(1): p. 10-5. 
339. Tamaki, M., et al., PPP2R1B gene alterations inhibit interaction of PP2A-
Abeta and PP2A-C proteins in colorectal cancers. Oncol Rep, 2004. 11(3): p. 
655-9. 
340. Soo Hoo, L., J.Y. Zhang, and E.K. Chan, Cloning and characterization of a 
novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. 
Oncogene, 2002. 21(32): p. 5006-15. 
341. Neviani, P., et al., The tumor suppressor PP2A is functionally inactivated in 
blast crisis CML through the inhibitory activity of the BCR/ABL-regulated 
SET protein. Cancer Cell, 2005. 8(5): p. 355-68. 
342. Neviani, P., et al., FTY720, a new alternative for treating blast crisis chronic 
myelogenous leukemia and Philadelphia chromosome-positive acute 
lymphocytic leukemia. J Clin Invest, 2007. 117(9): p. 2408-21. 
343. Dobrowsky, R.T., et al., Ceramide activates heterotrimeric protein 
phosphatase 2A. J Biol Chem, 1993. 268(21): p. 15523-30. 
344. Kim, S.W., et al., Ceramide produces apoptosis through induction of 
p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-
3 prostate cancer cells. J Toxicol Environ Health A, 2010. 73(21-22): p. 
1465-76. 
345. Kowluru, A. and S.A. Metz, Ceramide-activated protein phosphatase-2A 
activity in insulin-secreting cells. FEBS Lett, 1997. 418(1-2): p. 179-82. 
346. Nica, A.F., et al., Ceramide promotes apoptosis in chronic myelogenous 
leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. 
Cell Cycle, 2008. 7(21): p. 3362-70. 
347. Widau, R.C., et al., Protein phosphatase 2A (PP2A) holoenzymes regulate 
death-associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol 
Chem, 2010. 285(18): p. 13827-38. 
348. Sawai, H., et al., Requirement of AP-1 for ceramide-induced apoptosis in 
human leukemia HL-60 cells. J Biol Chem, 1995. 270(45): p. 27326-31. 
349. Schutze, S., et al., TNF activates NF-kappa B by phosphatidylcholine-specific 
phospholipase C-induced "acidic" sphingomyelin breakdown. Cell, 1992. 
71(5): p. 765-76. 
350. Conway, A., N.J. Pyne, and S. Pyne, Ceramide-dependent regulation of 
p42/p44 mitogen-activated protein kinase and c-Jun N-terminal-directed 
208 
 
protein kinase in cultured airway smooth muscle cells. Cell Signal, 2000. 
12(11-12): p. 737-43. 
351. Verheij, M., et al., Requirement for ceramide-initiated SAPK/JNK signalling 
in stress-induced apoptosis. Nature, 1996. 380(6569): p. 75-9. 
352. Aktas, O., et al., Fingolimod is a potential novel therapy for multiple 
sclerosis. Nat Rev Neurol, 2010. 6(7): p. 373-82. 
353. Cohen, J.A., et al., Oral fingolimod or intramuscular interferon for relapsing 
multiple sclerosis. N Engl J Med, 2010. 362(5): p. 402-15. 
354. Khatri, B., et al., Comparison of fingolimod with interferon beta-1a in 
relapsing-remitting multiple sclerosis: a randomised extension of the 
TRANSFORMS study. Lancet Neurol, 2011. 10(6): p. 520-9. 
355. Liu, Q., et al., FTY720 demonstrates promising preclinical activity for chronic 
lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008. 
111(1): p. 275-84. 
356. Matsuoka, Y., et al., A novel immunosuppressive agent FTY720 induced Akt 
dephosphorylation in leukemia cells. Br J Pharmacol, 2003. 138(7): p. 1303-
12. 
357. Chen, J., B.L. Martin, and D.L. Brautigan, Regulation of protein serine-
threonine phosphatase type-2A by tyrosine phosphorylation. Science, 1992. 
257(5074): p. 1261-4. 
358. Longin, S., et al., Selection of protein phosphatase 2A regulatory subunits is 
mediated by the C terminus of the catalytic Subunit. J Biol Chem, 2007. 
282(37): p. 26971-80. 
359. Ogris, E., et al., A protein phosphatase methylesterase (PME-1) is one of 
several novel proteins stably associating with two inactive mutants of protein 
phosphatase 2A. J Biol Chem, 1999. 274(20): p. 14382-91. 
360. Ravizza, R., et al., The piperidine nitroxide Tempol potentiates the cytotoxic 
effects of temozolomide in human glioblastoma cells. Int J Oncol, 2004. 25(6): 
p. 1817-22. 
361. Darr, D., K.A. Zarilla, and I. Fridovich, A mimic of superoxide dismutase 
activity based upon desferrioxamine B and manganese(IV). Arch Biochem 
Biophys, 1987. 258(2): p. 351-5. 
362. Huber, K.R., et al., Superoxide dismutase-like activities of copper(II) 
complexes tested in serum. Biochim Biophys Acta, 1987. 915(2): p. 267-76. 
363. Lam, M.A., et al., Nitric oxide and nitroxides can act as efficient scavengers 
of protein-derived free radicals. Chem Res Toxicol, 2008. 21(11): p. 2111-9. 
364. Nagano, T., T. Hirano, and M. Hirobe, Superoxide dismutase mimics based on 
iron in vivo. J Biol Chem, 1989. 264(16): p. 9243-9. 
365. Weser, U., et al., Structure of Cu2(indomethacin)4 and the reaction with 
superoxide in aprotic systems. Biochim Biophys Acta, 1980. 631(2): p. 232-
45. 
366. Burger, J.A. and R.J. Ford, The microenvironment in mantle cell lymphoma: 
Cellular and molecular pathways and emerging targeted therapies. Seminars 








List of Publications 
Low, I.C., Z.X. Chen, and S. Pervaiz, Bcl-2 modulates resveratrol-induced ROS 
production by regulating mitochondrial respiration in tumor cells. Antioxid Redox 
Signal, 2010. 13(6): p. 807-19. 
Low, I.C., J. Kang, and S. Pervaiz, Bcl-2: a prime regulator of mitochondrial redox 
metabolism in cancer cells. Antioxid Redox Signal, 2011. 15(12): p. 2975-87. 
Krishna, S., I.C. Low, and S. Pervaiz, Regulation of mitochondrial metabolism: yet 
another facet in the biology of the oncoprotein Bcl-2. Biochem J, 2011. 435(3): p. 
545-51. 
Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, Kaur S, 
Utomo V, Jones CM, Pervaiz S, Toone EJ, Virshup DM.., Modulation of Wnt/beta-
catenin signaling and proliferation by a ferrous iron chelator with therapeutic 




Low, I.C. and S. Pervaiz, Bcl-2 modulates resveratrol-induced ROS production by 
regulating mitochondrial respiration in tumor cells. European Molecular Biology 
Organization (EMBO) workshop on Mitochondria, Apoptosis & Cancer (MAC), 
Prague, Czech Republic. * 
 
Low, I.C. and S. Pervaiz, Bcl-2 as a regulator of mitochondrial respiration in tumor 
cells. International Cell Death Society annual meeting - South African chapter, Cape 
town, South Africa. ** 
 
Low, I.C. and S. Pervaiz, Nitration-mediated inhibition of Protein Phosphatase 2A as 
the mediator of superoxide-induced Bcl-2 phosphorylation. 18th Annual General 
Meeting of the Society for Free Radical Biology and Medicine (SFRBM), Atlanta, USA. *** 
 
 
*       Recipient of Best Poster Award.  
**     Presented a short talk. 
***   Received travel award and was selected for a talk at the opening session. 
 
